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Evidence for the association between vitamin D status and cardiovascular disease 
(CVD) is reviewed. Cross-sectional analysis of data from the CRESSIDA and MARINA 
trials revealed a strong association between vitamin D status and arterial stiffness. An 
increase in vitamin D status measured as serum 25-OH-D concentrations after 
following advice to consume 1-2 portions of oily fish/wk was demonstrated (9.2 
nmol/L, 95% CI 4.2, 14.2). The effects of malted milk drinks fortified with vitamin D2 or 
D3 at 5 and 10 μg/d vs. placebo taken for 4 wk on serum 25-OH-D metabolite 
concentrations were compared in 8 subjects/group in winter (minimal UVB exposure): 
mean increments ± SED vs. placebo were 9.4 ± 2.5 and 17.8 ± 2.4 nmol/L in 25-OH-D2  
after 5 and 10 μg D2/d and 15.1 ± 4.7 and 22.9 ± 4.6 nmol/L in 25-OH-D3 after 5 and 10 
μg D3/d. A total of 41 predominantly normotensive men and post-menopausal women 
(50-70 y) were randomly allocated to receive 10 µg/d D2 (Rx) or a placebo malted milk 
drink for 12 wk in winter. The specified primary outcomes of the trial were 24 h 
ambulatory blood pressure (BP) and flow mediated dilation (FMD) of the brachial 
artery. The mean increase ± SED in serum 25-OH-D2 on Rx vs. placebo was 22.8 ± 2.0 
nmol/L (P<0.001). The treatment effects (mean changes on Rx vs. placebo with 95% CI) 
were 0.17% (-1.62, 1.28; P=0.82) for FMD and -4.3 mm Hg (-7.3, -1.2; P=0.007) and -2.8 
mm Hg (-5.4, -0.2; P=0.032) for systolic and diastolic BP respectively. This BP lowering 
effect of vitamin D2 in the winter months and the null finding with regard to FMD need 
confirmation with a larger sample. A trial of several years duration is required to 
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This thesis reviews evidence for the association between vitamin D status and risk of 
cardiovascular disease (CVD), and examines the effects of vitamin D supplementation 
on risk factors for CVD and factors associated with the development of CVD. CVD 
encompasses a number of disorders affecting the heart and vasculature including 
atherosclerosis, myocardial infarction (MI), peripheral artery disease (PAD), heart 
failure and stroke/cerebrovascular disease (BHF 2013a). It is the largest cause of death 
globally and in the UK (WHO 2011; BHF 2013b) with more than a quarter of deaths (> 
161,000 people) in the UK occurring as a result of it (BHF 2013b). Coronary heart 
disease (CHD) is the leading cause of CVD death in the UK, Europe and North America, 
followed by stroke. However, in many Far Eastern countries, stroke rather than CHD 
accounts for the highest number of deaths (Gaziano et al. 2010). Many factors 
contribute to risk of CVD notably increasing age, male gender, smoking habit, heredity, 
exercise and diet. The World Health Organisation defines a risk factor as “any 
attribute, characteristic or exposure of an individual that increases the likelihood of 
developing a disease or injury” (WHO 2014). Some factors are unalterable (e.g. age, 
gender, genetics) but others are modifiable (e.g. smoking habit, high blood pressure 
(BP), hypercholesterolaemia, hyperglycaemia, obesity). BP is a stronger risk factor for 
stroke than CHD but elevated serum cholesterol, especially low density lipoprotein 
(LDL) cholesterol, is the major risk factor for CHD and a weaker risk factor for stroke 
(Gaziano et al. 2010). Various risk algorithms (e.g. QRISK (ClinRisk Ltd 2013), 
Framingham score) have been developed to estimate CVD risk based on age, gender, 
BP, lipid profile, smoking habit, body mass index and presence or absence of diabetes). 
However, whilst these algorithms are useful for identifying high risk individuals for 
pharmacotherapy they predict less than 45% of CVD events (Hippisley-Cox et al. 2008). 
Thus a large part of the variability in CVD incidence remains unexplained and inclusion 
of genetic factors does not substantially improve risk prediction (Humphries et al. 
2010). Novel risk factors may provide prognostic information beyond that of traditional 
risk factors (Bonetti et al. 2003; Cohn 2006). They include high sensitivity CRP (hsCRP), 
an acute phase reactant, fibrinogen, a plasma glycoprotein involved in clot formation 
(Torres et al. 2003; Kaptoge et al. 2012; Danesh et al. 2005), and markers of vascular 
function such as endothelial function and arterial stiffness (Green et al. 2011; Yeboah 





Prospective observational studies have found lower serum 25-hydroxyvitamin D (25-
OH-D) concentrations to be associated with a greater risk of CVD mortality, coronary 
heart disease and stroke (Wang et al. 2012b). However, a causal association cannot be 
inferred because other aspects of lifestyle, such as involvement in physical work 
outdoors, or disease processes may confound the relationship. Some evidence from 
long-term randomised controlled trials (RCTs) suggests that vitamin D supplementation 
(often in combination with calcium) reduces total mortality (Zheng et al. 2013; 
Bjelakovic et al. 2014; Chowdhury et al. 2014) but there is no clear evidence to support 
a beneficial effect on CVD incidence and mortality (Bolland et al. 2014; Bolland et al. 
2011; Myung et al. 2013).  
 
1.1 Vitamin D 
In order to be able to consider the mechanisms behind a potential association 
between vitamin D and CVD, it is first necessary to understand more about vitamin D. 
The section that follows provides some background information regarding the history 
of vitamin D, its chemical forms and sources, absorption, metabolism, physiological 
role, storage, excretion, biochemical assessment and toxicity as well as a description of 
status and intake in the UK. 
 
1.1.1 History and discovery 
Rickets was documented as a common disease of children in 1650 in England by 
Francis Glisson (Rajakumar 2003). At the turn of the 20th century, the prevalence of 
rickets was high in England especially in urban industrial areas. The pall of smoke from 
coal burning that hung over industrial cities would have decreased exposure to 
ultraviolet B (UVB) radiation from sunlight and the high consumption of cereals rich in 
phytate such as oats would have reduced calcium bioavailability (Rajakumar et al. 
2007). Although using cod liver oil to treat rickets has been recorded as early as 1824, 
its use for this purpose was questioned and was not widely acknowledged at the time 
(Rajakumar 2003; Rajakumar et al. 2007). However, in 1861, Trousseau correctly 
deduced that rickets was caused by a lack of exposure to the sun and an inadequate 
diet, and that cod-liver oil was an effective cure (Rajakumar 2003). In 1890, Palm 
argued that infants living in Britain were at a greater risk of developing rickets than 




Later in 1908, the Scottish group of Findlay were able to induce rickets in puppies fed 
oatmeal and whole milk if they were kept indoors, but reported that puppies given 
exercise outdoors remained healthy (Findlay 1908). Furthermore, Huldschinsky cured 
rickets in 1919 in infants using radiation from a sun quartz lamp or carbon arc lamp 
(Huldschinsky 1928). Subsequent studies showed that exposure of children with rickets 
to different periods of sunshine in New York City let to marked improvements in the 
disease (Hess et al. 1921).   
 
In 1918, Mellanby, working at King’s College for Women in London, showed that cod 
liver oil cured rickets in puppies (Mellanby 1918). As cod liver oil was also a rich source 
of vitamin A, some argued that this vitamin might be responsible (Mellanby 1919). 
However, in 1922, McCollum showed that the anti-rachitic properties remained when 
the oil was heated to remove its protectiveness against vitamin A deficiency 
(McCollum et al. 1922). He named the anti-rachitic component as ‘vitamin D’ as only 
three vitamins had previously been discovered (Rajakumar et al. 2007). A trial by 
Harriet Chick conducted in infants in Vienna at around the same time established 
beyond doubt that rickets could be prevented by cod liver oil and that the severity of 
rickets was seasonal (Carpenter 2008). Cod liver oil, in which vitamin D is present as 
cholecalciferol, or D3, was then widely administered to children in the UK up until the 
mid-1950s in order to prevent rickets. However, the Ministry of Health stopped its 
administration because of concerns around idiopathic hypercalcaemia, a condition that 
was associated with excess vitamin D that resulted in calcification of soft tissues 
(Rajakumar et al. 2007).  
 
From the 1950s onwards, a large amount of work was conducted to determine the 
functional metabolism of vitamin D (DeLuca 2014). Vitamin D from dietary and sunlight 
sources was found to be a precursor for the hormonal metabolite and active form of 
vitamin D, 1, 25-dihydroxyvitamin D (1,25(OH)2D). 1,25(OH)2D is a steroid hormone as 
it has a similar molecular structure to classic steroid hormones such as cortisol, and it 
functions by interacting with a high affinity nuclear hormone receptor, the vitamin D 
receptor (VDR) which is comparable to other steroid hormones (Norman 2008). 
Vitamin D is generally only an essential dietary factor in the absence of sunlight 




limited by clothing and is very low in the UK winter months so there is a need to 
specify a dietary intake for populations who receive little or no sunlight exposure 
(Vieth 2004a).  
 
1.1.2 Forms  
Diet can supply vitamin D3 (cholecalciferol) and vitamin D2 (ergocalciferol) (Figure 1.1). 
Vitamin D3 comprises 27 carbon atoms, and D2 28 carbons. The difference between 
them is an additional methyl group in D2 and a double bond between carbons 22 and 
23 (Binkley et al. 2011).   
 
Figure 1.1 Molecular structure of vitamins D2 and D3  
 
 Sources  1.1.2.1
Most vitamin D is derived from skin exposure to UVB radiation as vitamin D3. 
Synthetically D3 can be produced by irradiating 7-dehydrocholesterol obtained from 
lanolin in sheep’s wool with UVB (Holick 2007). Vitamin D3 is generally not found in 
foods of plant origin, although some Solanum species contain the 1,25(OH)2D3 
glycoside (Wasserman et al. 1976). Vitamin D2 is formed from the action of UVB 




exposed to sunlight contain significant amounts of vitamin D2, and D2 is manufactured 
commercially by irradiating yeast (Holick et al. 2008).   
 
UVB-mediated production of vitamin D begins when 7-dehydrocholesterol in the skin 
absorbs UVB radiation (290-315 nm) to generate the secosteroid previtamin D3 (Holick 
2007) (Figure 1.2). This process also generates steroids including pyrocalciferol, 
lumisterol and isopyrocalciferol, and the secosteroid tachysterol (Norman 1998). The 
amount of previtamin D3 produced for all skin types under normal UVB exposure is not 
more than about 15% of the available 7-dehydrocholesterol (Webb et al. 1988). Any 
additional sunlight exposure produces the biologically inactive photoproducts 
lumisterol and tachysterol from the photoisomerisation of previtamin D3. Following 
the production of previtamin D3 in the skin, it is immediately converted to vitamin D3 in 
a heat-dependent process via a hydrogen transfer from C-19 to C-9, and vitamin D3 
enters the circulation (Holick 2007).  
 
 





There are few sources of vitamin D in the diet. As vitamin D3, oily fish contains 5-16 
µg/100 g, eggs 1.8 µg/100 g and meat ~1 µg/100 g. In the case of poultry the content is 
greater in the skin at around 1.0 µg/100 g, whereas chicken meat contains less than 
0.2 µg/100 g (Table 1.1) (McCance and Widdowson 2002). Some fungi contain high 
amounts of vitamin D2 (Table 1.1). Several foods are fortified with vitamin D notably 
margarine and yellow fat spreads, some breakfast cereals, yoghurts and infant 
formulas (Expert Group on Vitamins and Minerals 2003), with most being fortified with 
D3 rather than D2. However, although cow’s milk is fortified in the US (10 μg/US quart) 
and US Airforce bases in the UK, only infant formula has statutory vitamin D 
fortification in the UK. Margarine has been fortified in the UK by statute (Parliament 
1999) to contain not less than 7.05 and not more than 8.82 μg vitamin D per 100 g 
product, but now legislation is covered by European Community Directives and 
Regulations. Most yellow fat spreads (except butter), which are not legally classed as 
margarine because of their lower fat content, are fortified on a voluntary basis at 7.5 
μg/100 g end product. Other fortified foods including breakfast cereals and some 
drinks e.g. (Horlicks™ and Complan™) provide up to about 5 µg/100 g end product 
(Table 1.1). Supplements are a popular source of vitamin D and supplements 
containing up to 25 µg vitamin D3 per capsule/tablet can be bought over the counter 
(Table 1.1). Tablets/capsules containing larger amounts >25 μg are pharmacy only 
products and both D2 and D3 are listed in pharmacopoeias as oral forms or prescription 
products for intra-muscular injections which typically contain 7500 µg to treat or 














Table 1.1 Dietary and supplemental sources of vitamins D2 and D3 (McCance and 
Widdowson 2002; Holick 2006). Adapted from (Holick 2007). 
Source Approximate vit D content (µg) 
Foods (average portion size)  
Herring, grilled (100g) 16.1  
Kipper, grilled (100 g) 9.4 
Mackerel, grilled (100 g) 8.8 
Salmon, steamed (100 g) 8.7 
Sardines, canned in brine, drained (70 g) 3.2 
Tuna, canned in brine, drained (70 g) 2.5 
Eggs, chicken, boiled (50 g) 0.9 
Liver, lamb, fried (55 g) 0.5 
Rump steak, fried, lean (112 g) 0.8 
Chicken, roasted, meat, average, light meat (100 g) 0.2 
Shiitake mushrooms, fresh (45g) 1.1 
Shiitake mushrooms, sun-dried (45g) 17.4 
  
Fortified foods in the UK (average portion size)  
Margarine (10 g) 0.75 
Breakfast cereal (30 g) 1.3 
Yoghurts (100 g)  0.85 
Yoghurt drink (100 g)  0.75 
Infant formula (100 mL) 1.2 
Soya milk (250 mL) 1.9 
  
Supplements available over the counter  
Multivitamin 5-10 D2 or D3 
Vitamin D3 10 or 25 D3 
 
 
 Comparison of vitamin D2 and D3 1.1.2.2
In the 1930s, vitamin D2 and D3 were found to be effective in preventing and treating 
infantile rickets (Trang et al. 1998). It was concluded in 1940 that “For practical 
purposes, the vitamin D in vitosterol (vitamin D2) may be regarded as being equal to 
the vitamin D in cod liver oil (vitamin D3)” (Park 1940) and pharmacopoeias still regard 
the two forms as equivalent and interchangeable with 1 international unit (IU) being 
equivalent to 25 ng of D2 or D3, even though D3 has a marginally lower molecular 
weight (384 g/mol) compared with D2 (399 g/mol) (Medicines Commission 1980; 
Committee of Revision 1997). Furthermore, studies have shown the two forms to be 




children (Gordon et al. 2008; Thacher et al. 2010).  Holick (Holick et al. 2008), a leading 
authority on vitamin D, continues to maintain that both forms are equipotent.  
Houghton and Vieth on the other hand suggest that D2 is inferior to D3 (Houghton et al. 
2006). In support of this, a meta-analysis of 7 RCTs which gave vitamin D as a bolus or 
daily dose, compared the ability of the two forms to increase serum concentrations of 
25-hydroxyvitamin D (25-OH-D), the major circulating form of vitamin D, and 
concluded that D2 was less effective than D3 (weighted mean difference of 15.23 
nmol/L, 95% CI 6.12, 24.34) (Tripkovic et al. 2012). However, the comparison for daily 
vitamin D supplementation found no significant difference between D2 and D3 
(weighted mean difference 4.83 nmol/L, 95% CI -0.98, 10.64). Furthermore, the 
conclusions of these meta-analyses are questionable as some of the studies included 
did not adjust for sunlight exposure (Binkley et al. 2011; Armas et al. 2004) or did not 
use assays that were specific for the two different 25-OH-D metabolites, 25-OH-D2 and 
25-OH-D3 (Romagnoli et al. 2008; Trang et al. 1998; Heaney et al. 2011; Armas et al. 
2004). Some studies also gave pharmacological doses of vitamin D by non-oral routes 
(ie. intramuscular administration of 7500 µg (Leventis et al. 2009)) or in tablet or 
capsule form (i.e. a single dose of 7500 µg (Romagnoli et al. 2008) or weekly dose of 
1250 µg (Heaney et al. 2011) and so are not appropriate comparisons for dietary 
intake where recommended intakes are 10 μg/d (Scientific Advisory Committee on 
Nutrition 2007).  
 
In relation to the biological activity of the two forms of vitamin D, some studies have 
shown 25-OH-D2 to have a lower affinity for the vitamin D binding protein (VDBP) 
compared with 25-OH-D3 (Hollis 1984; Nilsson et al. 1972). It has been suggested that 
this would lead to 25-OH-D2 having a shorter circulating half-life and a greater 
clearance rate. However, it would also result in greater free, unbound concentrations 
of 25-OH-D2. It has been suggested that the 25-hydroxylase enzyme may have a lower 
affinity for vitamin D2 than vitamin D3 resulting in a greater rate of production of 25-
OH-D3 compared with 25-OH-D2. A study in subcellular fractions of human liver found a 
five times greater rate of mitochondrial hydroxylation of D3 compared with D2 
(Holmberg et al. 1986), although these results are questionable as the assay used to 
detect 25-OH-D2 was less sensitive than that for 25-OH-D3, and another study in chick 




formed (Jones et al. 1976). After formation of the active form of vitamin D from both 
D2 and D3, a 24-hydroxylation step occurs converting 1,25(OH)2D to 1,24,25(OH)3D. The 
formation of 1,24,25(OH)3D2 deactivates vitamin D2, but 1,24,25(OH)3D3 continues to 
be biologically active and is still able to bind to the vitamin D receptor (VDR) as a 
further side-chain oxidation is needed to deactivate it (Horst et al. 1986; Houghton and 
Vieth 2006). However, the above differences in metabolism between the two forms do 
not necessarily mean that biological activity will differ. Many of these findings are 
based on experiments in animals, and it needs to be recognised that there are large 
species differences in the metabolism of vitamin D which limits the translation of 
findings in animals to man. In chicks, for example, vitamin D2 only has 8-11% of the 
activity of D3 in preventing rickets (Chen et al. 1964). Data on the comparative toxicity 
of vitamin D2 and D3 in humans are lacking according to the Expert Group on Vitamins 
and Minerals. However, vitamin D3 is significantly more toxic than D2 in non-human 
primates (Rhesus monkey) (Expert Group on Vitamins and Minerals 2003). 
 
1.1.3 Absorption, metabolism, storage and excretion 
Vitamin D is a steroid with chemical properties similar to cholesterol, being better 
absorbed dissolved in fat or in the presence of fat in the small intestine (Haddad et al. 
1993; IOM 2011). It is absorbed in lipid-containing micelles which diffuse into 
enterocytes (IOM 2011). This is likely to be why studies have shown absorption to be 
more efficient if vitamin D is consumed with fat-containing foods (Weber 1981). Both 
vitamin D2 and D3 from food and supplements, together with other sterols, are 
incorporated into chylomicrons in the intestinal wall and rapidly transported by the 
lymphatic system into the circulation (Holick 2007). 
 
Vitamin D in the circulation from sunlight and dietary sources is bound to the VDBP 
and transported to the liver (Holick 2007; Norman 1998). In the liver, 25-OH-D is 
formed from the addition of a hydroxyl group to the 25 position of the vitamin D 
molecule by 25-hydroxylase (Figure 1.3). 25-OH-D is biologically inactive and the major 
circulating form of vitamin D and is used to determine vitamin D status. It is 
transported in the circulation to the kidneys where it is converted to the active form 
1,25(OH)2D by the enzyme 25-hydroxyvitamin D-1α-hydroxylase (1α-hydroxylase) 




released which stimulates a greater production of 1,25(OH)2D. This has the effect of 
increasing serum calcium concentrations by increasing bone calcium re-absorption, 
increasing the intestinal absorption of calcium and phosphate, and decreasing the 
renal excretion of calcium (Makariou et al. 2011). A negative feedback loop then leads 
to a decreased synthesis of 1,25(OH)2D, and a decreased synthesis and secretion of 
PTH (Holick 2007). Levels of 1,25(OH)2D are tightly regulated in the blood and only 
lowered when there is a severe deficiency of 25-OH-D. 
 
Storage of vitamin D in the body is mainly as 25-OH-D bound to VDBP in the 
circulation, but it can also be stored in the liver or fat cells and later released (Holick 
2007). Experimental studies in rats have shown adipose tissue to accumulate the most 
vitamin D and have the slowest rate of release (Rosenstreich et al. 1971). Furthermore, 
serum 25-OH-D concentrations have been observed to increase after weight loss in 
obese subjects (Tzotzas et al. 2010).  
 
Calcitroic acid, a water soluble and biologically inactive form of vitamin D is the main 
excretory product of vitamin D which is excreted in the bile in the faeces (Figure 1.3). It 
is formed from the catabolism of 1,25(OH)2D and 25-OH-D by the enzyme 25-
hydroxyvitamin D-24-hydroxylase (CYP24) (Makariou et al. 2011; Holick 2007). Very 
little vitamin D is excreted in urine (IOM 2011). 
 
An alternative metabolic pathway through which vitamin D3 can be metabolised is the 
C-3 epimerisation pathway. This involves the conversion of the hydroxyl group at 
position C-3 of the A-ring from the alpha to the beta orientation, resulting in 
stereoisomers of vitamin D metabolites (Bailey et al. 2013). Evidence from in vitro 
studies supports that the epimers 3-epi-25-OH-D3, 3-epi-1α,25(OH)2D3 and 3-epi-
24,25(OH)2D3 can be produced via this pathway (Kamao et al. 2004) and the 3-epi-25-
OH-D3 has been identified in infants, children and adults (van der Ouweland et al. 
2011). The epimerisation appears to take place in extrarenal tissues, but it is not yet 
known which enzymes are responsible (Bailey et al. 2013). Currently the biological 
function of the epimers is uncertain, although evidence suggests that 3-epi-
1α,25(OH)2D3 may possess some but not all of the regulatory effects of 1,25(OH)2D 




suppressed to a similar extent by both forms (Brown et al. 1999), but 3-epi-
1α,25(OH)2D3 had only 12-13% of the transcriptional activity of 1,25(OH)2D for 
inducing the expression of the human osteocalcin and CYP24 genes (Kamao et al. 
2004).  
 
Figure 1.3  Metabolism of vitamin D in the body adapted from (Holick 2007). 
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2-, hydrogen phosphate; Ca2+, calcium; 25-OH-D, 25-hydroxyvitamin D; 
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1.1.4 Biochemical assessment of vitamin D status 
There are many different vitamin D metabolites, but there is some uncertainty as to 
which form best represents status and the bioavailability of vitamin D. Currently, 
although 1,25(OH)2D is the active form, vitamin D status is measured as plasma or 
serum concentrations of 25-OH-D. 1,25(OH)2D is present in the blood at very low 
concentrations and is unsuitable as a measure of status as it can be at normal or 
elevated levels even when a patient is vitamin D insufficient (Holick 2009). 
Furthermore, the half-life of 1,25(OH)2D in the circulation is only 4-6 h (Holick 2009), 
compared to about 2-3 wk for 25-OH-D (Lund et al. 1980). Serum/plasma 25-OH-D is 
not under tight homeostatic regulation and is therefore useful as it is representative of 
the supply and usage of vitamin D over a time period (Prentice et al. 2008). Its 
concentrations are dependent on the amount of vitamin D reaching the liver from 
dietary and sunlight sources, how much 25-OH-D the liver produces and how long it 
lasts in the circulation (its half-life). However, total 25-OH-D is not necessarily a good 
indicator of the ability of vitamin D to meet the body’s functional requirements 
(Prentice et al. 2008). Free or bioavailable 25-OH-D may provide a more meaningful 
marker of vitamin D status (Chun et al. 2013; Glendenning et al. 2013). Less than 1% of 
25-OH-D in the circulation exists as free and unbound; about 85-90% is bound with 
high affinity to DBP and a further 10-15% is bound to albumin (Bikle et al. 1986). Some 
authors have labelled the albumin-bound and free form together as ‘bioavailable’ 25-
OH-D because when it is bound to the VDBP some of its actions may be inhibited, 
preventing it from acting on target cells, and it binds to albumin with a lower affinity 
than VDBP (Bikle et al. 1989; Safadi et al. 1999). Powe et al. found that black 
Americans had lower total 25-OH-D concentrations compared to whites, but because 
they also had lower concentrations of VDBP, the amount of bioavailable 25-OH-D for 
both ethnic groups was similar (Powe et al. 2013). The same group found free 25-OH-D 
concentrations to be better correlated with bone mineral density than total 25-OH-D 
concentrations in young adults (Powe et al. 2011). It is hypothesised therefore that 
only free and bioavailable 25-OH-D are available for cellular processes making them a 
better indicator of physiological bioactivity compared to total 25-OH-D (Glendenning et 





In terms of representing function, PTH has also been suggested as a useful biomarker 
of vitamin D (Prentice et al. 2008). It is well-established that strong inverse correlations 
exist between plasma PTH and 25-OH-D concentrations (Bates et al. 2003; Krall et al. 
1989; Chapuy et al. 1997), although some suggest that PTH no longer falls when serum 
25-OH-D reaches a certain level (Need et al. 2000; Chapuy et al. 1997; Lappe et al. 
2006). However, it is important to note that 25-OH-D concentrations vary considerably 
at a given concentration of PTH and that PTH is not specific for vitamin D deficiency 
(Lips et al. 1988; Dawson-Hughes et al. 1997). Furthermore, the interaction between 
PTH and 25-OH-D may vary in different population groups as, for example, elevated 
PTH concentrations have been found in Africans who have a good vitamin D status, but 
a low calcium intake (Aspray et al. 2005). 
 
In summary, 25-OH-D is the preferred marker of vitamin D status, but it may also be 
useful to measure free and bioavailable 25-OH-D. 
 
1.1.5 Definition of vitamin D insufficiency and prevalence in the UK 
In the early 1970s adequate serum 25-OH-D concentrations used to be defined based 
on the levels that would be required to prevent osteomalacia or rickets. More recently, 
definitions have been based on the concentration that maximally suppresses PTH. 
However, estimates vary, and if vitamin D concentrations are causally associated with 
health outcomes other than bone health, defining an optimum intake is more complex. 
A review has concluded that the most advantageous serum concentrations of 25-OH-D 
begin at 75 nmol/L after summarising the evidence from previous studies that had 
evaluated the threshold for serum 25-OH-D concentrations in relation to bone mineral 
density (BMD), lower extremity function, dental health, risk of falls and fractures, and 
colorectal function (Bischoff-Ferrari et al. 2006). Whilst in agreement with this the 
Endocrine Society define serum 25-OH-D concentrations of 52.5-72.5 nmol/L as 
insufficient, most public health organisations have advised that 50 nmol/L should be 
sufficient to meet the needs of most people (Table 1.2). Vitamin D deficiency is usually 
defined as serum 25-OH-D concentrations less than 25 or 30 nmol/L (Table 1.2) and 
this may, although not in all cases, lead to rickets in children. In adults vitamin D 
deficiency causes a decrease in the efficiency of calcium and phosphorus absorption 




decrease in bone mineral density and the development of osteomalacia. This results in 
muscle and bone weakness and an increased risk of fractures in the elderly due to 
more frequent falls (Expert Group on Vitamins and Minerals 2003; Holick 2006; Holick 
2007; Zittermann et al. 2005).  
 
Table 1.2 Serum 25-OH-D thresholds used to assess vitamin D deficiency and 
sufficiency by different public health organisations.  
Public health 
organisation 
Serum 25-OH-D thresholds 
Institute of 
Medicine [1] 
25-OH-D at 50 nmol/L should cover the needs of 97.5% of the 
population. 40 nmol/L is the median requirement. Deficiency 









Deficiency is serum 25-OH-D <30 nmol/L. Concentrations 30-50 
nmol/L may be inadequate in some people and 25-OH-D>50 nmol/L 






A Vitamin D Working Group has been established to consider 
thresholds used and it has been agreed that achieving a serum     
25-OH-D concentration of at least 25 nmol/L should be used as the 
criterion for establishing the Reference Nutrient Intake (RNI) for 
vitamin D. 
1 (IOM 2011); 2 (Holick et al. 2011); 3 (National Osteoporosis Society 2013); 4 (SACN 
2014). 
Vitamin D insufficiency is common in the UK (Bates et al. 2014; Hypponen et al. 2007), 
particularly in the winter when a marked seasonal fall in plasma 25-OH-D 
concentrations occurs with the nadir in February/March (Figure 1.4). The fall is 
attributed to minimal UVB exposure between November and March due to the UK’s 
location between 50 ̊and 60 ̊N. Around 55-75% of the population exhibits 
concentrations below 50 nmol/L in the winter, and 17-39% have values below 25 
nmol/L (Bates et al. 2014; Ruston 2004). These proportions are lower in the summer 
months (Figure 1.4). Data from the most recent 2008-2012 National Diet and Nutrition 
Survey (NDNS) of 1769 individuals found mean 25-OH-D concentrations of 43.5 nmol/l 
in men and 47.3 nmol/l in women aged 19-64 y from blood samples collected 
throughout the year (Bates et al. 2014). Compared to these, concentrations were 
higher in men (47.3 nmol/L) and lower in women (42.5 nmol/L) in the older age group 




been found; in a study of 500 pregnant adolescents in the UK, serum 25-OH-D 
concentrations were significantly higher in white and mixed white-Caribbean subjects 
compared to black African and Caribbean subjects (P<0.001) and values were only 
seasonal in the whites and mixed-white Caribbean subjects (Baker et al. 2009). 
Additionally, in 830 outpatients from a multi-ethnic population in Birmingham, vitamin 
D deficiency defined as serum 25-OH-D <25 nmol/L was much more prevalent in black 
Afro-Caribbeans (31%) and Asians (36%) compared to whites (12%) (Ford et al. 2006).  
 
Figure 1.4 Mean (SD) serum 25-OH-D concentrations measured throughout the 
year in 19-64 y olds in the 2008-2012 National Diet and Nutrition Survey (NDNS) (top) 























































































1.1.6 Factors influencing vitamin D status 
Certain groups of people including older institutionalised individuals who are confined 
indoors and therefore do not have sufficient UVB exposure and the obese are at a 
greater risk of vitamin D deficiency compared to others. Obese subjects have been 
shown to have lower 25-OH-D concentrations than normal weight controls, and 
inverse associations have been found between BMI and serum 25-OH-D (Wortsman et 
al. 2000). It is thought that vitamin D is deposited in body fat compartments leading to 
a reduced bioavailability (Wortsman et al. 2000). Chronic renal or liver disease and 
inflammatory bowel disease patients are also at an increased risk of deficiency as 
disease processes result in a decreased capacity for intestinal absorption of vitamin D 
(Expert Group on Vitamins and Minerals 2003). Furthermore, certain medications, 
including anticonvulsants which, for example, are used to treat HIV/AIDS, can lead to a 
lower vitamin D status as they enhance the catabolism of 25-OH-D and 1,25(OH)2D 
(Zhou et al. 2006). High intakes of unrefined cereals may also increase the catabolism 
of vitamin D, most likely due to their high phytic acid content interfering with calcium 
absorption (Dagnelie et al. 1990). It has been found in twin studies that there is a large 
genetic contribution of around 40% to 25-OH-D concentrations (Hunter et al. 2001), 
and this may be due to genetic polymorphisms in the VDBP. Other studies have shown 
these polymorphisms to be responsible for a greater proportion of the variability in 
serum 25-OH-D than other factors including age and BMI (Powe et al. 2013), and 
healthy individuals have been found to have different percentage increases in 25-OH-D 
concentrations in response to vitamin D supplementation dependent on their VDBP 
genotype (Fu et al. 2009).  
 
Certain factors influence the ability of the skin to produce vitamin D including aging, 
use of a sunscreen or clothing/headscarves which cover the skin, and increased skin 
pigmentation (Holick et al. 2011). Aging has been shown to be associated with 
decreased concentrations of 7-dehydrocholesterol in the skin (MacLaughlin et al. 
1985), and older people may be less likely to spend time outdoors. Sunscreen use, 
even at a low sun protection factor of 15 can block up to 99% of vitamin D synthesis in 
the skin (Pearce and Cheetham 2010). Skin synthesis is also blocked through the 
wearing of a veil or concealing clothing which prevents UVB radiation reaching the skin 




produce vitamin D as melanin skin pigmentation competes for and absorbs UVB 
photons that are responsible for the photolysis of 7-dehydrocholesterol to previtamin 
D. This means that a person with dark skin may need to spend around 3-5 times as 
long in the sun compared to a person with white skin in order to make an equivalent 
amount of vitamin D (Clemens et al. 1982). Immigrants with darker skin moving to 
northern latitudes are particularly at risk of developing vitamin D deficiency (Solanki et 
al. 1995).  
 
Environmental factors including latitude, altitude, season and time of day have a huge 
influence on 25-OH-D concentrations as they affect the zenith angle of the sun and 
therefore the amount of UVB radiation that people are exposed to. The level of UVB 
radiation is lower at lower altitudes and at higher latitudes (Webb et al. 1988; Engelsen 
et al. 2005); above a latitude of 37  ̊ in the winter months there is very little, if any, 
vitamin D3 synthesis in the skin (Holick 2004). In the UK, a gradient in the prevalence of 
vitamin D deficiency occurs with it decreasing from Scotland to the South of England 
(Hypponen and Power 2007). 
 
1.1.7 Toxicity 
Whilst vitamin D deficiency is a health concern, it is also important to consider 
whether there are any negative consequences of too much vitamin D, particularly in 
relation to widespread food fortification where it is difficult to decide on a level 
suitable to meet the needs of the population at the same time as trying to ensure 
there are no toxic effects. In terms of vitamin D production from excessive UVB 
exposure, toxicity does not occur as any excess previtamin D3 or vitamin D3 is 
destroyed by sunlight (Holick 2007). This occurs because the photolysis of 7-
dehydrocholesterol is reversible and previtamin D is converted to the biologically 
inactive tachysterol by photo-isomerisation (Norval et al. 2010). However, in relation 
to exogenous sources of vitamin D, there is evidence that very high levels of 
supplementation are a cause of hypercalcaemia and hypercalciuria (Johnson et al. 
1980; Jacobus et al. 1992). The physiological role of vitamin D is primarily to promote 
calcium absorption and bone resorption (see section 1.1.3). In excess, vitamin D results 
in the calcification of soft tissues (Expert Group on Vitamins and Minerals 2003) 




toxicity of vitamin D is well known to veterinarians in a variety of species. At one stage 
vitamin D3 was used as a rodenticide because of its high toxicity per kg body weight 
(Murphy 2002). The mechanisms as to how hypervitaminosis D leads to toxicity are 
unclear (Jones 2008) although a few hypotheses have been put forward, with the most 
likely explanation being that the excess 25-OH-D causes displacement of 1,25(OH)2D 
from the VDBP resulting in excessive levels of “free” 1,25(OH)2D which may cause 
inappropriate gene expression (Vieth 1990; Jones 2008). Over-fortification of milk with 
vitamin D in a population of 11,000 households in Boston between 1987 and 1991 is 
thought to have led to 56 cases of hypervitaminosis D, defined as serum 25-OH-D ≥225 
nmol/L, and 2 deaths related to hypercalcaemia (Blank et al. 1995). The dairy supplying 
the milk to the community was adding an unmeasured amount of vitamin D to the milk 
due to a broken instrument. Mandatory fortification of milk required that no more 
than 12.5 µg vitamin D was added per quart, but analysis of milk samples from the 
dairy indicated levels of between 70 and 600 times this. Strong correlations were 
observed between hypervitaminosis D and consumption of milk from this particular 
dairy, implying that the milk was the cause of the hypervitaminosis D. Symptoms of 
these individuals included anorexia, weakness, fatigue, weight loss and dehydration, 
and at least 41 were hospitalised (Blank et al. 1995). In a trial by Johnson et al. in which 
63 individuals (females over 60 y, males over 65 y) took vials of oil containing 50 µg 
vitamin D/d for 6 months, two individuals developed hypercalcaemia (Johnson et al. 
1980). However, other studies in which 100 µg/d was given to 61 healthy men and 
women aged 41 ± 9 y for 2-5 months (Vieth et al. 2001), or 32 male and female 
outpatients aged 55 ± 9 for more than 6 months were unable to detect a change in 
serum or urine calcium (Vieth et al. 2004b).  
 
Due to a lack of data, the UK has not established a safe upper level for long-term 
vitamin D intake, although for guidance purposes, 25 µg/d has been considered as safe 
and unlikely to cause adverse effects in the general population (Bassuk et al. 2009). In 
North America and Europe the tolerable upper intake level is 50 µg/d at which no 
adverse health effects are likely (European Commission Health Consumer Protection 
Directorate-General 2002; IOM 1997); for a 50 kg reference woman that would be 1 
µg/kg. However, a review by Vieth in 2007 claims that 50 µg/d is too conservative and 




the majority of the general population (Vieth 2007b). There appears to be very little 
evidence for this conclusion though. In summary, whilst it would seem from the above 
that it is better to source vitamin D from sunlight as it poses no risks of toxicity, 
concerns over the risk of skin cancer, and difficulties in obtaining sufficient UVB 
exposure in certain countries and particular groups of people (see section 1.2.5) mean 
that diet remains an important source. 
 
1.1.8 Intake in the UK 
In the UK, the most recent dietary reference values were set in 1991 (Committee on 
Medical Aspects of Food Policy 1991). They were based on the vitamin D intake 
required to maintain 25-OH-D concentrations during the winter months and prevent 
deficiency (Committee on Medical Aspects of Food Policy 1991). Pregnant and 
lactating women, adults over 65 y of age, and specific at-risk groups who are not 
receiving sufficient UVB exposure due to, for example, being confined indoors or 
wearing clothing that fully covers the skin, have a Reference Nutrient Intake (RNI) of 10 
µg/d (Scientific Advisory Committee on Nutrition 2007). Infants 0 to 6 months and 7 
months to 3 y have a RNI of 8.5 and 7 µg/d, respectively. Children and adults aged 4-64 
y were assumed to obtain sufficient vitamin D from UVB exposure and therefore there 
are currently no RNIs for people in this age group. In 1998, a review was conducted by 
the Department of Health to assess evidence on the association between 25-OH-D 
concentrations and bone health. The Committee, based on the conclusions of the 
review, decided that no changes to the RNIs were required (Department of Health 
1998). More recently, a Scientific Advisory Committee on Nutrition (SACN) Working 
Group was assembled in 2011 to “review the Dietary Reference Values for vitamin D 
intake and make recommendations” (Scientific Advisory Committee on Nutrition 
2014). Although there is no current UK RNI for adults, for food labelling purposes, an 
intake of 5 μg represents the recommended daily amount in the European Union 
(European Commission Health Consumer Protection Directorate-General 2008). 
Vitamin D intake recommendations in other parts of the world are similar to those of 






Table 1.3 Recommended vitamin D intakes (μg/d) in different countries 









IOM (US) [1]  10 15 15 15 15 20 
Ireland [2] 7.5-8.5 10 0-10 0-15 0-10 10 
Netherlands 
[3]  
10 10 10 10 10 20 
Nordic 
countries [4]  
10 10 10 10 10 20 
UK [5]  8.5 7 - - - 10 
WHO/FAO [6]  5 5 5 5 5 10-15 
IOM, Institute of Medicine (US); WHO/FAO, World Health Organisation/Food and Agriculture 
Organization for the United Nations. 1 (IOM 2011); 2 (Food Safety Authority of Ireland 1999); 3 
(Health Council of the Netherlands 2012); 4 (Nordic Council of Ministers 2012); 5 (Committee 
on Medical Aspects of Food Policy 1991); 6 (FAO 2001). 
 
The most recent UK nationwide assessment of vitamin D intake was the NDNS Rolling 
Programme for which data has been published on information collected between 2008 
and 2012 (Bates et al. 2014). For adults aged over 65 y (n=753), the mean dietary 
vitamin D intake from food sources was only 33% of the RNI of 10 µg/d, although 
inclusion of supplements increased this to 51% (Bates et al. 2014). In children aged 1.5-
3 y of age (n=604) for whom the RNI is 7 µg/d, the corresponding intakes were 27% 
and 32% of the RNI. For adults aged 19-64 (n=2697), the median vitamin D intakes 
from foods sources only were 2.5 µg/d in men (n=1126) and 2.1 µg/d (n=1571) in 
women (Bates et al. 2014). When supplements were included, intakes increased to 2.7 
µg/d in the men and 2.5 µg/d in the women. The intakes were higher in men and 
women aged 65 y and over. From food sources only they were 3.2 and 2.5 µg/d 
respectively, but they increased to 5.1 and 5.2 µg/d respectively on inclusion of 
supplements.  
 
In adults aged 19-64, vitamin D in the diet was coming from meat and meat products 
(30%), fat spreads (19%), fish and fish dishes (17%), cereals and cereal products (13%), 
eggs and egg dishes (13%), and milk and milk products (5%). Most (65%) of the vitamin 
D from the fish and fish dishes came from oily fish (Bates et al. 2014). Another survey 




found similar results to the NDNS; vitamin D intake from food sources only was 3.7 
µg/d in men and 2.8 µg/d in women, and this increased to 4.4 µg/d and 4.0 µg/d when 
supplements were included. Meat and meat products were the primary contributors to 
vitamin D intake (30.1%), although fish and fish products (14.3%) and eggs and egg 
dishes (9.1%) were also important. Compared to the above findings, a study in 2235 
healthy adults aged 21-82 y from Scotland found slightly higher vitamin D intakes. The 
mean intake from food sources was 4.7 µg/d in the 74% of participants who did not 
take supplements. When looking at intake from food sources and supplements, the 
mean intakes were 9.8 µg/d in men and 8.1 µg/d in women. Here the most important 
dietary contribution to vitamin D intake was fish, followed by meats, eggs, cakes and 
breakfast cereals (Zgaga et al. 2011). Although the contribution from cakes may be 
partly due to the mandatory fortification of margarine, the contribution of fortified 
foods to dietary vitamin D intake is very small compared to in the US where it is the 
main contributor, mostly as fortified milk (Moore et al. 2005).  
 
Whilst research suggests that UVB exposure contributes more to average vitamin D 
status than diet (Ashwell et al. 2010), the above figures from the different surveys 
show that adults in the UK are not receiving enough vitamin D from the diet based on 
the recommendation of 10 µg/d for those confined indoors or the even higher 15 µg 
RDA in the US (IOM 2011). However, an important question is if dietary intake was 
averaging at 10 µg/d or more, would this actually be enough to produce an adequate 
vitamin D status in the majority of the general population, particularly in the winter 
months when there is very little UVB exposure? In terms of preventing deficiency, 2 
Irish RCTs (Cashman et al. 2008; Cashman et al. 2009) which gave 238 adults aged 20-
40 y and 225 adults aged 64+ y doses of 0, 5, 10 or 15 µg/d vitamin D3 for 22 wk in the 
winter months found that an intake of 9 µg vitamin D/d would be needed to maintain 
winter 25-OH-D concentrations in 97.5% of the population above 25 nmol/L. However, 
to maintain levels at more than 50 nmol/L in 97.5% of the population, it was estimated 
that a much higher intake of 28 µg/d would be needed for adults aged 20-40 y and 25 
µg/d for adults aged 64+ y (Cashman et al. 2008; Cashman et al. 2009).  
 
The fact that dietary requirements for vitamin D vary markedly between different 




variations in UVB exposure means that it is difficult to define recommended intakes. 
Furthermore, the lack of availability of vitamin D in foods makes it difficult to obtain 
even low intakes from the diet, although food fortification and supplementation help 
boost intakes. 
 
1.1.9 Actions and effects of vitamin D 
 Calciotropic 1.1.9.1
The calciotropic actions of vitamin D, as described in section 1.1.3, are fairly well 
established. In its active form, vitamin D causes a number of effects in order to 
maintain adequate concentrations of calcium (Ca2+) and phosphorus (HPO4
2-) in the 
blood to promote mineralisation of the skeleton (McConnell et al. 2009). Initially when 
plasma calcium levels drop in the body, PTH is released leading to the conversion of 
25-OH-D to 1,25(OH)2D which then interacts with the vitamin D receptor-retinoic acid 
x-receptor complex (VDR-RXR). This leads to an increased expression of the epithelial 
calcium channel and calbindin, a calcium binding protein, resulting in an increased 
intestinal absorption of calcium (Holick 2007). An effect on bone resorption occurs 
when the VDR present in osteoblasts (bone-forming cells) recognises 1,25(OH)2D 
causing the cells to increase their expression of the receptor activator of nuclear 
factor-κB ligand (RANKL). RANKL binds to its receptor RANK on preosteoclasts which 
are then converted to mature osteoclasts (bone cells that resorb bone tissue) (Holick 
2007). The increase in PTH also enhances renal reabsorption of calcium and decreases 
phosphorus reabsorption (Holick 2006). In vitamin D deficiency, the absorption of 
calcium and phosphorus from the diet can be reduced to levels of only 10-15% and 50-
60%, respectively, and this can cause rickets in children and osteomalacia in adults 
(Holick 2006). Usually infants and children with rickets have serum 25-OH-D 
concentration <25 nmol/L (Holick 2006). However, this is not always the case as 
African and Bangladeshi children with rickets have been shown to have no evidence of 
vitamin D deficiency (Pfitzner et al. 1998; Fischer et al. 1999). It is thought that rickets 
is occurring in these children due to a low calcium supply which leads to urinary 






Evidence has emerged to suggest potential effects of vitamin D on other aspects of 
health. Studies have shown associations between vitamin D status and cancer, 
autoimmune disease, cardiovascular disease (CVD), infectious diseases, obesity and 
even cognitive function (Wang et al. 2012b; Bolland et al. 2014; Myhr 2009; Annweiler 
et al. 2013; Nnoaham et al. 2008). There are also studies to suggest that 1,25(OH)2D 
stimulates insulin secretion in β cells in the pancreas (Gedik et al. 1986; Kadowaki et al. 
1984). This area of research is expanding and developing but it is unknown as to 
whether vitamin D deficiency is a consequence of, or plays a causal role in disease 
processes. Much of the research stems from the discovery over the last few decades of 
the expression of the VDR and 1α-hydroxylase in different tissue types (Zehnder et al. 
2002; Hewison et al. 2007; Rahman et al. 2007; Wang et al. 2008; Giovannucci 2009). 
The active form of vitamin D, 1,25(OH)2D, produced by the action of 1α-hydroxylase on 
25-OH-D, exerts its effects by binding to the VDR, leading to heterodimerisation of the 
receptor with the retinoid X receptor. This complex then binds to the vitamin D 
response element in the promoter region of target genes, and together with 
transcription factors and co-regulator molecules alters gene expression (Brancaccio et 
al. 2007; Reddy et al. 2010). The vitamin D receptor also activates CYP3A, a 
cytochrome P450 enzyme that detoxifies lithocholic acid in the liver and intestine 
(Makishima et al. 2002) which could explain the relationship with colorectal cancer. 
 
The evidence surrounding an effect of vitamin D on all of the aforementioned 
outcomes is uncertain. For cancer, a few meta-analyses have been conducted of 
prospective studies (Yin et al. 2013; Maalmi et al. 2014; Kim et al. 2014) which suggest 
a modest association between 25-OH-D concentrations and risk of cancer, but a much 
stronger association between serum 25-OH-D and risk of cancer mortality. For CVD, 
meta-analyses of observational studies suggest a significant reduction in CVD risk with 
higher serum 25-OH-D concentrations (Grandi et al. 2010; Parker et al. 2010; Wang et 
al. 2012b). Cross-sectional analyses have found strong associations between 25-OH-D 
concentrations and BMI and obesity (Brock et al. 2010), however, a meta-analysis of 12 
RCTs found that the obesity measures body weight, body mass index (BMI), fat mass, 
percentage fat mass or lean body mass were not influenced by the final vitamin D 




al. conducted a vitamin D supplementation trial sequential meta-analysis looking at 
several outcomes including myocardial infarction or ischaemic heart disease, stroke or 
cerebrovascular disease, and cancer for which there were 9, 8 and 7 RCTs included, 
respectively (Bolland et al. 2014). Thresholds were calculated using a 15% risk 
reduction which was thought to represent the smallest effect that would be clinically 
relevant for an individual. Vitamin D supplementation alone or with calcium did not 
change the relative risk (RR) of any of the aforementioned outcomes by 15% or more; 
for all studies with or without calcium, the RRs (95% CI) were 1.02 (0.93, 1.13) for 
myocardial infarction or ischaemic heart disease, 1.01 (0.90, 1.13) for stroke or 
cerebrovascular disease, and 0.99 (0.93, 1.05) for cancer.  
 
 Vitamin D and mortality 1.1.9.3
A few meta-analyses assessing the effect of vitamin D supplementation on mortality 
have been conducted (Chowdhury et al. 2014; Zheng et al. 2013; Bjelakovic et al. 
2014). One of these, by Bjelakovic et al. was conducted as part of a Cochrane review. 
This included 56 RCTs, 48 of which were in healthy participants, and most of which 
were in women over 70 y of age (Bjelakovic et al. 2014). The mean supplementation 
length was 4.4 y and vitamin D supplementation was found to decrease mortality risk 
(RR, 95% CI 0.97, 0.94-0.99). Zheng et al. conducted another meta-analysis of 42 RCTs 
which suggested that vitamin D supplementation was protective against all-cause 
mortality if given for longer than 3 y (RR, 95% CI 0.95, 0.90-0.98), but was not 
protective if taken for less than 3 y (RR, 95% CI 1.04, 0.97-1.12) (Zheng et al. 2013). The 
RCTs included in this were mostly in older adults aged over 60 y with an age range of 
37-89 y. Supplementation was predominantly in the form of vitamin D3 and ranged 
from 5 μg/d to 5000 μg/wk, although most studies gave at least 20 μg/d and many 
gave a much higher dose. Trials in adults with chronic kidney disease and heart failure 
were included, as were those which gave calcium in addition to vitamin D (Zheng et al. 
2013). The above two meta-analyses and another by Chowdhury et al. (Chowdhury et 
al. 2014) all found D3 to have a greater effect on mortality compared with D2. 
Chowdury et al. included data from 22 RCTs (14 and 8 trials on the effects of D3 and D2 
respectively) and found that the risk of all-cause mortality was 11% lower with D3 
supplementation (RR, 95% CI 0.89, 0.80-0.99), but there were no significant effects of 




confidence intervals overlap those for D3, so no conclusions can be inferred on the 
inferiority of D2. The Cochrane review included 38 trials that reported effects of D3, but 
only 12 that reported the effect of D2. It found significant reductions in mortality after 
D3 supplementation (RR, 95% CI 0.94, 0.91-0.98) but not D2 (RR, 95% CI 1.02, 0.96-
1.08) (Bjelakovic et al. 2014). Comparison of doses of D2 <20 μg/d (RR, 95% CI 0.82, 
0.17-3.98) with doses ≥20 μg/d (RR, 95% CI 1.02, 0.95-1.10) revealed no differences 
but confidence intervals were large and only one D2 study used a dose of <20 μg/d. For 
D3, although there were no significant differences between the effects of the high and 
low doses, doses of <20 μg/d showed a reduction in mortality (RR, 95% CI 0.92, 0.87-
0.97) whereas doses ≥20 μg/d did not (RR, 95% CI 0.96, 0.92-1.00) (Bjelakovic et al. 
2014). In summary, it seems that there may be a risk-reducing effect of vitamin D on 
mortality in the older population, but in order to determine whether this effect occurs 
solely in the elderly, and whether only D3, or both forms have an effect, more well-
conducted RCTs are needed, particularly those using D2. Furthermore, the majority of 
RCTs have used high dose supplementation and there are fewer studies examining the 
effect of doses in line with recommendations. 
 
1.2 Cardiovascular Disease 
The focus of this thesis is the non-calciotropic effects of vitamin D and their 
relationship to CVD. A common feature to most CVD is atherosclerosis and the 
consequences of atherosclerotic plaque rupture leading to vessel occlusion or 
aneurism resulting in haemorrhage. The sequence of events in atherosclerosis are 
depicted in Figure 1.5 (Frayn 2005; Libby et al. 2011). Atherosclerosis develops over 
many decades without any overt symptoms and the clinical horizon where CVD events 
occur is usually in the fifth decade of life and beyond. It is nodular hardening of large 
to medium size arteries that is characterised by the accumulation of lipids derived 
from low density lipoprotein cholesterol (LDL-C) in the sub-endothelial intima. Picture 
a shows a normal healthy artery which consists of three layers; the tunica intima is the 
inner layer facing the blood which contains smooth muscle cells (SMCs) and is lined by 
a monolayer of endothelial cells (Libby et al. 2011). The middle layer, the tunica media, 
is also made up of SMCs and these are embedded in an extracellular matrix. The 
adventitia is the outer layer which contains mast cells, nerve endings and microvessels. 




adhere to the endothelial cells and migrate into the intima layer along with LDL-C 
particles which become oxidised (Libby et al. 2011; Sherer et al. 2006). In the intima, 
monocytes differentiate into macrophages that take up oxidised LDL-C and become 
foam cells (Sherer and Shoenfeld 2006). Accumulation of foam cells in the arterial wall 
forms fatty streaks which are the first visible stage in atherosclerosis (Frayn 2005). 
Apoptosis of foam cells appears to be a critical phase in the development of 
atherosclerotic plaques. As the atherosclerotic lesion progresses (picture c), SMCs in 
the media migrate into the intima via the actions of matrix-metalloproteinase-9 (MMP-
9) and other proteinases which help degrade the extracellular matrix. Proinflammatory 
cytokines and growth factors produced by foam cells result in proliferation of these 
SMCs (Packard et al. 2008) which secrete extracellular matrix macromolecules 
including collagen and elastin. As the atherosclerotic lesion advances, some 
macrophages and SMCs in the plaque die by apoptosis and a lipid core forms as 
extracellular lipid from these dead or dying cells builds up in the centre of the plaque. 
If the fibrous cap of the plaque remains firm it does not cause acute damage, only 
obstruction to blood flow (Frayn 2005). Alternatively, the cap can be weakened and 
made rupture prone. For example, inflammatory cytokine production can stimulate 
macrophages to express collagenases which break down collagen in the fibrous cap. It 
can also lead to apoptosis of the plaque’s smooth muscle cells which are important for 
the repair and maintenance of the fibrous cap (Libby 2001). Furthermore, 
macrophages in the vessel wall secrete metalloproteinases (such as MMP-9) and 
cathepsins which can destabilise the fibrous cap. If the cap fractures (picture d) a 
thrombus forms as coagulation components in the blood make contact with tissue 
factors inside the plaque, and this has the potential to suddenly obstruct arterial blood 









1.3 Vitamin D and Cardiovascular Disease 
Ecological data was initially the basis for suggesting a potential association between 
vitamin D and CVD. Higher latitudes experience greater CVD mortality than lower 
latitudes (Zittermann et al. 2005), there is an inverse relationship between altitude and 
CVD mortality (Mortimer et al. 1977), and there is a greater CVD mortality in the 
winter months compared to late summer and early autumn (Douglas et al. 1991). In 
the UK, CVD prevalence is generally higher in the north of the UK especially the rural 
areas of Scotland compared with southern England (Elford et al. 1989). Scragg et al. 
hypothesised in 1981 that this variation in CVD mortality could be due to variations in 
UV exposure which influences production of vitamin D, and that vitamin D may be 
having a protective effect against CVD (Scragg 1981). However, it could also be argued 
that cold weather increases risk of CVD as it increases BP (Brennan et al. 1982). Since 
then, observational studies have found inverse associations between vitamin D status 
and cardiovascular outcomes/CVD risk (Kendrick et al. 2009; Kim et al. 2008; Kilkkinen 
et al. 2009). For example, the third National Health and Nutrition Examination Survey 
(NHANES) (1988-1994) that included 16,603 men and women aged >18 y found that 
participants with 25-OH-D deficiency (defined as serum concentrations <50 nmol/L) 
had an increased risk of prevalent CVD (OR 1.20, 95% CI 1.01-1.36) (Kendrick et al. 
2009) comapred to those who were not deficient. In addition, Anderson et al. 
prospectively analysed data from an electronic medical records database for 41,504 
subjects and found strong associations between serum 25-OH-D concentrations and 
incident heart failure, coronary artery disease/myocardial infarction (all P<0.0001) and 
stroke (P = 0.003) (Anderson et al. 2010). Several systematic reviews of observational 
studies have been published (Grandi et al. 2010; Parker et al. 2010; Pittas et al. 2010; 
Wang et al. 2012b).  Wang et al. conducted the most recent of these in which 19 
prospective studies up until February 2012 were included, with 6123 CVD cases in 
65,994 participants (Wang, et al. 2012b). Comparing the lowest study-defined 25-OH-D 
category with the highest, the pooled relative risks (95% CIs) for total CVD, CVD 
mortality, CHD and stroke were 1.52 (1.30-1.77), 1.42 (1.19-1.71), 1.38 (1.21-1.58) and 
1.64 (1.27-2.10) respectively. A regression analysis determined that the increment in 
CVD risk with decreasing 25-OH-D concentrations was generally linear for serum 25-
OH-D levels between 20 and 60 nmol/L, but that above 60 nmol/L there were only a 




et al. 2012b). Two other meta-analyses that only included studies up until 2009 found 
a greater risk of incident CVD, CVD mortality (Grandi et al. 2010), and prevalent 
cardiometabolic disorders (Parker et al. 2010; Grandi et al. 2010) in participants with 
lower 25-OH-D concentrations. An umbrella review of the above meta-analyses 
summarised the findings and showed that the greatest effect of serum 25-OH-D 
concentrations was on CVD mortality compared to prevalent and incident CVD 
(Theodoratou et al. 2014). However, despite these observational findings, causality 
cannot be assumed. 
 
Although there have been relatively few trials investigating the effect of vitamin D 
supplementation on CVD, three meta-analyses of RCTs have been conducted (Bolland 
et al. 2011; Bolland et al. 2014; Myung et al. 2013). Bolland et al. reanalysed data from 
the Women’s Health Initiative Calcium/Vitamin D supplementation (WHI CaD) trial, a 7 
year study in which 36282 community dwelling postmenopausal women were 
randomly assigned to placebo or a calcium and vitamin D supplement (containing 500 
mg calcium and 5 µg vitamin D3) twice daily (Bolland et al. 2011; Hsia et al. 2007). Data 
from this trial were combined with that from two other trials (Grant et al. 2005; Lappe 
et al. 2007) in a meta-analysis which showed that calcium and vitamin D increase the 
risk of myocardial infarction (RR = 1.21, P=0.04) and stroke (RR = 1.20, P=0.05) (Bolland 
et al. 2011). Myung et al. (Myung et al. 2013) conducted a meta-analysis of RCTs that 
as well as trials of only vitamin D, also included those that gave other vitamins (Mark et 
al. 1996) or calcium in addition to vitamin D (Brazier et al. 2005; Hsia et al. 2007; 
Berggren et al. 2008; Prince et al. 2008). After the inclusion of 7 RCTs (Mark et al. 
1996; Komulainen et al. 1999; Trivedi et al. 2003; Brazier et al. 2005; Hsia et al. 2007; 
Berggren et al. 2008; Prince et al. 2008), it was concluded that there was no effect of 
vitamin D supplementation on major CVD events (RR 1.02, 95% CI 0.98, 1.07). This was 
the case for low dose (2 trials) and high dose (5 trials) supplementation, whether 
vitamin D was given singly (2 trials) or in combination with other supplements (5 trials), 
and for the outcomes CVD mortality (3 trials), MI (2 trials), and stroke (5 trials) (Myung 
et al. 2013). However, in the two meta-analyses described above, it is not possible to 
disaggregate the calcium/vitamin D effects. If calcium has a negative effect on CVD, it 
may be masking a potential protective effect of vitamin D. The most recent meta-




analyses to assess the effect of vitamin D alone (this included studies that had given 
the same calcium supplement to both treatment groups) and vitamin D with or 
without calcium. For both, there were no significant results for MI or ischaemic heart 
disease, or for stroke or cerebrovascular disease. When all trials were combined, the 
relative risks (95% CI) were 1.02 (0.93, 1.13) for the former outcome (nine trials, 
48,647 patients) and 1.01 (0.90, 1.13) for the latter outcome (eight trials 46,431 
patients) (Bolland et al. 2014).  
 
In summary, the observational evidence suggests an association between vitamin D 
status and CVD, but the evidence from meta-analyses of RCTs does not show a benefit 
of vitamin D supplementation on CVD.  
 
1.4 Vitamin D and CVD risk factors/factors associated with the development of 
CVD 
It is difficult and costly to study CVD as an endpoint in primary prevention because of 
the large number of people and the long follow-up period required. Furthermore, it is 
uncertain what dose level should be chosen. This is important because if the level is 
too low it will lack efficacy and if it is too high there is a risk of toxicity. As a prelude to 
any intervention it is worthwhile assessing the effects of vitamin D on surrogate 
markers of CVD risk rather than disease endpoints. Such an approach is more feasible 
and also facilitates the investigation of possible mechanisms by which vitamin D may 
influence CVD risk.  The following section reviews the effects of vitamin D status on 
CVD risk factors and factors associated with the development of CVD. 
 
1.4.1 Established risk factors and factors associated with the development of CVD 
There are several well-established and conventional CVD risk factors including 
hypercholesterolaemia, dyslipidaemia (atherogenic lipoprotein phenotype), elevated 
BP, and type 2 diabetes which is preceded by insulin resistance. HsCRP, an acute phase 
reactant, and fibrinogen, a plasma glycoprotein involved in clot formation, have also 
been shown to be important in predicting risk of CVD (Torres and Ridker 2003; Kaptoge 







The progression of atherosclerotic disease is mediated by circulating blood lipids 
(Quinn et al. 1987; Frostegard et al. 1990). Initial studies investigating effects on CVD 
risk have focused on elevated total cholesterol (TC) and LDL-C. Familial 
hypercholesterolaemia which is an autosomal dominant inherited disorder affecting 
1:500 people is associated with a hugely increased risk of CVD under the age of 50 y 
(Austin et al. 2004). More moderate elevations of total and LDL-C are prevalent in the 
general population over the age of 50 in the UK and confer substantial risk. However, 
low concentrations of high density lipoprotein (HDL-C) are also strongly associated 
with risk (Boden 2000) and the Prospective Triallist Collaboration found the ratio of 
total cholesterol:HDL-C (TC:HDL) ratio in particular to be up to twice as informative as 
other lipid metrics of CVD (Lewington et al. 2007).  
 
Cross-sectional studies have suggested an association between vitamin D and HDL-C 
(Maki et al. 2009) and triglycerides (Ford et al. 2005; Hypponen et al. 2008), but two 
meta-analyses of randomised trials suggest little, or no effect of vitamin D 
supplementation on lipid fractions (Elamin et al. 2011; Wang, et al. 2012a). Elamin et 
al. included 11-12 randomised trials which predominantly gave D3 as the form of 
supplementation and were mostly in older adults. Not every study was placebo-
controlled, but all had a comparison group that was not receiving the intervention. No 
significant differences between treatment groups were found for changes in total 
cholesterol (TC), triglycerides, LDL-C or HDL-C (P=0.25-0.91). (Elamin et al. 2011). 
Another meta-analysis by Wang et al. was conducted a year later in 2012 (Wang et al. 
2012a). This found LDL-C to significantly increase with vitamin D supplementation 
(pooled mean net change 0.084 mmol/L, 95% CI 0.014, 0.153) and this was strongest in 
studies in obese people (0.090 mmol/L, 95% CI 0.004, 0.099) and those of less than 1 y 
duration (0.097 mmol/L, 95% CI 0.015, 0.179). No treatment effects were found for TC, 
HDL-C or triglycerides, apart from in studies lasting longer than 1 y for which there was 
a significant reduction in HDL-C concentrations (-2.01 mg/dl, -3.83 to -0.18). A total of 
12 RCTs with data on 1346 participants were included in this meta-analysis and the age 
range was 18-80 y, although the majority of studies were in older adults. Most studies 
(7) gave D3, only one used D2, and the remaining studies supplemented with alpha-




between 7.5 and 83 μg/d, but the majority of studies gave pharmacological doses such 
as a weekly dose of 1000 μg D3 (Jorde et al. 2010a). However, the heterogeneity of the 
studies included in the meta-analysis, and their lack of power to detect a change in 
lipid concentrations mean the evidence is inconclusive regarding an effect of vitamin D 
supplementation on lipids (Wang et al. 2012b).  
 
 Blood pressure 1.4.1.2
BP is linearly associated with risk of CVD (Lewington et al. 2007). Most studies report 
clinic BP, which is measured seated with the subject at rest to yield systolic (SBP) and 
diastolic (DBP) BP. British Hypertension Society Guidelines recommend taking three 
measures, discarding the first and taking the average of the two (O'Brien et al. 2001), 
but BP can vary during the day (Mancia et al. 2007). More recent guidelines 
recommend that if clinic BP is more than a SBP/DBP of 140/90 mm Hg, 24 h 
ambulatory BP (ABP) monitoring should be used to confirm the diagnosis of 
hypertension as a day-time average SBP/DBP ≥ 135/90 mm Hg (National Institute for 
Health and Clinical Excellence 2011). 24 h ABP has been shown to be better at 
predicting cardiovascular risk compared with clinic BP (Mancia et al. 2007; Staessen et 
al. 1999). Furthermore, evidence has demonstrated that it is able to more accurately 
measure the size of reduction in BP brought about by a treatment compared to clinic 
BP, due to the results being more reproducible over time (Coats et al. 1992), and the 
unlikelihood of a ‘white coat’ or placebo effect (Mancia et al. 2007; Mancia et al. 
1995).  
 
Many observational studies have investigated a possible association between vitamin 
D status and BP and their results have been summarised in a meta-analysis by Burgaz 
et al. which included 4 prospective and 14 cross-sectional studies. All studies either 
diagnosed hypertension using office BP or used self-reported data; they did not 
measure ABP (Burgaz et al. 2011). The pooled odds ratio (OR) for hypertension in 
participants in the highest 25-OH-D category compared with those in the lowest 
category was 0.73 (95% CI 0.63, 0.84) (Burgaz et al. 2011).  
 
A number of RCTs have looked at changes in BP, primarily as seated BP in response to 




al. 2013; Jorde et al. 2010a; Muldowney et al. 2012; Nagpal et al. 2009; Witham et al. 
2010; Wood et al. 2012). Only a few trials have used ABP monitors (Judd et al. 2010; 
Larsen et al. 2012; Witham et al. 2013c; Witham et al. 2014) (Table 1.4) and these 
were in participants who had hypertension (Witham et al. 2013c; Witham et al. 2014; 
Judd et al. 2010; Larsen et al. 2012) or had previously suffered from a stroke (Witham 
et al. 2012). None showed a significant difference in the change in BP between 
treatment and placebo groups after treatment with vitamin D3 (Judd et al. 2010; Larsen 
et al. 2012; Witham et al. 2012; Witham et al. 2013c; Witham et al. 2014)  or vitamin 
D2 (Witham et al. 2012). Several meta-analyses of RCTs investigating the effect of 
vitamin D supplementation on BP have been published (Pittas et al. 2010; Elamin et al. 
2011; Witham et al. 2009; Wu et al. 2010; Kunutsor et al. 2014). Most of these have 
concluded that there is no significant effect of vitamin D on SBP or DBP (Pittas et al. 
2010; Elamin et al. 2011; Kunutsor et al. 2014). However, one meta-analysis that 
included 8 RCTs found a significant decrease in DBP (-3.1 mm Hg, 95% CIs –5.5 to -0.6), 
(Witham et al. 2009). By contrast, Wu et al. in a meta-analysis of 4 RCTs observed that 
vitamin D supplementation decreased SBP by 2.44 mm Hg (Weighted mean difference 
-2.44, 95% CI -4.86, -0.02), but had no significant effect on DBP (Wu et al. 2010). Both 
these meta-analyses were limited by the small size of the studies included and 
significant heterogeneity between studies. Kunutsor et al. performed the most recent 
meta-analysis of 16 studies aiming to investigate the effects of oral vitamin D 
supplementation alone and found no significant treatment effects; weighted mean 
differences (95% CIs) were -0.94 (-2.98, 1.10) mm Hg and -0.52 (-1.18, 0.14) mm Hg for 
SBP and DBP, respectively (Kunutsor et al. 2014).  
 
Although the above demonstrates that the evidence is uncertain with regards to an 
association between vitamin D and BP, mechanisms have been suggested for a 
possible link between the two. It has been shown that vitamin D in its active form 
(1,25(OH)2D) is a negative endocrine regulator of the renin-angiotensin system (RAS) 
(Li et al. 2004) which is a regulatory cascade essential for the long-term control of BP, 
electrolyte levels, and volume homeostasis (Jeunemaitre et al. 1992; Li 2003). Renin is 
a rate-limiting component of this system which acts to cleave angiotensin I (Ang I) from 
angiotensinogen, and it is suppressed when there is an increase in 1,25(OH)2D 




blood vessels to constrict, resulting in an increased BP (Li 2003; Li et al. 2004). Li et al. 
found a several-fold increased expression of renin and production of angiotensin II in 
VDR-null mice. They also found evidence that this led to hypertension and cardiac 
hypertrophy (Li et al. 2002). Another possible mechanism for an effect of vitamin D on 
BP is via changes in PTH. PTH has been found in vascular endothelium and smooth 
muscle cells (Fitzpatrick et al. 2008) which would allow for it to have direct regulatory 
effects on the vessel wall (Larsen et al. 2012). Further, observational studies have 
found a positive association between parathyroid hormone and both SBP and DBP 
(Snijder et al. 2007), and PTH intravenous infusion has been shown to increase BP in 
normal subjects (Hulter et al. 1986). A different suggested mechanism is via direct 
effects of 1,25(OH)2D on the vasculature. This is supported by the expression of 1α-
hydroxylase in endothelial cells and evidence that 1,25(OH)2D may affect vascular 


















age y  
Duration 
of study 
Mean baseline and follow-up 
25-OH-D in nmol/L  
Effect of treatment vs. control 
Treatment Control 




Black or African American 
adults with 25(OH)D 25 - 75 
nmol/L, and SBP 130 - 150 
mm Hg. 
5000 µg vitamin D3 
weekly for 3 wk, 0.5 
µg 1,25(OH)2D  
twice daily for 1 wk, 
or placebo 
7 47 3 wk 46 in 
1,25(OH)2D 
group and 24 
in D3 group  
27 No treatment effect for D3 group. 
1,25(OH)2D group experienced a 
9% decrease in mean SBP 
compared with placebo (P<0.001) 
but this was not sustained 1 wk 




Hypertensive adults with 
24h SBP ≤150 mm Hg 
and/or 24 h DBP ≤95 mm 
Hg  
75 µg/d vitamin D3 
or placebo 
112 61 20 wk 57 to 110 57 to 50 No significant treatment effects. 
Between group differences: SBP -3 
mm Hg (P=0.26), DBP -1 mm Hg 
(P=0.18)   
Witham et 
al. (2012) 
Stroke patients Single oral dose of 
2500 µg D2 at 
baseline or placebo 
55 67 16 wk 59  to 51  38 to 40  No significant treatment effects at 
8 wk or 16 wk. At 8 wk  between 
group differences:  -0.7 mm Hg 
(95% CI -5.5, 4.2) for SBP and -1.1 
mm Hg (95% CI -4.1, 1.8) for DBP 
Witham et 
al. (2013c) 
Older patients with SBP > 
140 mm Hg and DBP < 90 
mm Hg 
2500 µg D3 every 3 
mo or placebo 
142 77 1 y 45 to 70 45 to 52 No significant treatment effects. 
Between group differences: SBP 0 
mm Hg (95% CI -2 ,2), DBP 0 mm 
Hg (95% CI -1, 2) 
Witham et 
al. (2014) 
Patients with hypertension 
resistant to conventional 
treatment 
2500 µg vitamin D3 
every 2 mo or 
placebo 
61 63 6 mo 41 to ? 42 to ? No significant treatment effects.  
Between group differences: SBP 
+3 mm Hg (95% CI -4 ,11), DBP -2 




 Insulin resistance 1.4.1.3
Insulin resistance is associated with increased CVD risk (Rader 2007); it is characterised 
by elevated fasting insulin concentrations and is strongly associated with obesity (Kahn 
et al. 2000). Several large epidemiological studies have found 25-OH-D concentrations 
to be associated with improved insulin resistance and sensitivity (Chiu et al. 2004; 
Kayaniyil et al. 2010; Liu et al. 2009). However RCTs have found mixed results; some 
have found a significant beneficial effect of supplementation (Nagpal et al. 2009; 
Nikooyeh et al. 2011; von Hurst et al. 2010) whilst others have shown no effect (Jorde 
et al. 2010a; Patel et al. 2010). A RCT in 100 apparently healthy, but centrally obese 
men observed an improvement in postprandial insulin sensitivity measured by the oral 
glucose insulin sensitivity index (OGIS) after supplementation with 3000 µg D3 once a 
fortnight for 6 wk (mean difference in change in OGIS between placebo and the D3 
group was 41.1 ± 15.5, P=0.01) (Nagpal et al. 2009). Similarly, Nikooyeh et al. 
conducted a 12 wk D3 supplementation trial in 90 diabetic subjects and showed a 
significant decrease in the homeostasis model assessment of insulin resistance 
(HOMA-IR) after 25 µg/d D3  compared to placebo (P<0.001). In contrast to these 
findings, a RCT of 438 overweight or obese subjects found no significant difference in 
insulin sensitivity in the fasting state from baseline to 1 y between the placebo group 
and two D3 groups that received either 500 µg or 1000 µg/wk (Jorde et al. 2010a). 
Furthermore, 10 or 30 µg/d D3 did not lead to significant improvements in insulin 
sensitivity in a 4 month RCT of patients with type 2 diabetes (Patel et al. 2010).  
 
A meta-analysis has been published to summarise the effects of vitamin D 
supplementation on glycaemic control and insulin resistance (George et al. 2012). For 
insulin resistance, 11 studies were included, 4 of which were in individuals with normal 
fasting glucose and 6 in individuals with abnormal glucose tolerance. When all 11 
studies were combined there was no effect of vitamin D supplementation on insulin 
resistance; the standard mean difference favouring vitamin D supplementation was       
-0.07 (95% CIs -0.20, 0.06). This was also the case when looking at only patients with 
normal fasting glucose, but in patients with diabetes or impaired glucose tolerance, 
there was a small improvement in insulin resistance (standard mean difference 





Several mechanisms have been suggested as to how vitamin D may affect insulin 
sensitivity and release. Receptors for 1,25(OH)2D and 1α-hydroxylase have been found 
in pancreatic β cells (Bland et al. 2004) and 1,25(OH)2D may either directly alter insulin 
action at the level of the adipocyte, or increase insulin release from pancreatic β cells 
(Teegarden et al. 2009). Vitamin D may also influence insulin resistance through its 
effects on PTH. PTH has been implicated in impaired insulin release from β cells (Fadda 
et al. 1990) and it may cause a decrease in insulin signalling and reduced insulin 
sensitivity (Teegarden and Donkin 2009). Alternatively, insulin secretion may be 
effected by changes in the balance between extracellular and intracellular pools of 
calcium as insulin secretion is a calcium dependent process and vitamin D influences 
the absorption of calcium from the small intestine (Pittas et al. 2007b).  
 
 C-reactive protein 1.4.1.4
Inflammation plays an important pathogenic role in all stages of atherosclerosis (Ross 
1999). Currently, the best available inflammatory biomarker is C-reactive protein 
(CRP), an acute phase reactant which is a reliable, independent predictor of the risk of 
myocardial infarction (MI), stroke and cardiovascular death (Torres and Ridker 2003). 
CRP is a member of the pentraxin family as it is made up of a central pore surrounded 
by 5 symmetrically arranged non-covalently associated protomers. It is produced in the 
liver and is primarily under the control of interleukin-6 (IL-6) which increases its 
hepatic synthesis and secretion (Jialal et al. 2004). In endothelial cells, CRP has been 
shown to decrease nitric oxide production (Venugopal et al. 2002). Other effects in 
monocyte-macrophages include the induction of tissue factor secretion (Cermak et al. 
1993), increased production of reactive oxygen species (Tebo et al. 1991) and 
increased release of proinflammatory cytokines (Ballou et al. 1992). 
 
Cross-sectional studies have shown conflicting results as to whether vitamin D has an 
effect on CRP levels with some showing an inverse association between the two (Amer 
et al. 2012; Ngo et al. 2010), some finding that adjustment for adiposity (Hypponen et 
al. 2010) or BMI (Jorde et al. 2007) removed initial inverse associations, and others 
finding no association (Michos et al. 2009). Clinical trials also show inconsistent results; 
some find no effect of supplementation on CRP levels (Asemi et al. 2013a; Belenchia et 




2010; Wood et al. 2012; Yiu et al. 2013; Zittermann et al. 2009), but decreases in CRP 
have been found following vitamin D supplementation in others (Asemi et al. 2013b; 
Timms et al. 2002; Witham et al. 2013b). Witham gave patients with a history of MI 
2500 µg D3 or placebo at baseline, 2 months and 4 months and found that at 6 months 
CRP had decreased significantly in the D3 group compared to placebo (-1.3 vs. 2.0 
mg/L, P=0.03) (Witham et al. 2013b). Similarly, a significant decrease in high sensitivity 
C reactive protein (hsCRP) concentrations was observed after 9 wk of 10 µg/d D3 (-1.41 
± 0.55 mg/L), compared to placebo (1.50 ± 0.94 mg/L) (P = 0.01) in 48 pregnant women 
aged 18 to 40 y at week 25 of gestation (Asemi et al. 2013b). In contrast, two larger 
placebo-controlled RCTs that supplemented type 2 diabetic patients with 125 µg/d 
vitamin D3 for 12 wk (Yiu et al. 2013), or overweight and obese subjects with 1000 or 
500 µg D3/wk for 1 y (Jorde et al. 2010b), found no significant difference in the change 
in hsCRP between groups. After smaller vitamin D3 doses of 10 or 25 µg/d for 1 y 
(Wood et al. 2012), or 5, 10 or 15 µg/d for 22 wk in healthy young and older adults 
(Muldowney et al. 2012), hsCRP levels were unaffected. Whilst there is significant 
heterogeneity between published trials due to differences in baseline hsCRP 
concentrations, dose of vitamin D and duration of the trials, a meta-analysis has found 
that vitamin D supplementation significantly reduces hsCRP by 1.08 mg/L (95% CI -
2.13, -0.03) (Chen et al. 2014). This included 10 RCTs in 924 participants published 
between 2009 and 2014. The median dose of vitamin D was 100 µg/d with a range of 
10 to 179 µg/d. Participants who had higher baseline hsCRP levels of ≥5 mg/L had a 
greater reduction of 2.21 mg/L (95% CI -3.50, -0.92) in hsCRP after supplementation.  
 
Mechanisms as to how vitamin D may affect CRP levels are uncertain, but experimental 
studies have shown that treatment with 1,25(OH)2D inhibits the production of several 
other pro-inflammatory cytokines such as interleukin – 6 (IL-6) (Talmor et al. 2008; 
Muller et al. 1992) and tumour necrosis factor-α (TNF-α) (Muller et al. 1992; Cohen-
Lahav et al. 2007) and down-regulates IL-10 expression via the binding of VDR to the 
promoter region of the IL-10 transcription start site (Matilainen et al. 2010). In mice 
models, deficiency of vitamin D and the VDR has been shown to lead to the 
acceleration of certain autoimmune diseases such as inflammatory bowel disease (IBD) 
(Cantorna et al. 2004) suggesting that vitamin D may modulate the expression of 





Fibrinogen is involved in a coagulation cascade that helps to arrest bleeding in 
response to vascular injury, but when disrupted can lead to thrombosis and bleeding 
(Borissoff et al. 2011). It is an acute phase protein and it is thought that high 
concentrations may directly promote atherogenesis or thrombosis, or increase the risk 
of thrombosis though effects on platelet aggregation, viscosity, fibrin (an insoluble 
protein essential in the clotting process and formed from fibrinogen by the action of 
thrombin), and/or clot deformability (Meade 1997). In 1964, experiments using pig’s 
plasma demonstrated that fibrinogen was an essential cofactor in platelet aggregation 
(Born et al. 1964), and since then, human studies have found positive associations 
between plasma fibrinogen concentrations and platelet aggregation (Lowe et al. 1979; 
Meade et al. 1985) which may promote platelet thrombus formation (Lowe 1995). 
Fibrinogen is a large, elongated molecule that increases blood viscosity, and studies 
looking at arterial disease as an outcome that have shown associations with plasma 
fibrinogen have also shown an association with plasma and blood viscosity (Lowe et al. 
1993; Yarnell et al. 1991). Large prospective studies such as the Northwick Park Heart 
Study (NPHS) and Prospective Cardiovascular Munster (PROCAM) Study have found 
fibrinogen concentrations to be strongly and independently associated with a higher 
risk of CVD death and fatal and non-fatal ischaemic heart disease (Meade et al. 1980; 
Meade et al. 1986; Heinrich et al. 1994), and this finding has been supported further 
by a meta-analysis of 31 prospective studies which found that for every 1g/L increase 
in usual fibrinogen, the age- and gender- adjusted hazard ratio was 2.42 (95% CI 2.24, 
2.60) for CHD, 2.06 (95% CI 1.83, 2.33) for stroke, and 2.76 (95% CI 2.28, 3.35) for other 
vascular mortality (Danesh et al. 2005).  
 
Several cross-sectional studies have investigated whether vitamin D is associated with 
fibrinogen concentrations in humans and found inconsistent results. Some have found 
significant inverse associations between the two (Parikh et al. 2012; Targher et al. 
2006; Landin-Wilhelmsen et al. 1995) whilst others (Shea et al. 2008; Hypponen et al. 
2010), including the Framingham Offspring Study (Shea et al. 2008) of 1381 subjects 
found no association (Hypponen et al. 2010). There are few published trials 
investigating the association between vitamin D and fibrinogen. Bjorkman et al. in 




randomised to receive 10 µg/d or 30 µg/d vitamin D3, or placebo for 6 months. A 
significant increase in 25-OH-D concentrations was found in the supplementation 
groups, but the changes in fibrinogen were insignificant (Bjorkman et al. 2009). 
Similarly a 12 wk trial in 90 type 2 diabetes patients found no significant differences in 
the change in fibrinogen between groups that received 25 µg/d D3 or placebo in a 
yoghurt drink (P=0.357) (Neyestani et al. 2012). There is a clearly a need for further 
studies to investigate the potential association between vitamin D and fibrinogen.  
 
1.4.2 Novel factors associated with the development of CVD 
Other factors have more recently been found to be strongly predictive of 
cardiovascular events including endothelial function measured using flow mediated 
dilation (FMD) of the brachial artery, and arterial stiffness, most reliably measured by 
determining the carotid-femoral aortic pulse wave velocity (PWVc-f) (Green et al. 2011; 
Yeboah et al. 2007; Mattace-Raso et al. 2006; Terai et al. 2008). Furthermore, there is 
evidence that MMP-9, which is involved in the pathogenesis of atherosclerotic lesions 
(Siefert et al. 2012) may be a novel marker of CVD mortality in patients with coronary 
artery disease (Blankenberg et al. 2003) and that Factor VII (FVII), which together with 
tissue factor initiates the coagulation cascade (Borissoff et al. 2011) is associated with 
an increased risk of CVD mortality (Meade et al. 1986). The possible association that 
vitamin D may have with the above factors will be discussed in this section. 
 
 Markers of vascular function 1.4.2.1
The relatively small number of clinical trials that have been conducted to investigate 
the effect of vitamin D supplementation on endothelial function and arterial stiffness 
in people without pre-existing CVD are summarised in Table 1.5. Sections 1.4.2.1.1 and 
1.4.2.1.2 will provide more detail on these markers and their potential associations 




Table 1.5 Summary of clinical trials investigating the effect of vitamin D supplementation on endothelial function measured using flow 
mediated dilation (FMD) and arterial stiffness measured as pulse wave velocity (PWV) in individuals without pre-existing CVD. 
Study Population 
Characteristics 




age y  
Duration 
of study 











(boys and girls) 
Experimental group 
receiving 50 µg D3/d 
or control group 
receiving 10 µg/d 
44 16 16 wk 33 to 86  34 to 60  Arterial 
stiffness 





with serum 25-OH-D 25-
150 nmol/L 
Placebo or 62.5 µg 
D3/d  





American men and women 
Placebo or 1500 µg 
monthly oral vitamin 
D3 




Hypertensive men and 
women 
Placebo or 75 µg 
vitamin D3/d 




Men and women with type 
II diabetes mellitus and 
serum 25-OH-D <50 
nmol/l. 
Placebo or single oral 
dose of 2500 µg 
vitamin D2. 




†Values are means. ‡Compared to baseline value. 
Study Population 
Characteristics 




age y  
Duration 
of study 












Healthy men and 
women 
Treatment group with 25-OH-
D<25 nmol/l  7500 µg D3 intra-
muscularly monthly for 3 mo, 
or control group with 25-OH-D 
≥ 75 nmol/L no 
supplementation 





Men and women with 
type 2 diabetes and 
baseline 25-OH-D<100 
nmol/l 
Placebo, or two treatment 
groups receiving a single dose 
at baseline of either 2500 µg 
or 5000 µg D3 
58 66 16 wk 41 to 59 in the 
2500 µg group and 
48 to 76 in the 
5000 µg group 




Healthy South Asian 
women with baseline 
25-OH-D<75 nmol/L 
Placebo or single oral dose of 
2500 µg D3 at baseline 
49 41 8 wk 27 to ?. Sig. ↑ at 8 
wk in comparison 
to placebo (10 
nmol/L, 95% CI 6, 
14) 
27 to ? FMD, PWV None 
Yiu et al. 
(2013) 
Men and women with 
type 2 diabetes and 
serum 25-OH-D levels 
<75nmol/L 




1.4.2.1.1 Endothelial function 
Disruption of the functional integrity of the vascular endothelium is an important 
process in the development of atherosclerosis (Bonetti et al. 2003). Normal functioning 
of the endothelium is dependent on the bioavailability of the vasodilator nitric oxide 
(NO) and the capacity of the vascular endothelium to synthesise NO, which appears to 
have both anti-thrombotic and anti-atherosclerotic properties (Bonetti et al. 2003). NO 
is produced from the amino acid L-arginine via the action of endothelial nitric oxide 
synthase (eNOS) expressed by the endothelium (Figure 1.6) (Griendling and Fitzgerald 
2003). Cofactors involved in this process include calmodulin and reduced nicotinamide 
dinucleotide phosphate (NADPH). The release of NO activates guanylate cyclase in 
smooth muscle cells resulting in an increased production of cyclic guanosine 
monophosphate (cGMP) and a decrease in intracellular calcium (Behrendt and Ganz 
2002). This has the effect of relaxing the smooth muscle cells and causing vasodilation. 
In endothelial dysfunction, impairment of endothelium-dependent vasodilation occurs 
due to a decrease in the bioavailability of vasodilators including nitric oxide (NO), and 
an increase in endothelium-derived contracting factors (Griendling and FitzGerald 
2003). Endothelial dysfunction results in an increased production of inflammatory 
cytokines which lead to the initiation and progression of atherosclerotic lesions and 
later contribute to plaque instability and rupture (Behrendt and Ganz 2002). 
Endothelial function can be measured using flow mediated dilation (FMD) of the 
brachial artery, a method which in humans has been shown to represent endothelium-
derived nitric oxide (NO) bioavailability (Green et al. 2014). FMD involves measuring 
the dilation of the brachial artery in response to occlusion-induced increased blood 
flow (hyperaemia) caused by deflation of a cuff on the forearm after occlusion at 
suprasystolic BP. It is regarded as a reliable in vivo, non-invasive measurement of 
endothelial function (Uehata et al. 1997; Donald et al. 2008) and has been found to be 
strongly predictive of cardiovascular events in patients at moderate to high risk of CVD 







Figure 1.6 The Nitric Oxide signalling pathway adapted from (Behrendt and Ganz 
2002). BH4, tetrahydrobiopterin; cGMP, cyclic guanosine monophosphate; eNOS, 
endothelial nitric oxide synthase; GC, guanylate cyclise; GTP, guanosine triphosphate; 
NADPH reduced nicotinamide-adenine dinucleotide phosphate and NO, nitric oxide. 
 
The association between vitamin D status and endothelial function is a relatively new 
area of research. In the last few years cross-sectional studies have been published 
which have shown lower serum levels of 25-OH-D to be associated with increased 
endothelial dysfunction in healthy adults (Al Mheid et al. 2011; Jablonski et al. 2011). 
In addition, several clinical trials have been conducted to investigate effects of vitamin 
D supplementation on FMD (Table 1.5). Some show an improvement (Tarcin et al. 
2009; Harris et al. 2011; Sugden et al. 2008) whilst others shown no effect (Witham et 
al. 2010; Witham et al. 2013a; Yiu et al. 2013; Gepner et al. 2012) (Table 1.5). Three of 
these trials recruited only participants with type 2 diabetes, a group of people that 
have been shown to have impaired endothelial function (Guerci et al. 2001). Two 
showed no effect on FMD after 12 wk of 125 µg D3/d (Yiu et al. 2013) or 12 wk after a 
single baseline dose of either 2500 µg or 5000 µg D2 (Witham et al. 2010). In contrast, 















that participants in the vitamin D group experienced a significant improvement in FMD 
compared with placebo (2.35 vs. 0.06%, P=0.048) (Sugden et al. 2008). This RCT gave a 
single dose of 2500 µg D3 at baseline in the winter to older participants with a mean 
age of 64 y and measured FMD at 8 wk. Further evidence for a positive effect of 
vitamin D comes from two studies in younger participants (Harris et al. 2011; Tarcin et 
al. 2009). In a study that was not placebo controlled, Tarcin et al. recruited 46 healthy 
men and women with a mean age of 23 y. Half of these were vitamin D-deficient (25-
OH-D<25 nmol/l), and half had a mean 25-OH-D of 75 nmol/l (control group). The 
vitamin D deficient subjects received 7500 µg D3 per month as intramuscular 
injections, and FMD measurements were significantly improved at 3 months compared 
with the control group (P = 0.001) (Tarcin et al. 2009). Harris et al. recruited 45 healthy 
African Americans with a mean age of 30 y and randomly allocated them to either 
placebo (n=23) or a monthly dose of 1500 µg oral vitamin D3 (n=22) for 16 wk. A 
significant treatment x time interaction was found (P=0.047) and at 16 wk, FMD had 
significantly improved in the supplementation group (1.8 ± 1.3%) compared with the 
placebo group (-1.3 ± 0.6%) (Harris et al. 2011). Other studies in post-menopausal 
women (Gepner et al. 2012) and healthy South Asian women (Witham et al. 2013a) 
failed to show an improvement in FMD after D3 supplementation. All of the trials 
mentioned above have either given participants very high doses of vitamin D daily or 
pharmacological doses as a single or monthly dose. To the author’s knowledge, there 
are no trials of doses in line with dietary recommendations. The study by Tarcin et al. is 
poorly controlled and none of the studies have a duration of longer than 16 wk. Most 
have only measured FMD at baseline and at the end of the study, rather than taking 
repeated measures throughout the intervention period. Two of the studies showing an 
improvement in FMD were in diabetes patients (Sugden et al. 2008; Witham et al. 
2010), and the findings may not be applicable to healthy participants. Whilst the cross-
sectional evidence is suggestive of an association between vitamin D and endothelial 
function, no firm conclusions can be made, and more good quality RCTs are warranted 
to investigate this further. 
 
Although much is still to be elucidated, mechanisms as to how vitamin D may affect 
endothelial function have been suggested through the results of cellular and animal 




and the VDR have been found in vascular endothelial cells (Merke et al. 1989; Zehnder 
et al. 2002; Jablonski et al. 2011) suggesting that vitamin D may modulate endothelial 
function via a possible autocrine mechanism whereby 1,25(OH)2D, produced in 
endothelial cells binds to the VDR to mediate endothelial effects (Merke et al. 1989). It 
has been shown in human umbilical vein endothelial cells (HUVEC) that 1,25(OH)2D3 
can cause a significant concentration-dependent increase in endothelial NO production 
via eNOS activation (Molinari et al. 2011). To support this, a study by Andrukhova et al. 
carried out experiments in mice carrying a mutant, functionally inactive VDR and 
showed that they had a lower bioavailability of NO as a result of a reduced expression 
of eNOS (Andrukhova et al. 2014).  
 
1.4.2.1.2 Arterial stiffness 
Arterial stiffness is determined by structural and functional components of the artery 
(Arnett et al. 1994). Collagen and elastin are two important scaffolding proteins which 
are present in the vascular wall; collagen provides strength and allows the artery to 
cope with high pressure, and elastin allows for reversible extensibility of the artery 
(Wagenseil and Mecham 2012). Their relative contribution determines the stability, 
resilience and compliance of the vascular wall. Normally these proteins are kept in a 
stable state, but several factors can lead to an overproduction of abnormal collagen 
and decreased quantities of normal elastin (Figure 1.7). Elastin can be degraded by 
proteases such as matrix-metalloproteinases (MMPs) and damaged in aging and tissue 
injury (Wagenseil and Mecham 2012). This can result in the production of more 
collagen fibres which are 100-1000 times stiffer than elastic fibres, and therefore the 
mechanical properties of the artery are shifted into the stiffer range. Calcium deposits, 
which increase significantly with age, can build up in the media of large arteries and 
also increase the stiffness of the arterial wall (Wagenseil and Mecham 2012). 
Furthermore, additional cross-linking on the elastin and collagen fibres by advanced 
glycation end-products (AGEs) can increase the stiffness of the fibres. AGEs increase 
with age and form crosslinks in more places along the collagen and elastin fibres 
compared with normal cross-linking (Wagenseil and Mecham 2012). In addition to a 
lower ratio of elastin to collagen, an increase in smooth muscle tone or smooth muscle 
cell hypertrophy contributes to an increase in vascular stiffness (Zieman et al. 2005; 




Arterial stiffness can be estimated using pulse wave velocity (PWV) which involves 
dividing the path distance between two arterial recording sites by the transit time of 
the arterial pulse wave; the faster the PWV, the stiffer the artery. Carotid-femoral PWV 
(PWVc-f), based on estimating the velocity of the pressure wave travelling between 
the carotid and femoral arterial sites, is considered to be the ‘gold-standard’ 
measurement (Shahin et al. 2013; Laurent et al. 2006).  Arterial stiffness is a strong 
predictor of cardiovascular events, particularly in older participants (Mattace-Raso et 
al. 2006; Terai et al. 2008). A systematic review of 16 cohort studies included 17,635 
participants, 1,785 of which had a CVD event in the follow-up period. The pooled age- 
and gender- adjusted hazard ratio per 1-SD change in loge aortic PWV was 1.45 (95% CI 
1.30, 1.61) for CVD (Ben-Shlomo et al. 2014). 
 
 
Figure 1.7 Factors that increase vessel wall stiffness adapted from (Wagenseil 
and Mecham 2012). AGE, advanced glycation end-products; MMPs, matrix-
metalloproteinases 
 
Many cross-sectional studies have shown inverse associations between vitamin D and 
arterial stiffness (Al Mheid et al. 2011; Andrade et al. 2008; Giallauria et al. 2012; Lee 
et al. 2012; Lieberman et al. 2013; Pirro et al. 2012; Seker et al. 2013; Webb et al. 
2012; Zagura et al. 2011; Rezai et al.). However, there are relatively few clinical trials 




(Table 1.5). Only three have been in healthy subjects; one in adolescents (Dong et al. 
2010), one in postmenopausal women (Gepner et al. 2012), and the other in South 
Asian women (Witham et al. 2013a). The study in adolescents randomised subjects 
aged 14-18 y to either a control group (10 µg vitamin D3/d) or an experimental group 
(50 µg vitamin D3/d) for 16 wk. A significant time x treatment interaction was observed 
for PWVc-f measured using applanation tonometry (SphygmoCor). PWV significantly 
increased in the control group from 5.38 ± 0.53 m/sec to 5.71 ± 0.75 m/sec, but 
decreased in the experimental group from 5.41 ± 0.73 m/sec to 5.33 ± 0.79 m/sec.  
However, this study was flawed in that it did not have a placebo group and was only 
investigator-blinded (Dong et al. 2010). Gepner et al. conducted another study in 
which 114 postmenopausal women were randomised to 62.5 µg vitamin D3 daily or 
placebo for 4 months. This was a well-conducted study, but it showed no significant 
differences between groups in the change in PWV (P=0.65) measured using 
applanation tonometry (SphygmoCor). This lack of an effect on PWV may be due to the 
women’s baseline concentrations of total 25-OH-D being quite high though (80.6 ± 
26.2 nmol/L in the placebo group and 75.6 ± 26.7 nmol/L in the treatment group) 
(Gepner et al. 2012). However, an 8 wk RCT in South Asian women with mean baseline 
serum 25-OH-D concentrations of 27 nmol/L also found no change in PWV measured 
using applanation tonometry (SphygmoCor) in a group given a single oral dose of 250 
µg D3/d compared with placebo (P=0.046) (Witham et al. 2013a). Other trials have 
been in subjects with type 2 diabetes mellitus (Breslavsky et al. 2013; Yiu et al. 2013) 
or hypertension (Larsen et al. 2012). These 3 studies have all been placebo-controlled 
and double-blinded, but their findings cannot be extrapolated to healthy populations. 
Two showed no change in arterial stiffness in response to treatment (Larsen et al. 
2012; Yiu et al. 2013), but the other showed arterial stiffness (Breslavsky et al. 2013) 
measured as aortic augmentation index (AI) using SphygmoCor to significantly 
decrease in a group receiving 25 µg/d D3 compared with placebo (-7.0% ± 6.0 vs. 0.3 ± 
8.7, P=0.01). The trial showing a positive effect of vitamin D supplementation was the 
one out of the 3 which used the lowest dose of vitamin D in the treatment group (25 
µg/d compared to 75 µg/d (Larsen et al. 2012) and 125 µg/d (Yiu et al. 2013)). 
However, it was the study with the longest treatment period (12 months compared to 
20 wk (Larsen et al. 2012) and 12 wk (Yiu et al. 2013)) and also the one with the lowest 




2012) and 54 (Yiu et al. 2013) nmol/L). It may be that trials of a longer duration and 
with lower baseline 25-OH-D levels are needed in order to see an improvement in 
arterial stiffness with vitamin D supplementation.  
 
Mechanisms have been suggested for a potential effect of vitamin D on arterial 
stiffness. One possibility is via changes in calcium homeostasis. Vitamin D deficiency 
may lead to an increased vascular calcification which contributes to stiffening of the 
arteries (Watson et al. 1997). Other suggestions are via effects on the vascular wall by 
inhibition of the renin-angiotensin system as described in section 1.4.1.2 (Li et al. 
2002) or suppression of vascular smooth muscle cell proliferation (Chen et al. 2010). 
 
 Matrix-metalliproteinase-9 1.4.2.2
Matrix metalloproteinases (MMPs) are a family of Zn2+ and Ca2+-dependent proteolytic 
enzymes which, on activation, are responsible for the breakdown of extracellular 
matrix in both normal physiological processes and pathological states (Dollery et al. 
1995). Currently in humans there are 23 known MMPs, and MMP-9 is responsible for 
cleaving type 4 collagen and gelatine (Baker et al. 2014). MMPs are involved in the 
pathogenesis of atherosclerotic lesions (Siefert and Sarkar 2012) and MMP-9 and 
MMP-3 in particular mediate a remodelling process in which the fibrous cap in 
atherosclerotic plaques is resorbed (matrix degradation) or redeposited (matrix 
synthesis). This process is in balance under stable conditions, but under 
proinflammatory conditions, degradation of the cap is favoured over synthesis, leading 
to plaque rupture (Liu et al. 2006). In patients with coronary artery disease, serum 
MMP-9 levels may represent a marker of inflammation (Ferroni et al. 2003). Studies 
have also shown that compared to normal human arteries, MMPs have an increased 
expression in atherosclerotic vessels, particularly within the regions of the plaque cap 
that have a thinner wall and are at a higher risk of rupture (Galis et al. 1995a). 
Furthermore, MMP-2 and MMP-9 in particular have been found in monocyte-derived 
foam cells. Secretion of these MMPs provides a continuous source of extracellular 
matrix degradation within the lesions, contributing to the disruption of plaques as 





There are a few cross-sectional studies which have investigated whether vitamin D is 
associated with levels of MMP-9 (Baker et al. 2014; Timms et al. 2002; Wasse et al. 
2011). Timms et al. recruited 171 healthy British adults of Bangladeshi origin aged 35-
65 y and found that serum 25-OH-D concentrations independently determined plasma 
MMP-9 levels (r= -0.41, P<0.0001) (Timms et al. 2002). Similarly, in a population of 92 
submariners, naval officers and support crew, MMP-9 levels were significantly and 
inversely correlated with 25-OH-D levels (r= -0.41, P=0.01) (Baker et al. 2014).  
 
The sparse clinical trial data for the association between vitamin D and MMP-9 has 
shown mixed results; 2 studies have observed no treatment effect (Muldowney et al. 
2012; Timms et al. 2002) and one has found a significant decrease in MMP-9 
concentrations with supplementation (Shab-Bidar et al. 2011). Muldowney et al. 
conducted a double-blind RCT in which men and women aged 20-40 y (n=202) and 
≥64y (n=192) received cholecalciferol at doses of 5, 10, or 15 µg/d of vitamin D3, or 
placebo during the winter in Ireland. After 22 wk of supplementation, there was no 
difference between groups in the mean change in MMP-9 (P=0.91 in the younger age 
group and P=0.97 in the older age group) (Muldowney et al. 2012). The study 
mentioned above by Timms et al. also conducted an intervention study in which 
subjects with 25-OH-D levels <27 nmol/L (n=54) were randomly allocated into two 
groups which were given three monthly injections of vitamin D3; one a high dose of 
1250 µg, and the other 12.5 µg. After 1 y of supplementation, reductions in MMP-9 
were similar in both groups; in the high dose group, the change was -57.84% compared 
to -64.68% in the low dose group (Timms et al. 2002). A smaller study randomly 
allocated 100 type 2 diabetes patients to receive a plain yoghurt drink containing 170 
mg calcium and no vitamin D/250 mL or a vitamin D3-fortified yoghurt drink containing 
170 mg calcium and 12.5 µg D3/250 mL twice a day for 12 wk. This RCT found a 
significant difference in the mean change in MMP-9 between groups (-2.3 ± 3.7 in the 
fortified yoghurt group vs. +0.44 ± 7.1 in the plain yoghurt group, P=0.02) (Shab-Bidar 
et al. 2011). The above demonstrates uncertainty surrounding the effect of vitamin D 
on MMP-9 and there is a need for further well-conducted RCTs that are powered to 
detect a change in MMP-9. It is not known what the mechanisms for a potential effect 
may be, although cellular work has found that 1,25(OH)2D down-regulates and 




the presence of TNF-α which is a powerful inducer of MMP-9 (Bahar-Shany et al. 
2010).  
 
 Factor VII (FVII) 1.4.2.3
FVII, like fibrinogen is involved in the coagulation cascade (Borissoff et al. 2011). It can 
be measured as FVII coagulant activity (FVIIc) or activated FVII (FVIIa). FVIIa, together 
with tissue factor, initiates the coagulation cascade through the extrinsic pathway 
(section 2.4.1) and high levels of FVII have been shown to be associated with CVD 
(Meade et al. 1986). Data from 1511 white men aged 40 to 64 y, recruited into the 
Northwick Park Study, found that an increase of about one SD in FVIIc increased the 
risk of IHD death within 5 y of recruitment by 62% (Meade et al. 1986). Furthermore, 
higher baseline levels of FVIIc were found in those who died of CVD compared to those 
who survived in the Northwick Park Study (Meade et al. 1980), and in those who had a 
coronary event after 8 y of follow-up compared to those who did not in the 
Prospective Cardiovascular Münster study (PROCAM) study of 2780 men (Junker et al. 
1997). To the author’s knowledge, only one study has investigated the effect of 
vitamin D on FVII. This cross-sectional study recruited 206 subjects and measured both 
FVIIa and FVIIc, but found no significant associations between these and either serum 
25-OH-D or 1,25(OH)2D concentrations (Jorde et al. 2007). Mechanisms as to how 
vitamin D may affect FVII concentrations have not been suggested.  
 
1.5 Vitamin D and cognitive function/mood 
In addition to CVD, this thesis also investigates whether vitamin D supplementation 
can improve cognitive function in healthy older men and women. Vitamin D may have 
a direct effect on the brain as supported by the finding of the enzyme 1α-hydroxylase 
and the VDR for 1,25(OH)2D in the human brain in neurons and glial cells (Eyles et al. 
2005). This is supported by experiments in rat models which have shown that 
1,25(OH)2D can modulate calcium binding proteins with neuroprotective roles 
(Alexianu et al. 1998), and also the production of nerve growth factor (Neveu et al. 
1994) and nitric oxide synthase (Garcion et al. 1998) in the brain.  
 
A few meta-analyses of observational studies have shown associations between a 




van der Schaft et al. 2013), executive dysfunction (Annweiler et al. 2013) and 
Alzheimer disease (Balion et al. 2012). One of the meta-analyses included 9 
observational studies and 3 vitamin D supplementation trials (Annweiler et al. 2013). 
Cross-sectional comparisons were made between participants with a low, study-
defined vitamin D status and those with a high vitamin D status. Lower 25-OH-D 
concentrations were associated with lower scores for episodic memory assessed using 
tests based on learning and retrieval of items (effect size -0.16, 95% CIs -0.25, -0.07), 
and worse scores on tests to assess executive function. Whilst the observational 
evidence summarised in these meta-analyses suggests a beneficial effect of vitamin D 
on cognitive performance, many of the studies included have not adjusted for 
important confounders such as gender, age, BMI, seasonality and education (van der 
Schaft et al. 2013) and therefore causality cannot be assumed. There are a few vitamin 
D supplementation trials that have been conducted with cognitive function as an 
outcome but these have shown mixed results and were either not randomised or 
placebo-controlled (Annweiler et al. 2012; Przybelski et al. 2008) or had short follow-
up periods of 6 wk or less which is unlikely to be long enough to see an effect (Dean et 
al. 2011; Przybelski et al. 2008). Their effects on executive function were summarised 
in the meta-analysis by Annweiler et al. which compared vitamin D supplementation 
groups (n=234) to control groups (n=257) and found no significant difference in the 
change in test score between groups (effect size 0.14, 95% CIs -0.04, 0.32) (Annweiler 
et al. 2013). In addition to these studies, analysis of data from 4143 women aged ≥65 y 
in the Women’s Health Initiative (WHI) Calcium and Vitamin D Trial and the WHI 
Memory Study found that supplementation over a mean follow-up of 7.8 y did not 
result in any treatment effects compared to placebo for domain-specific cognitive 
function. However, calcium as 1000 mg of calcium carbonate/d was given in addition 
to 10 μg D3/d and it was not possible to separate the effects of the two (Rossom et al. 
2012).  
 
Similar to cognitive function, trials assessing the effect of vitamin D supplementation 
on mood have shown inconsistent results (Lansdowne et al. 1998; Harris et al. 1993; 
Jorde et al. 2008; Vieth et al. 2004b). Jorde et al. conducted a RCT in which 441 
participants aged 21-70 y were randomised to placebo or 500 μg or 1000 μg D3/wk for 




multiple choice questionnaire. Although statistical analyses don’t appear to have been 
conducted for a comparison between groups, which would have been the correct way 
of testing for a true effect of supplementation on mood, there were significant 
improvements in scores in the two supplementation groups, but not in the placebo 
group (Jorde et al. 2008). Another trial of 1 y duration in 250 women with a mean age 
of 62 y gave 277 mg calcium and 10 μg vitamin D/d to half the women and only 277 
mg/d calcium to the other half. Mood was measured using a scale that measures six 
mood factors including Depression-Dejection, Tension-Anxiety, Anger-Hostility, Vigour-
Activity, Fatigue-Inertia and Confusion-Bewilderment, but no differences between 
groups were found (Harris et al. 1993). From the above, it might be considered that 
high dose supplementation is needed to see an effect. However, whilst they were not 
placebo controlled, two trials of lower dose supplementation have found positive 
effects of supplementation on measures of mood and wellbeing (Vieth et al. 2004b; 
Lansdowne and Provost 1998). One of these trials by Vieth et al. assessed wellbeing 
using a short questionnaire based on conventional depression-screening tools which 
asked questions about energy and mood (Vieth et al. 2004b). A significant 
improvement was found in winter wellbeing scores in 51 outpatients after both 15 and 
100 μg/d D3 for a few months. Landsdowne et al. gave 44 healthy subjects with a mean 
age of 22 y 10 or 20 μg D3/d, or no vitamin D for 5 days in the winter months. Positive 
Affect, measured using a self-reported measure of both positive and negative 
affectivity was significantly enhanced in both treatment groups compared to the 
control group (P<0.001) (Lansdowne and Provost 1998), although there were no 
significant effects on negative affectivity.  
 
In summary, evidence of a relationship between vitamin D and cognitive function and 
mood is inconclusive and much of the evidence is of poor quality. There is a need for 
well-conducted, placebo-controlled and randomised trials investigating the effect of 
vitamin D supplementation on these outcomes. 
 
1.6 Conclusions 
The above review of the literature identifies that there are limitations and 
inconsistencies in the current knowledge base regarding the effect of vitamin D on CVD 




and relatively few vitamin D supplementation trials have been conducted. Many have 
either have not been placebo controlled or double-blinded, or have been under-
powered (too small a sample size) to detect a change in particular outcomes. Others 
have not adequately controlled for potential confounding factors. Furthermore, it 
would seem that the majority of published trials have used high, often 
pharmacological doses of vitamin D which are irrelevant to real life and intakes in line 
with recommendations. Due to the uncertainty in the evidence, this thesis sets out to 
address some of these issues. 
 
1.7 Aims and objectives of thesis 
i) To investigate cross-sectional associations between serum 25-OH-D 
concentrations and vitamin D intake, age, BMI, physical activity, gender, 
season and skin pigmentation in baseline data from two previously 
conducted RCTs (MARINA and CRESSIDA) in healthy men and women aged 
40-70 y.  
ii) To assess, using data from the CRESSIDA trial, the impact on vitamin D 
status of advice to consume 1-2 portions of oily fish per wk. 
iii) To investigate using data from the MARINA and CRESSIDA studies whether 
low vitamin D status measured as serum 25-OH-D concentrations is 
associated with a higher 24 h BP, increased arterial stiffness measured as 
PWV, impaired endothelial function measured as FMD and higher 
concentrations of the inflammatory marker hsCRP, adjusting for potential 
confounders. 
iv) To conduct a RCT to evaluate the effect on serum 25-OH-D metabolites of 
intakes of 5 and 10 μg/d of vitamins D2 and D3, provided in a malted milk 
drink, in the UK winter months. The aim of this study was to help decide on 
the dose and form to use in a RCT investigating whether low dose vitamin D 
in the dietary range may affect a range of CVD risk factors and factors 
associated with the development of CVD. The objective was to determine 
whether a dose of 10 μg/d results in significantly greater increases in serum 
25-OH-D concentrations compared with 5 μg/d and whether low dose 
vitamin D2 supplementation results in meaningful increases in 25-OH-D 




D3 at increasing vitamin D status, but using D2 in the RCT investigating 
effects on CVD risk factors would allow differentiation between the effects 
of sunlight and diet as 25-OH-D2 is produced from D2 whereas 25-OH-D3 is 
produced in response to skin UVB exposure as well as from D3. 
v) To conduct a randomised placebo controlled trial to investigate whether 
low dose vitamin D2 in the dietary range provided in a malted milk drink in 
healthy men and post-menopausal women aged 50-70 y during the winter 
months will lower 24 h BP and improve endothelial function in healthy 
older men and women. This will also investigate whether D2 has effects on 
arterial stiffness, haemostatic and inflammatory risk factors, fasting 
glucose, indices of insulin secretion and sensitivity and, as an exploratory 








































This chapter describes the methods used to collect anthropometric, physiological and 
blood analyte measurements in the studies covered in the later chapters. It also 
provides an outline of previously run studies on which vascular function measures 
were made and vitamin D status later measured. 
 
2.1 Anthropometric measurements 
2.1.1 Height 
Height was measured using a wall mounted stadiometer. The investigator ensured that 
the volunteer removed his/her shoes and was standing upright with heels and 
shoulders against the measuring rod, knees and back straight, and looking forward. 
The measuring slide was then pushed slowly onto the head, compressing the hair, so 
that it touched without bending. The reading was taken to the nearest 0.1 cm. 
 
2.1.2 Weight 
Participants were weighed at their initial screening visit on a Tanita body composition 
analyser (Tanita model BC-418). They removed any outer clothing and shoes and 
stepped onto the weighing platform with bare feet. Participants were asked to hold 
the handgrips firmly in each hand with their arms slightly out to the side, but held 
straight to facilitate assessment of body composition. The scales were tared to 1 kg to 
allow for clothing weight. Measurements at other occasions were made on calibrated 
scales accurate to 0.1 kg, Model 764 Seca, 40 Barn Street, Birmingham, B5 5QB). 
 
2.1.3 Waist circumference 
Waist circumference was either measured against the skin, or over light clothing so 
that the tape could be brought as close to the body as possible. The participant was 
asked to stand upright and still whilst the measurement was being taken. The tape was 
placed at the mid-point between the bottom of the rib cage and top of the iliac crest 
parallel to the floor, and the measurement read to the nearest 0.1 cm. 
 
2.2 Physiological measurements 
2.2.1 Endothelial function measured by flow mediated dilation 
Endothelial function was measured using the flow mediated dilation (FMD) technique. 




function (Uehata et al. 1997; Donald et al. 2008) and in humans, it represents 
endothelium-derived nitric oxide (NO) bioavailability (Green et al. 2014). It involves 
measuring the dilation of the brachial artery in response to occlusion-induced 
increased blood flow (hyperaemia) caused by deflation of a cuff on the forearm after 
occlusion at suprasystolic BP. The dilation of the brachial artery is measured by high 
resolution ultrasound scanning of the brachial artery. The hyperaemia increases shear 
stress parallel to the long axis of the vessel (Niebauer et al. 1996) which is then 
transduced to endothelial cells through mechanoreceptors. Consequently, the G-
protein expression of phosphokinase A is increased leading to an increase in 
endothelial NO synthase activity which acts as a catalyst for the conversion of L-
arginine to NO (Sessa 2004). The diffusion of this NO into the media leads to the 
activation of guanylate cyclase, which converts Guanosine-5'-triphosphate (GTP) into 
Guanosine monophosphate (GMP). GMP has the effect of inducing smooth muscle 
relaxation and therefore vasodilation. FMD is calculated as the percentage increase in 
brachial artery diameter from baseline to maximal dilation (Harris et al. 2010). 
Endothelial independent dilation can be estimated by the administration of glycerol 
trinitrate sublingually, although this was not determined. 
 
A high resolution ultrasound system with a 7-10 MHz linear array transducer (Acuson 
Aspen, Acuson Corporation, Mountain View, CA, USA) (Figure 2.1) was used. In order 
to become proficient in the method, the author underwent training by an experienced 
ultrasonographer. Measurements were made according to the recommendations of 
the International Brachial Artery Reactivity Task Force Guidelines for the ultrasound 
assessment of endothelial-dependent FMD vasodilation of the brachial artery (Corretti 
et al. 2002). Participants were asked in advance to avoid strenuous physical activity, 
foods high in fat, caffeine and alcohol the day before the visit as these have been 
shown to influence FMD (Papamichael et al. 2005; Clarkson et al. 1999; Harris et al. 
2010; Vogel et al. 1997; Agewall et al. 2000). To begin with, the measurement 
procedure was explained to the participant to help ensure that they were comfortable 
with it and would remain as still as possible during the measurement. In a temperature 
controlled room (22-26  C̊) (Harris et al. 2010), the participant was asked to rest supine 
on a height adjustable bed for at least 15 min before starting the measurement. It was 




changing the position of the bed/pillow. Labelled electrocardiogram (ECG) monitors 
were placed under the left and right collar bone and above the hip bone on the 
stomach on the right hand side of the participant. A pneumatic tourniquet cuff was 
wrapped around the forearm with the far edge in line with the elbow crease (distal to 
ultrasound probe) (Betik et al. 2004). Ultrasound gel was applied to the upper arm just 
above the elbow crease and a longitudinal section of the brachial artery, 2 to 15 cm 
above the elbow, was scanned using the ultrasound probe. Once a clear picture of the 
brachial artery was obtained, the probe holder and clamp were tightened to help 
secure the position of the probe (Figure 2.2). A tape measure was used to measure the 
distance in cm from the edge of the cuff to the edge of the probe and this was 
recorded. The positions of the participant’s head and hand (up/on the side, and 
comments) were recorded and it was ensured that the same positions were used in 
future measurements. Using the ultrasound machine controls, the clearest area of the 
brachial artery was made to fill the scan area visible on the screen. The screen cursor 
was placed in the centre of the brachial artery and the angle altered to be in line with 
the direction of blood flow. In order to confirm that an artery was being scanned and 
not a vein, and that the ECG was still working, it was checked that there were regular 
waveforms appearing at the bottom of the screen. The brightness of the screen in 
different sections was altered to provide the clearest possible picture of the vessel 
wall. In addition to the ultrasound screen, the scan picture was visible on a separate 
computer which had computer assistant edge detection software uploaded onto it 
(BrachialAnalyser, Medical Imaging Applications, LCC, Iowa, USA). The participant’s 
anonymous ID was entered into the program and the software set up to record a total 
of 220 frames at a speed of 0.333/s, i.e 20 frames per min for 11 min in total. The 
images were recorded continuously throughout, including 1 min at baseline. After 
baseline, reactive hyperaemia was induced by the quick inflation of the pneumatic 
tourniquet cuff to a pressure of 250 mm Hg for 5 min, followed by quick release and 
the recording of frames for another 5 min. Throughout the recording period, small 
movements of the probe could be made using a micrometer attached to the clamp in 
order to improve the clarity of the vessel walls. After the test, the image was saved 
before unclamping the probe and informing the participant that they were able to 
move again. Post-visit, the clearest section of the brachial artery (region of interest, or 




diameter at that section for each frame (Figure 2.3). It is important that the diameter 
measurements occur at the same time in the cardiac cycle for each frame. End diastole 
is used, rather than end systole, as the size of systolic expansion is affected by the 
vessel compliance and possibly factors such as aging and hypertension. The software 
detects end diastole using the onset of the R-wave from the integrated ECG output 
(Corretti et al. 2002) (Figure 2.4). It was determined at which point after cuff release 
the maximum dilation occurred, by looking at frames recorded between 30 seconds 
and 2 min after frame 120, when the cuff was released (Corretti et al. 2002) (Figure 
2.5). The 20 frames during the baseline measurement and the frames at maximum 
dilation were studied to check that the software was picking up the correct part of the 
arterial wall. Occasionally, the walls in the ROI were blurred in parts where the probe 
had moved slightly. Where it seemed obvious to the eye where the wall actually was, 
but the software had not picked up the correct part, manual adjustments were made 
to correct for this. Most of the time, the luminal side of the intima was selected, but 
occasionally this was not clear enough in the frame and the software would select the 
intima side of the media wall. In this case, it was ensured that the same wall was used 
for repeated measures later on in the study. Frames that were so unclear it was felt an 
accurate estimation of the arterial wall diameter could not be made, were rejected. 
Averages were worked out for all of the good quality frames from the first 20 frames 
and for the 3 largest diameter measurements at maximum dilation. FMD was 
calculated as the percentage increase in brachial artery diameter from baseline to 
maximal dilation (Corretti et al. 2002). For later measurements in the study on the 
same participant, the probe was placed the same distance away from the cuff as for 
the baseline measurement. Additionally, the baseline scan was brought up on the 
computer to act as a comparison in order to find the same section. Training data from 
the author are displayed in Table 2.1. The within person coefficient of variation (CV) 






Figure 2.1 Ultrasound machine, scan table and bed for participant to lie on. 
 
 






Figure 2.3 Ultrasound scan showing brachial artery (green lines represent 
researcher-selected region of interest (ROI), and red lines represent software 











Figure 2.5 Output from Brachial Analyser showing change in brachial artery 
diameter over the 11 min recording period. The cuff was tightened at frame 20 and 




Table 2.1 Author FMD training data on 7 volunteer participants (2 measurements taken on separate days) 
 
n 
First measurement Second measurement       
BAD Max 
AD 
% FMD BAD Max AD % FMD Mean BAD SD BAD CV % BAD Mean 
FMD% 
SD FMD % CV % FMD 
% 
1 2.74 3.03 10.58 2.69 3 11.52 2.715 0.035 0.013 11.050 0.665 0.060 
2 4.3 4.51 4.88 4.19 4.3 2.63 4.245 0.078 0.018 3.755 1.591 0.424 
3 2.67 2.82 5.62 2.87 3.1 8.01 2.77 0.141 0.051 6.815 1.690 0.248 
4 2.3 2.47 7.39 2.53 2.69 6.32 2.415 0.163 0.067 6.855 0.757 0.110 
5 4.67 4.69 0.43 4.54 4.56 0.44 4.605 0.092 0.020 0.435 0.007 0.016 
6 3.68 3.83 4.08 3.87 4.1 5.94 3.775 0.134 0.036 5.010 1.315 0.263 
7 3.24 3.45 6.48 3.04 3.32 9.21 3.14 0.141 0.045 7.845 1.930 0.246 
        Average 
CV% 








2.2.2 Arterial stiffness  
Large artery stiffness can be estimated using pulse wave velocity (PWV) which involves 
dividing the path distance between two arterial recording sites by the transit time of 
the arterial pulse wave; the faster the PWV, the stiffer the artery. Carotid-femoral 
pulse wave velocity (PWVc-f) is widely regarded as the ‘gold-standard’ measurement 
for arterial stiffness (Shahin et al. 2013). It is computed from the time delay between 
the upstroke of the arterial pressure wave at the carotid and femoral arteries and the 
anatomical carotid to femoral distance. It can be measured using several different 
devices including SphygmoCor (ArtCor Medical, Sydney, Australia), the Complior 
System® (Colson, Les Lilas, France) and, most recently, the Vicorder (Skidmore Medical, 
Bristol, UK) (Laurent et al. 2006; Shahin et al. 2013; Jatoi et al. 2009; Rajzer et al. 
2008). The SphygmoCor method is regarded as the ‘gold-standard’ method and 
involves measuring carotid to femoral transit time use a tonometer which is applied to 
the carotid and femoral arteries. This technique requires some skill to be reproducible 
and the major difficulty is locating the femoral pulse on the inside of the thigh which 
makes it intrusive (Hickson et al. 2009). The Vicorder method has been developed to 
be used by less skilled operators and is less intrusive for the participant. It uses two 
cuffs placed on the leg and around the neck to determine the transit time. Hickson et 
al. obtained similar results using the Vicorder compared with the SphygmoCor based 
on analysis of 122 subjects with an average age of 53 y (Hickson et al. 2009). Data were 
available from the MARINA (Modulation of Atherosclerosis Risk by Increasing dose of 
N-3 fatty Acids) study (Sanders et al. 2011) (section 2.6.2) in which measurements had 
been made in a larger number of participants (335 male and female non-smoking 
adults aged 45-70 y) using both SphygmoCor and Vicorder techniques. Figure 2.6 
shows a comparison of the results of the two methods. The Vicorder resulted in higher 
values than the SphygmoCor but the slope was close to 1.0. If participants were 
divided into quintiles according to the method used, the Vicorder technique classified 
80% of the participants into the correct or adjacent quintile (Table 2.2). The error 
associated with the measurement using the Vicorder technique was significantly lower 
(P<0.001) at 3.0% (SD 2.4) than that for the SphygmoCor technique (8.7%, SD 4.1) for 






Figure 2.6 Correlation between SphygmoCor and Vicorder measurements of 
carotid to femoral pulse wave velocity in the MARINA study in 45-70 y old men and 
women (n = 335). 
 
Table 2.2. Percentage of participants in each quintile of PWV measured by 
SphygmoCor and Vicorder in the MARINA study in 45-70 y olds (n = 335). 
 
Vicorder Quintile 







1 38% 38% 16% 4% 4% 
2 39% 15% 33% 8% 6% 
3 15% 31% 17% 25% 12% 
4 6% 12% 28% 39% 16% 







Measurements were made by the author or other trained personnel who were blinded 
to the treatment allocation. Initially, the measurement procedure was explained to the 
participant to help ensure that they were comfortable with it and would remain as still 
as possible during it. The participant was asked to rest supine on a height adjustable 
bed for at least 10 min before starting the measurement. After 10 min rest, BP was 
recorded once on the upper left arm (unless requested to be the right arm by the 
participant), using an OMRON 705CPII or equivalent automatic upper arm BP monitor, 
positioned with the cuff sensor over the brachial artery. Red and blue Vicorder cables 
were attached to the neck and thigh cuffs, respectively. The carotid pulse was found 
and the neck cuff placed carefully and gently around the participant’s neck with the 
inflatable section directly over the pulse. The thigh cuff was placed tightly around the 
participant’s right thigh, ensuring that it was as close to the femoral artery as possible 
(Figure 2.7). In order to estimate the difference in path length between the carotid and 
femoral arteries, the distance between the surface markings of the suprasternal notch 
and the top of the thigh cuff was used. Other distances were also measured as there is 
some debate as to which measurement to use (Van Bortel 2006). These included 
carotid pulse to suprasternal notch, suprasternal notch to femoral pulse (estimated 
location), and neck cuff to top of thigh cuff. All distances were measured in the supine 
position keeping the tape measure as straight as possible. The bed was then raised to a 
45   ̊angle. The participant’s ID, gender, date of birth, BP, suprasternal notch to thigh 
cuff measurement, and the proximal (carotid)/distal (femoral) pulse points used were 
entered into the Vicorder software. The participant was informed that the 
measurement was about to begin, and the recording was started. Once the trained 
researcher had decided that a clear picture had been obtained of both arterial 
waveforms, the recording was stopped (Figure 2.8). If a clear picture could not be 
obtained, the recording was stopped after a short period to avoid any discomfort to 
the participant. Adjusting the pillow to lift the neck slightly, or raising the bed a little 
more usually enabled clear waveforms to be found. Carotid to femoral transit time (TT) 
and PWV values were calculated by the software. Training data from the author are 






Figure 2.7 Vicorder cuffs attached to volunteer and output shown on laptop 
 
 





Table 2.3 Author Vicorder training data on 10 volunteer participants (means and 
SDs of 3 PWV measurements taken consecutively) 
Participant Mean (m/s)  SD  CV (%) 
1 5.0 0.06 1.2 
2 4.5 0.12 2.6 
3 5.7 0.00 0.0 
4 5.4 0.15 2.8 
5 5.0 0.06 1.1 
6 5.1 0.23 4.6 
7 5.3 0.10 1.9 
8 4.7 0.12 2.5 
9 4.9 0.21 4.3 
10 4.5 0.15 3.4 
  
Average CV (%) 2.4 
 
 SphygmoCor 2.2.2.2
In the CRESSIDA (Cardiovascular risk REduction Study: Supported by an Integrated 
Dietary Approach) (section 2.6.1) and MARINA (section 2.6.2) studies, PWV was 
measured using the non-invasive SpygmoCor apparatus (ArtCor Medical, Sydney, 
Australia) and SphygmoCor analysis software (SphygmoCor version 7.01 AtCor Medical 
Pty, Australia). Measurements were made by the study groups. Subjects were rested 
supine for 15 min and fitted with 3 ECG monitoring electrodes on their chest before BP 
was recorded supine using an automated sphygmomanometer (Omron 70CP). The 
distance from the femoral artery to suprasternal notch was measured by finding the 
pulse in the femoral. After ensuring that the ECG trace was of good quality with a 
prominent R wave, a probe (applanation tonometer) was used to obtain a pulse 
waveform from the carotid and then the femoral artery. The software calculated 
transit time and PWV. In order for the results to be acceptable, it was ensured that the 
coefficient of variation was less than 5% for 3 measurements, with no more than 6 
measurements being made.  
 
2.2.3 Blood pressure 
BP and heart rate measurements were taken using an A & D UA-779 auto upper arm 
BP monitor that met the A/A standard of the British Hypertension Society. Participants 
were allowed to rest quietly at a comfortable room temperature for 10 min before the 




During the measurement, the participant was asked to not talk and to sit quietly with 
their legs uncrossed and feet flat on the floor. The arm from which the measurement 
was being taken was comfortably supported at heart level. The appropriate sized cuff 
(normal or large) was selected and the bladder of the cuff placed 2-3 cm above the 
elbow crease. The cuff was placed snugly around the arm, with the tube positioned 
off-centre toward the inner side of the arm in line with the little finger. It was ensured 
that there was only enough space for a finger between the participant’s arm and the 
cuff. The start button was pressed, and on completion of the measurement, the 
readings for DBP, SBP and heart rate were recorded. At screening, measurements were 
made in triplicate at 2-5 min intervals. For these triplicate measures, the first reading 
was discarded and the mean taken of the two following readings according to the 
British Hypertension Society Guidelines (O'Brien et al. 2001). BP measurements at 
visits from baseline onwards were made alone. 
 
2.2.4 Ambulatory blood pressure (ABP) 
Measurements of 24 h ambulatory BP were made using A&D TM-2430 (A & D 
Instruments) devices in accordance with UK guidelines (O'Brien et al. 2005). These 
have been given A/A grading and have been approved for clinical use by the British 
Hypertension Society (Williams et al. 2004). At the end of the screening, baseline, mid-
point and end-point visits, participants were fitted with the ABP monitor by a trained 
researcher. Using the ABP monitor after the screening visit allowed the subject to 
familiarise themselves with it and learn how to use it before the study started. Their 
upper arm circumference was measured and they were provided with a suitable left 
arm cuff (standard size if circumference was 20-31 cm, large size if circumference was 
28-36 cm), a brief instruction card (Appendix 4) and a diary card (Appendix 5). 
Participants who were left-handed were given a right-handed cuff. The cuff was fitted 
so that the yellow mark was over the brachial artery and the lower edge of the cuff 
was about 1 inch above the inside of the elbow. It was fitted snugly, but with a large 
enough gap to fit two fingers underneath. The air hose was positioned over the 
shoulder and the carrying case positioned on the right hand side of the participant (if 
right-handed) using a belt or strap, depending on the participant’s preference (Figure 
2.9). The participant was instructed to stop what they were doing and relax their arm 




following each measurement to report what they were doing immediately prior to the 
measurement (lying down, sitting, standing or walking plus any other details or 
problems that may have occurred) and to record when they went to bed and woke up. 
The ABP was programmed to take measurements every 30 min during the day (0700-
2200) and hourly at night (2200-0700). The trained researcher nearly always fitted the 
monitor, and recorded the monitor number in the case report form. In a small number 
of cases, it was inconvenient for the participant to wear the monitor immediately after 
the visit (this was not the case for any screening visits). If this occurred, it was checked 
that the participant had a friend or relative who could fit the monitor for them when 
convenient with the help of the instruction card. The trained researcher also went over 
with the participant the important points to remember in fitting the monitor correctly, 
and demonstrated this at the end of the visit to remind them. After each visit, the data 
were downloaded onto a computer, analysed using TM-2430-13 Doctor-Pro Software 
and checked for accuracy by the author. The first 3 readings obtained were discarded. 
Other values were rejected if the measurements of DBP and SBP were too close, DBP 
was ≥ 105 mm Hg or the heart rate (HR) or SBP showed a sudden sharp increase. If it 
was considered by the researcher that there were not enough accurate measurements 
(at least 22 awake measurements and 6 sleep measurements), the participant was 
requested to wear the monitor again for 24 h. SBP, DBP and HR values and the number 
of accurate readings were recorded for the day-time, night-time and 24 h readings. 
After fitting the monitor, the researcher recorded details of where and when (date and 
time) the monitor could be collected and the contact information of the participant. 
Monitors were usually collected within a day or two of the measurements being taken. 






Figure 2.9 Fitting of the ABP monitor 
 
2.3 Collection and handling of blood samples 
2.3.1 Venepuncture  
Screening blood samples were obtained following a 3 h fast. For the vitamin D2/D3 
study, participants were not required to fast for any of the blood samples once on the 
study. In the DRISK study, participants were required to fast (nothing but water) from 
10 pm the previous evening for each visit, once on the study. The participant was 
made aware of how much blood would be taken and explained the procedure clearly, 
prior to taking the sample. They were given a choice as to which arm they would prefer 
blood to be taken from. If the participant mentioned feeling faint on previous blood 
taking occasions, they were given the option of lying down on the couch. Otherwise, 
they were asked to sit in a phlebotomy chair and rest their arm on a pillow on top of 
the chair arm. All phlebotomy was performed by a trained phlebotomist and careful 
hand washing was performed before each procedure. Initially, a tourniquet was placed 
around the upper section of the arm and pulled tight. An antiseptic swab was then 
used to clean the site where blood was to be taken from. The vacutainer method 
(Becton-Dickinson) was used for all sample collections. This involved screwing the 
needle into the disposable vacutainer holder, unsheathing it, and inserting it into the 




tourniquet released. Details of the vacutainers used can be found in the blood 
handling protocols detailed in Appendix 6 (D2/D3 study) and Appendix 7 (DRISK study). 
They were collected in the following order according to the Becton-Dickinson 
Vacutainer Order of Draw for Multiple Tube Collections: Sodium Citrate Tube, Serum 
Separator Tube, EDTA Tube and Fluoride Oxalate Tube. On removal of the needle, a 
cotton wool ball was placed at the site and the participant asked to apply pressure to it 
until the bleeding had stopped. The needle was disposed of in a sharps bin and a 
plaster applied to the site if the participant had no known allergies to plasters on 
enquiry by the phlebotomist. 
 
2.3.2 Sample processing 
After collection of the blood, the vacutainers were inverted a number of times 
according to the Becton-Dickinson Vacutainer Order of Draw for Multiple Tube 
Collections. They were placed in ice or kept at room temperature before centrifugation 
according to the processing requirements for specific samples. Precise details of 
sample handling are listed in Appendix 6 (D2/D3 study) and Appendix 7 (DRISK study). 
 
2.3.3 Coding and storage of samples 
All vacutainers were labelled before each appointment with subject ID, gender and 
date of birth using permanent marker. Eppendorf tubes (2.0 mL Everyday SC 
Microtube Skirt NS, Cat. No. CP5518) were labelled prior to each visit using printed 
stickers resistant to -80  ̊C freezing (Tubees® HI-LOW Labels for laser printers, 25x13 













Table 2.4 Standard label format for eppendorf tubes. VDS, D2/D3 study); DRS, 
DRISK study. Visits were labelled A=screening, B=baseline, C=visit 1 etc. 
PI Study Name ID Visit 






Croyovial boxes with 100 wells were used to store the samples. Due to the small 
number of participants, two or three different outcomes were stored in one box. Each 
box was clearly labelled with the PI’s name, the author’s name, King’s College London 
(KCL), the study name, the type of samples inside and the date of initial sample 
collection. As soon as possible and no more than 2 h after collection, the 
plasma/serum samples were stored in a -80  ̊C freezer at KCL (if screening samples, or 
D2/D3 study samples), or at the clinical research facility (CRF) at St Thomas’ Hospital (all 
DRISK study samples). 
 
2.3.4 Transport of blood samples 
Screening visit samples were analysed fresh by the CPA (Clinical Pathology Accredited) 
laboratory of the Department of Clinical Biochemistry (King’s College Hospital (KCH), 
London) under the supervision of Roy Sherwood and Tracy Dew. They were placed in a 
clear plastic sealable bag per subject and then into a sealed padded envelope with 
biohazardous tape placed around it. An accredited medical courier (City Sprint PLC) 
collected the samples from the 4th Floor main reception, Franklin-Wilkins Building at 
KCL on the day of collection and transported them to KCH.  
 
Samples collected during the study were packed and transported according to the 
UN3733 guidelines for shipment of biological samples. These guidelines specified that 
the samples be stored in a primary water-tight inner receptacle (Eppendorf tubes), 
have enough absorbent material (paper towels) between the primary and secondary 
receptacle to absorb the entire contents of the primary receptacle, be packaged inside 




packaging (a polystyrene box filled with dry ice). The polystyrene box was then placed 
in a snug fitting cardboard box which was sealed using tape. The cardboard box had 
the following labels: contact details of the sender and receiver, a UN3373 label and a 
Class 9 danger label UN1845 which had the weight of dry ice inside the box written on 
it.  
 
2.4 Analytical methods 
Unless stated otherwise below, all plasma and serum samples were sent to the CPA 
accredited laboratory at the Department of Clinical Biochemistry at KCH. 
 
2.4.1 Glucose 
The ADVIA 2400 and reagents were supplied by Siemens Healthcare Diagnostics Ltd 
(Newton House, Sir William Siemens Square, Frimley, Camberley, Surrey, GU16 8QD). 
Blood was collected into a 4 mL fluoride oxalate tube (Becton-Dickinson, Cat no. 
368920) and centrifuged at 4  ̊C at 1300 g for 15 min to separate the plasma. Initially, 
glucose present in the plasma was phosphorylated by adenosine triphophosphate 
(ATP) via the action of hexokinase. This produced glucose-6-phosphate which was then 
converted to 6-phosphogluconate in the presence of oxidized nicotinamide adenine 
dinucleotide (NAD), by glucose-6-phosphate dehydrogenase. The reduction of NAD+ to 
NADH resulted in an increase in absorbance at 340 nm which was proportional to the 
glucose concentration in the sample. The inter-assay precisions (% coefficient of 
variation, CV) were 1.6% and 1.2% and the intra-assay CVs were 0.6% and 0.5% for low 
and high QCs, respectively. 
  
2.4.2 Haematology 
A full blood count was performed at screening to confirm normal haematology. Blood 
was collected into a 2 mL vacutainer containing Ethylenediaminetetraacetic acid 
(EDTA) (Becton-Dickinson, Cat no. 367836) and kept at room temperature before being 
sent to KCH. The Siemans Advia 2120 and reagents were supplied by Siemans Medical 
Solutions Diagnostics Limited. Reference ranges for each of the haematology outcomes 
are displayed in Table 2.5. If values were outside of the ranges, they were checked by a 




recommend that another blood sample was taken and tested, or advise that the 
subject was not suitable for participation in the study. 
 
Table 2.5 Normal reference ranges for haematology outcomes 
Haematology Outcome  Males Females 
WBC (109/L) 4.0 – 11.0 
RBC (1012/L) 4.5 – 5.8 3.8 – 5.8 
HB (g/dl) 13.0 – 16.5 11.5 – 15.5 
MCV (fL) 77 - 95 
MCH (pg) 25 – 34 
MCHC (g/dL) 33.0 – 37.0 
PLT (109/L) 150 – 450 
Neutrophils (109/L) 2.2 – 6.3 
Lymphocytes (109/L) 1.3 – 4.0 
Monocytes (109/L) 0.2 – 1.0 
Eosinophils (109/L) 0 – 0.4 
Basophils (109/L) 0 – 0.1 
 
WBC, white blood cells; RBC, red blood cells; HB, haemoglobin; MCV, mean corpuscular 
volume; MCH, mean corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin 
concentration; PLT, platelet count. 
 
2.4.3 Liver function 
Normal liver function was confirmed for eligible subjects at screening in both the D2/D3 
and DRISK study using a number of colourimetric assays. Blood was collected into a 5 
mL gel separator serum tube (Becton-Dickinson, Cat no. 367954) and, after leaving to 
stand at room temperature for 30 min, centrifuged at 1300 g for 15 min at 4  ̊C. Serum 
was dispatched to KCH on the same day, and spare serum stored at -80  C̊. The ADVIA 
2400 Clinical Chemistry System and reagents were supplied by Siemens Healthcare 
Diagnostics Ltd. Total protein was measured using a Biuret reagent (an alkaline 
solution of copper ions) that reacts with proteins and polypeptides containing at least 
two peptide bonds to produce a violet coloured complex, the absorbance of the 
complex at 540/660 nm is directly proportional to the concentration of protein in the 
sample. Albumin was measured using the dye Bromocresol green (BCG) which 
preferentially binds serum albumin to cause a shift in the absorption spectrum. The 




concentration. Alkaline Phosphatase (ALP) was measured by the addition of para-
nitrophenyl phosphate (PNPP) which is hydrolysed by ALP to form free phosphate and 
para-nitrophenol, a yellow coloured dye. The rate of increase in absorbance measured 
at 410 nm is directly proportional to ALP activity in the sample. The addition of the 
Siemen’s Healthcare Diagnostics reagents to Bilirubin led to its oxidation and 
consequently a decrease in its concentration. Bilirubin concentrations were measured 
at 451 nm using the change in absorbance over a 5 min reaction period. GGT, on 
addition of the Siemen’s reagents, catalyses a reaction which liberates 4-nitroaniline. 
The increase in absorbance of 4-nitroaniline at 410 nm is directly proportional to the 
activity of GGT in the sample. Reference ranges for each of the liver function outcomes 
are displayed in Table 2.6. If values were outside of the ranges, they were checked by a 
clinician who would sign the subject off as suitable for participation in the study, 
recommend that another blood sample was taken and tested, or advise that the 
subject was not suitable for participation in the study. 
 
Table 2.6 Normal reference ranges for liver function outcomes 
Liver Function Outcome  Males Females 
Total protein (g/L) 60 - 80 
Albumin (g/L) 35 - 50 
Total Bilirubin (µmol/L) 3 - 20 
ALP (IU/L) 30 - 130 45 - 130 
AST (IU/L) 10 - 50 3 - 35 
GGT (IU/L) 1 - 55 
Globulin (g/L) 25 - 35 




Blood samples were collected into 5 mL (Becton-Dickinson, Cat no. 367954) or 8.5 mL 
(Becton-Dickinson, Cat no. 367958) gel separator tubes, left to stand at room 
temperature for 30 min, centrifuged at 1300 g for 15 min, and the serum separated. 
The ADVIA 2400 Clinical Chemistry System (Siemens Healthcare Diagnostics Ltd) was 
used to run colourimetric assays to measure TC, HDL-C and triglycerides. Screening 




determination within 4 days of collection. The other samples were stored at -80  ̊C and 
analysed in batches once the study was finished. LDL-C was calculated by the 
Friedwald formula: 
 
            LDL cholesterol = Total cholesterol - HDL cholesterol - (Triglyceride/2.2) 
(The calculation becomes invalid if triglyceride is > 4.5) 
 
 Total cholesterol 2.4.4.1
Serum TC was determined using an enzymatic method in which cholesterol esterase 
completely hydrolyses cholesterol esters to free cholesterol, which is in turn oxidised 
by cholesterol oxidase, generating hydrogen peroxide. The hydrogen peroxide formed 
combines with 4-aminophenazone and a phenol to form a red quinone amine dye. The 
absorbance of this was measured at 505/694 nm with the increase in dye absorbance 
being directly proportional to the concentration of cholesterol in the sample. The 
cholesterol reagent was supplied by Siemens Healthcare Diagnostics Ltd. The inter-
assay CVs were 1.1%, 1.5% and 1.0% and the intra-assay CVs were 0.6%, 0.6% and 0.6% 
for low, medium and high QCs, respectively. 
 
 HDL cholesterol 2.4.4.2
HDL-C was measured in serum using a two-step automated procedure using reagents 
supplied by Siemens Healthcare Diagnostics Ltd. In the first step, cholesterol esterase 
and cholesterol oxidase react to remove non-HDL-C from the sample. The hydrogen 
peroxide produced is then removed by the enzyme catalase. In stage 2, detergent is 
added to allow HDL-C to react with the enzyme system. Sodium azide inhibits the 
reaction of the hydrogen peroxide formed with catalase. The hydrogen peroxide then 
reacts with 4-aminoantipyrine to produce a quinoneimine pigment measured at 596 
nm. The resulting colour is proportional to the concentration of HDL-C. The inter-assay 
CVs were 2.2%, 2.1% and 2.5% and the intra-assay CVs were 1.1%, 1.4% and 1.5% for 
low, medium and high QCs, respectively. 
 
 Triglycerides 2.4.4.3
Reagents were supplied by Siemens Healthcare Diagnostics Ltd. Triglycerides were first 




then converted to glycerol-3-phosphate by glycerol kinase and glycerol-3 phosphate 
was subsequently converted to hydrogen peroxide by glycerol-3-phosphate-oxidase. 
The hydrogen peroxide produced reacted with a chromophore under the catalytic 
influence of peroxidise and the absorbance of the complex, which is proportional to 
the triglyceride concentration, was measured as an endpoint reaction at 505/694 nm. 
The inter-assay CVs were 2.5% and 1.5% and the intra-assay precisions were 0.6% and 
0.5% for low and high QCs, respectively. 
 
2.4.5 Calcium 
Calcium was measured on the ADVIA 2400 Clinical Chemistry System (Siemens 
Healthcare Diagnostics Ltd) using a colourimetric assay. Blood samples were collected 
into 5 mL (Becton-Dickinson, Cat no. 367954) or 8.5 mL gel separator tubes (Becton-
Dickinson, Cat no. 367958), left to stand at room temperature for 30 min, and 
centrifuged at 1300 g for 15 min at 4  ̊C. The sample was sent at room temperature on 
the day of collection to KCH for analysis. Calcium reagents were supplied by Siemens 
Healthcare Diagnostics Ltd. Reagent 1 (ethanolamine buffer) provided an alkaline 
medium in which calcium was able to react with cresolpthalein complex one (from 
reagent 2) to form a violet coloured chromophore which was monitored at its 
absorbance maximum of 545 nm. The absorbance was proportional to the sample’s 
calcium concentration. The inter-assay CVs were 2.3%, 2.3% and 1.9% and the intra-
assay CVs were 0.8%, 2.0% and 0.7% for low, medium and high QCs, respectively. 
 
2.4.6 Vitamin D 
There are several available methods for measuring 25-OH-D metabolites (Table 2.7). 
The two main types of methods used are competitive immunoassays 
[radioimmunoassay (RIA), enzyme-linked immunoassay (EIA) and chemiluminescence 
immunoassay (CIA)] and those which involve a chromatographic separation, followed 
by detection of the analyte without the use of antibodies [High-Pressure Liquid 
Chromatography with UV Detector (HPLC-UV) and liquid chromatography tandem 
mass spectrometry (LC-MS/MS)]. Inter-laboratory discrepancies have been reported 
between the results of these different assays (Binkley et al. 2004). Standardisation of 
methods is necessary to bring laboratories into alignment and ensure accuracy in order 




The National Institute of Standards and Technology (NIST) has developed a Standard 
Reference Material, SRM 972 which consists of four blood serum sample pools with 
varying levels of 25-OH-D and certified values for 25-OH-D2, 25-OH-D3, and 3-epi-25-
OH-D3 (Phinney 2008). This can be used as a reproducible point of comparison of 
accuracy between methods and to validate new methods as they are developed 
(Phinney 2008). DEQAS (International Vitamin D External Quality Assessment Scheme) 
is also available for laboratories to participate in to ensure the analytical reliability of 
25-OH-D assays. Human unprocessed serum is distributed quarterly to participating 
laboratories and a Proficiency Certificate is issued to those whose returned results 
meet the performance targets set by the DEQAS Advisory Panel (DEQAS 2014). 
Dependant on what the purpose of the 25-OH-D measurement is, certain methods 
may be more appropriate to use than others. For example, only the HPLC-UV and LC-
MS/MS methods are able to measure 25-OH-D2 and 25-OH-D3 separately and equally 
well (de la Hunty et al. 2010), whereas generally immunoassays, although able to 
detect both metabolites, may not be able to accurately detect the proportion of 25-
OH-D2 (Carter et al. 2007). In terms of precision, all the methods are similar (de la 
Hunty et al. 2010), apart from LC-MS/MS which is better. For diagnosis purposes, all 
the methods described above are able to measure 25-OH-D concentrations <25 nmol/L 
which represents deficiency, although LC-MS/MS has the highest sensitivity. LC-MS/MS 
has greater accuracy compared to competitive immunoassays; compared to the target 
value of the NIST SRM 972, LC-MS/MS results showed a smaller mean deviation (% 
bias) of +1.9% compared to between -14.7% and -11.6% for two different CIAs (Moon 
et al. 2012). The advantage of the immunoassays is that they are more convenient and 
have high throughput capabilities. HPLC-UV and LC-MS/MS both require an initial 
sample extraction stage which, although useful as it removes interfering substances, is 
time-consuming and labour-intensive, meaning that less samples can be processed in a 
certain time period (de la Hunty et al. 2010). Furthermore, although semi-automated 
or automated procedures have been developed for HPLC-UV and LC-MS/MS, 
immunoassays have much quicker run times, particularly if an automated procedure is 
used (Wallace et al. 2010). The cost of the assay is another factor to take into account 
when deciding which assay to use. LC-MS/MS and HPLC-UV are expensive (£25-£27 per 
sample) due to the high cost of equipment and need for highly skilled staff, compared 




sample is around £10-£17 (Wallace et al. 2010). Another factor to consider is the 
potential interference of 3-epi-25-OH-D3. In October 2011 a DEQAS survey assessed 
the ability of immunoassays, HPLC and LC-MS/MS to distinguish between epi-25-OH-D3 
and 25-OH-D3 by giving laboratories two matched samples; one containing only 25-OH-
D3 and the other additionally containing 50 nmol/L epi-25-OH-D3. The majority of 
immunoassays including the ADVIA Centaur CIA do not recognise 3-epi-25-OH-D3, but 
HPLC and LC-MS/MS detected both epi-25-OH-D3 and 25-OH-D3. With LC-MS/MS, 
many laboratories are unable to resolve 3-epi-25-OH-D3 from 25-OH-D3 as most 
methods cannot differentiate between compounds which have an identical elemental 
composition but different structure, and this can result in an overestimation of the 
true 25-OH-D3 concentration (Bailey et al. 2013). However, in adults, the percentage 
contribution of 3-epi-25-OH-D3 to total 25-OH-D3 appears to be small (Bailey et al. 
2013). Overall, LC-MS/MS is considered to be the best assay for detection and 
quantification of serum 25-OH-D, although if cost is an issue and it is not necessary to 
obtain the proportions of 25-OH-D2 and 25-OH-D3 that are contributing to total 25-OH-
D, it may be preferable to use an immunoassay (de la Hunty et al. 2010).  
 
For both the D2/D3 and DRISK studies, it was necessary to be able to measure 25-OH-D2 
and 25-OH-D3 separately to measure the responses to D2 and D3 supplementation and 
to check that there was no increase in 25-OH-D3 as a consequence of UVB exposure. It 
was decided to use LC-MS/MS for the duration of both studies as it is able to measure 
the two 25-OH-D metabolites separately with high specificity and high precision. The 
present study used an improved method which uses a smaller sample (0.1 mL) in ultra 
high pressure liquid chromatography tandem mass spectrometry (UPLC-MS/MS) (Ding 
et al. 2010) compared with conventional LC-MS/MS assays which use 0.5-1.0 mL. In 
order to reduce run-to-run variability, samples were batched so that the analyses for 
the same individual were completed in the same run. The uHPLC method was 
developed by HFL Sport Science (Fordham, Cambridgeshire) which are now part of the 
Laboratory of the Government Chemist. For screening in the DRISK study, and in the 
CRESSIDA and MARINA studies, plasma total 25-OH-D was determined by a 
chemiluminescent immunoassay as detailed below because of the lower cost and the 
speed of turnaround of samples to enable a decision to be made to exclude 




Table 2.7 Summary of methods for measurement of 25-OH-D adapted from (de 
la Hunty et al. 2010) and (Wallace et al. 2010).  
 RIA CIA HPLC-UV LC-MS/MS 
uHPLC 
MS/MS 
Ability to measure 
25OHD2 and 
25OHD3 separately 
Poor Poor Excellent Excellent Excellent 




Acceptable Acceptable Excellent Excellent Excellent 
Precision Acceptable Good Good Good Excellent 
Cost per sample 
(approx) 
£17 £10 £15 £25 £27 
RIA, Radioimmunoassay; CIA, Chemiluminescent immunoassay; HPLC-UV, High-Pressure Liquid 




 Measurement of 25-OH-D metabolites by UPLC-MS/MS 2.4.6.1
25-OH-D2 and 25-OH-D3 were measured using UPLC-MS/MS. Blood samples were 
collected into 5 mL gel separator tubes (Becton-Dickinson, Cat no. 367954), left to 
stand at room temperature for 30 min, and centrifuged at 1300 g for 15 min at 4  ̊C. 
The serum was pipetted into eppendorfs and stored in the -80  ̊C freezer until the end 
of the study. It was then sent along with all the other vitamin D samples from the rest 
of the study to HFL Sport Science (Fordham, Cambridgeshire) for analysis. Internal 
standards used were hexadeuterated 25-OH-D2 and 25-OH-D3 (25-hydroxyvitamin D2-
(26,26,26,27,27,27-D6) and 25-hydroxyvitamin D3-(26,26,26,27,27,27-D6)). These were 
spiked into 100 µl of sample along with a protein precipitation reagent, mixed, and 
placed in a centrifuge in order to precipitate out all of the protein before being 
analysed by UPLC-MS/MS. The LC stage uses a reverse phase chromatography column 
(Waters C18 Acquity column 1.8 μm  2.1 x 50 mm) with a flow rate of 0.6 mL/min. 
which flushes away hydrophilic interfering compounds. Hydrophobic compounds, 
including 25-OH-D in the sample and the internal standards, stick to alkyl chains on the 




away these compounds. The remaining sample then travels to a mass spectrometer 
(MS) analytical column which ionises the compounds in a vacuum into positively 
charged ions. As there are many steroids with a similar ratio, the compounds are then 
forced through a filter filled with inert gas to fragment the ions; the way in which 
fragmentation occurs is specific to the compound. Subsequently, the ion fragments are 
accelerated so that they all have the same kinetic energy. They are then deflected by a 
magnetic charge according to their mass:charge ratio (M/E), with the lighter and more 
charged ions being deflected more. The MS counts the number of ion fragments 
deflected for each mass:charge ratio. The output has peaks for 25-OH-D2, 25-OH-D3 
and the two deuterated internet standards (Figure 2.10). The assay was fully validated, 
including the elements of dynamic range, sensitivity, selectivity, matrix effects, carry 
over, precision and accuracy. Each sample batch contained quality control (QC) 
samples at three concentrations (low, medium and high) with each QC level analysed 
in duplicate. Batch acceptance criteria were that no more than two QC samples were 
allowed to deviate by more than 15% from their target value within each batch, with 
those two failed QCs having to be at different concentrations. The inter-assay 
precisions (%CV) for low, medium and high QCs for 25-OH-D2 were 5.9%, 6.7% and 
7.3%, and accuracies (%RE) were 1.2%, 2.3% and 0.5% respectively. The intra-assay 
precisions for low, medium and high QCs for 25-OH-D3 were 5.4%, 7.5% and 8.2%, and 
accuracies were 6.6%, 5.6% and 3.4% respectively. The assay was validated over the 
range 1 to 150 ng/mL for 25-OH-D2 and 3 to 150 ng/mL for 25-OH-D3. The lowest 











 Measurement of 25-OH-D by competitive chemiluminescence 2.4.6.2
immunoassay 
Total 25-OH-D was measured in the DRISK study at screening and in the MARINA and 
CRESSIDA studies using a chemiluminescent immunoassay at the Department of 
Clinical Biochemistry at KCH (KingsPath). This laboratory participates in DEQAS (DEQAS 
2014), and has been issued a Proficiency Certificate (Appendix 8). Blood samples were 
collected into 5 mL gel separator tubes (Becton-Dickinson, Cat no. 367954), left to 
stand at room temperature for 30 min, and centrifuged at 1300 g for 15 min at 4  ̊C. 
The serum was sent at room temperature on the day of collection to KCH for analysis. 
Vitamin D reagents were supplied by Siemens Healthcare Diagnostics Ltd and the assay 
was run on the Siemens Advia Centaur analyser. The serum was added to a cuvette 
and treated to remove 25-OH-D from binding proteins. The resulting mixture was then 
incubated with an antibody to 25-OH-D bound to acridinium ester. A vitamin D 
analogue (labelled with fluorescein) was added together with an antibody to 
fluorescein bound to paramagnetic particles (PMP). 25-OH-D in the sample competes 
with the vitamin D analogue for binding to the 25-OH-D antibody, such that when 
there is a higher concentration of 25-OH-D present in the sample, less of the analogue 
binds. A magnetic field was applied to the reaction mixture causing the solid-phase 
PMP (which is bound to the antibody-antigen complex) to be held at the side of the 
reaction cuvette while the liquid phase was aspirated. After a couple of washes of the 
cuvette contents with a phosphate-buffered saline, acid reagent (containing hydrogen 
peroxide) was added to the cuvette to begin the light-emission reaction with the 
acridinium ester. The cuvette was then moved to the luminometer where base reagent 
was added to enhance the light reaction. The light intensity was measured 
immediately and converted to 'relative light units' (RLU). The RLU value has an inverse 
relationship with 25-OH-D concentration (the higher the RLU value, the lower the 25-
OH-D concentration). The inter-assay CVs were 11.1%, 9.8% and 4.8%, and the intra-
assay CVs were 7.0%, 5.8% and 2.7% for low, medium and high QCs, respectively. The 
assay was validated for serum concentrations up to 374 nmol/L. The lowest detectable 







2.4.7 Parathyroid hormone (PTH) 
PTH was measured on a Siemens Centaur by immunoassay, and PTHi reagent was 
supplied by Siemens Healthcare Diagnostics Ltd. Blood samples were collected into 2 
mL (Becton-Dickinson, Cat no. 367836) or 4 mL EDTA tubes (Becton-Dickinson, Cat no. 
367839), stored in ice, and centrifuged at 1300 g for 15 min at 4  ̊C before being stored 
within 2 h of collection at -80  ̊C. Plasma samples were sent at the end of the study to 
KCH for analysis with all other PTH samples collected during the study. The plasma 
sample was incubated with two PTH-specific antibodies. The first was labelled with 
acridinium ester (AE) and the second was a biotinylated polyclonal goat anti-human 
PTH antibody. Streptavidin (biotin-binding protein) in the Solid Phase is covalently 
coupled to paramagnetic particles (PMP). PTH forms a 'sandwich' between the two 
antibodies. After the incubation period a magnetic field is applied to the reaction 
mixture causing the solid-phase PMP (including the 'sandwich') to be held at the side 
of the reaction cuvette while the liquid phase is aspirated. The cuvette contents are 
washed with deionised water which is then aspirated, again with the magnetic field 
applied. Acid reagent (containing hydrogen peroxide) is added to the cuvette to begin 
the light-emission reaction with the acridinium ester. The cuvette is moved to the 
luminometer at which point base reagent is added to enhance the light reaction. The 
light intensity is measured immediately and converted to 'relative light units' (RLU). 
The RLU value has a direct relationship with PTH concentration (i.e. the higher the RLU 
value, the higher the PTH concentration). The inter-assay CVs were 5.2%, 3.4% and 
3.5% and the intra-assay precisions were 4.3%, 23.7% and 91.1%, for low, medium and 
high QCs, respectively. The assay was validated for serum concentrations up to 374 
nmol/L. The limit of detection was 8.0 nmol/L.  
 
2.4.8 Renin  
Renin was measured by chemiluminescence immunoassay in the DRISK study at 
baseline, mid-point and end-point on a Liaison chemiluminescence analyser (Diasorin, 
Charles House, Toutley Road, Wokingham, Berkshire) using the Diasorin Liaison direct 
renin reagent. Blood samples were collected into 4 mL EDTA tubes (Becton-Dickinson, 
Cat no. 367839) and centrifuged at 1300 g for 15 min at room temperature before 
being stored at -80  ̊C. Plasma samples were sent at the end of the study to KCH for 




recognises both renin and prorenin and another monoclonal antibody specific for renin 
which is linked to an isoluminol derivative (isoluminol-antibody conjugate). During the 
incubation, renin and prorenin in samples bind to the solid phase monoclonal 
antibody. Subsequently the antibody conjugate reacts with renin already bound to the 
solid phase to form a soluble sandwich complex. Following incubation, the unbound 
material is removed by a wash cycle. The wells containing the washed magnetic 
particles are transported into the system luminometer which initiates a flash 
chemiluminescence reaction by the addition of hydrogen peroxide and an alkaline 
solution to oxidise the isoluminol derivative. The light produced is quantified by the 
luminometer and expressed as relative light units (RLU). The amount of bound labelled 
antibody is directly proportional to the concentration of renin in the sample. The inter-
assay CVs were 10.0%, 12.4% and 5.7% and the intra-assay CVs were 3.7%, 2.8% and 
2.0% for low, medium and high QCs, respectively. 
 
2.4.9 High sensitivity C-reactive protein 
HsCRP was measured using Immuno Turbidimetry. Blood samples were collected into 
8.5 mL gel separator tubes (Becton-Dickinson, Cat no. 367958), left to stand at room 
temperature for 30 min, and centrifuged at 1300 g for 15 min at room temperature 
before being stored at -80  ̊C. HsCRP was analysed using an anti-CRP antibody 
sensitized to latex particles (P.Z. Cormay, Lubin, Poland) which coats latex particle 
surfaces and then reacts with CRP in the sample resulting in visible agglutination. The 
degree of agglutination was detected by turbidimetry at 572 nm as a reduction in the 
intensity of transmitted light on an ADIVA 2400 analyser (Sieman’s Healthcare 
Diagnostics, Frimley, Surrey, UK). The inter-assay CVs were 6.97, 3.34 and 1.23% and 
the intra-assay CVs were 5.74, 1.99 and 1.16% for low, medium and high QCs. 
 
2.4.10 MMP-9 
MMP-9 was measured using a Quantikine MMP-9 enzyme-linked immunosorbent 
assay (ELISA) kit distributed by R & D Systems Europe (19 Barton Lane, Abingdon 
Science Park, Abingdon, Oxon, OX14 3NB) on serum. Blood samples were collected 
into 8.5 mL gel separator tubes (Becton-Dickinson, Cat no. 367958), left to stand at 
room temperature for 30 min, and centrifuged at 1300 g for 15 min at room 




study to KCH for analysis. The assay employs the quantitative sandwich enzyme 
immunoassay technique. A monoclonal antibody specific for MMP-9, pre-coated onto 
a microplate is provided in the kit. Standards and samples were pipetted into the wells 
and any MMP-9 present was bound by the immobilsed antibody. After washing away 
any unbound substances, an enzyme-linked monoclonal antibody specific for MMP-9 
was added to the wells. Following a wash to remove any unbound antibody-enzyme 
reagent, a substrate solution was added to the wells and colour developed in 
proportion to the amount of MMP-9 bound in the initial step. The colour development 
was stopped and the intensity of the colour measured. The inter-assay CVs were 7.9%, 
7.8 and 6.9% and the intra-assay CVs were 2%, 1.9% and 2.9% for low, medium and 
high QCs, respectively. 
 
2.4.11 C-peptide 
C-peptide was measured by immunoassay on the Siemens Immulite 2000 analyser in a 
solid-phase, two-site chemiluminescent immunometric assay. Reagents were supplied 
by Siemens Healthcare Diagnostics Ltd (Newton House, Surrey GU16 8QD). Blood 
samples were collected into 8.5 mL gel separator tubes (Becton-Dickinson, Cat no. 
367958), left to stand at room temperature for 30 min, and centrifuged at 1300 g for 
15 min at room temperature before being stored at -80  ̊C. Serum samples were sent 
at the end of the study to KCH for analysis. The solid phase (bead) was coated with a 
monoclonal anti-C-peptide antibody. The liquid phase consisted of alkaline 
phosphatase (ALP) conjugated to monoclonal anti-C-peptide antibody in buffer. The 
sample and reagent were incubated together with the coated bead for 30 min. During 
this time, C-peptide in the sample forms an antibody sandwich complex with 
monoclonal anti-C-peptide antibody in the reagent. Unbound sample and enzyme 
conjugate were then removed by centrifugal washes.  Finally, a chemiluminescent ALP 
substrate was added to the reaction tube containing the bead. ALP bound to the 
antibody complex dephosphorylates the substrate and this releases light which is 
measured by a luminometer. The signal generated is in proportion to the 
concentration of C-peptide. The inter-assay precisions CVs were 2.9%, 2.5 and 1.6%, 






2.4.12 Haemostatic assays – Fibrinogen and Factor VII 
Fibrinogen and FVII are involved in a coagulation cascade that helps to arrest bleeding 
in response to vascular injury, but when disrupted can lead to thrombosis and bleeding 
(Borissoff et al. 2011). Initially, following vascular injury, tissue factor is exposed to the 
blood and this triggers a coagulation cascade beginning with the tissue factor 
(extrinsic) pathway shown in Figure 2.11. When thrombin is generated, an intrinsic 
pathway can be triggered and the two pathways converge (Davie et al. 1991). Here, 
only the extrinsic pathway will be discussed as it involves FVII and fibrinogen which are 
relevant to this thesis. Tissue factor has a high affinity for FVII, and the two form a 
catalytic complex in the presence of calcium ions which facilitates the conversion of 
FVII to FVIIa. Subsequently, the FVIIa-tissue factor complex converts factor X to factor 
Xa. These two reactions rely on tissue factor acting as a cofactor to accelerate the 
conversions. In order for prothrombin to be converted to thrombin, Factor Xa, in the 
presence of calcium ions and phospholipid, forms a complex with Factor Va known as 
prothrombinase. Once thrombin is formed, it converts fibrinogen to fibrin. After the 
formation of fibrin, the conversion of Factor XIII to Factor XIIIa by thrombin, in the 
presence of calcium ions is accelerated. Factor XIIIa enables incorporation of other 
plasma proteins into the fibrin clot. In addition to converting fibrinogen to fibrin, 
thrombin has an important role in the activation of platelets. It activates Factor XIII 
which induces side-by-side fibrin polymerisation to generate an insoluble, stable, fibrin 
clot, or thrombus in atherosclerosis. Additionally, it supports positive-feedback 
activation of the Factors V, VIII and XI, allowing for the amplification and propagation 
of coagulation. Further amounts of tissue factor, Factor V, Fibrinogen, and Factor XIII 







Figure 2.11 Tissue Factor Extrinsic Pathway taken from (Borissoff et al. 2011). 
Numbered Factors are abbreviated as IX, X, VII etc. 
 
 Factor VII 2.4.12.1
FVIIc was measured on frozen citrated plasma samples that were rapidly thawed and 
brought to 37 ̊C to avoid cold activation. Blood samples were collected into 4.5 mL 
sodium citrate tubes (Becton-Dickinson, Cat no. 367958) and centrifuged at 1300 g for 
15 min at room temperature before being stored at -80  ̊C within 2 h of collection. FVIIc 
was measured using a one-stage bioassay on the STart® 4 Hemostasis Analyzer 
(coagulometer) (Diagnostica Stago UK Ltd, 2 Theale Lakes Business Park, Moulden 
Way, Theale, RG7 4GB). The sample plasma was thawed in a water bath set at 38 ̊C. It 
was then diluted 1:40 in Imidazole buffer (Diagen, Diagnostic Reagents Ltd, Thame, 
Oxon, OX9 3NY) before adding 50 µl of it to an equal volume of bovine FVII deficient 
plasma (prepared as described elsewhere (Miller et al. 1994)) in a cuvette well on the 
coagulometer. A metal bead was added, and the mixture warmed for 60 seconds at 
38  ̊C. Coagulation was initiated by the addition of 100 µl of Calcium Rabbit Brain 
Thromboplastin (Diagen, Diagnostic Reagents Ltd, OX9 3NY) and the time taken for clot 
formation measured as when the metal ball stopped moving. FVIIc was expressed as a 





































Diagnostica Stago UK Ltd, 2 Theale Lakes Business Park, RG7 4GB) by reference to its 
standard curve (Figure 2.12). This standard was calibrated against the WHO 2nd 
International Standard for FVII Concentrate (NIBSC code number: 10/252). The 
standard had a FVIIc activity of 93%. It was reconstituted with 1.0 mL of distilled water 
and dilutions were prepared at 1:10, 1:20, 1:40 and 1:60 with imadazole buffer. The 
activity of the dilutions was recorded as 413.3%, 206.7%, 103.3% and 68.9% 
respectively (worked out as 5/4.5 x activity, to adjust for the fact that 0.5 mL in the 
vacutainer was sodium citrate and 4.5 mL plasma). Samples for each subject were 
analysed in the same run to avoid between-assay variation; the within-run CV was 
2.0%. 
 
Before measuring FVIIc in the study samples, experimental work was carried out to 
optimise the method described above. The volume of plasma in each study sample 
eppendorf tube was approximately 1-1.5 mL. In order to work out how long to leave 
the sample in the water bath for and how long the FVIIc in the sample was stable for 
once thawed, two samples of 1 mL and 1.5 mL plasma were taken from volunteers by a 
trained phlebotomist. Each sample was placed in the 38  ̊C water bath and 
temperature readings were taken every 30 seconds. The 1 mL and 1.5 mL samples took 
5 min and 6.5 min respectively to reach 38  ̊C, and so it was decided to thaw the study 
samples for 6 min in order to prevent loss of activity by keeping the sample at 38  ̊C  for 
too long. This experiment further demonstrated that thawing of the samples in the 
water bath led to a very quick rise in temperature of around 5 to 20  ̊C over a 30 sec 
period, so cold activation of FVIIc at around 4-10  ̊C was unlikely. The stability of the 
plasma was also tested once it had reached 38  ̊C by running the assay every 5 min. 
Clotting times started to increase after 15 to 20 min so it was decided to only defrost 4 
samples at once in order to run them all in duplicate on the coagulometer within 15 
min. If the duplicate values were not within around 2-3% of each other, the sample 
was re-run. Another experiment was run to determine how long the deficient plasma 
remained stable for. The activity of a QC was measured every half an hour after 
thawing the deficient plasma to 38  ̊C, demonstrating that it remained stable for 2.5 – 3 
h as the clotting time started to increase after this time. This experiment also 
demonstrated that the QCs, which were 1:40 diluted SHP, are stable when snap frozen 





Figure 2.12 Standard curve showing clotting times for different dilutions of 
standard human plasma (SHP) for calibration purposes. 
 
 Fibrinogen 2.4.12.2
Fibrinogen was measured on frozen citrated plasma that was rapidly thawed and 
mixed. Blood samples were collected into 4.5 mL sodium citrate tubes (Becton-
Dickinson, Cat no. 367958), centrifuged at 1300 g for 15 mins at room temperature 
before being stored at -80  ̊C within 2 h of collection. Fibrinogen concentration was 
determined using the von-Clauss thrombin-clotting method (A 1957) on the STart® 4 
Hemostasis Analyzer (coagulometer) (Diagnostica Stago UK Ltd, 2 Theale Lakes 
Business Park, RG7 4GB). The sample plasma was diluted 1:20 in Owren-Koller buffer 
solution (Diagnostica Stago UK Ltd, 2 Theale Lakes Business Park, RG7 4GB) and 100 µl 
placed in a cuvette well in the coagulometer (Diagnostica Stago UK Ltd, 2 Theale Lakes 
Business Park, RG7 4GB), along with a metal bead. After warming in the well at 38  ̊C 
for 60 seconds, clot formation was initiated by the addition of 50 µl Fibri-Prest® 
Automate (Diagnostica Stago UK Ltd, 2 Theale Lakes Business Park, RG7 4GB). This 
mechanical clotting end point method measures the time it takes for the clot to form 
by measuring the time at which the metal ball stops vibrating. The fibrinogen 
concentration of the plasma was calculated by reference to a standard curve created 
by serial dilutions of a plasma of known fibrinogen concentration (Unicalibrator – 
Diagnostica Stago UK Ltd, 2 Theale Lakes Business Park, RG7 4GB) (Figure 2.13). 
Samples for each subject were analysed in the same run to avoid between-assay 































variation; the within-run CV was 1.54%. Calculations for fibrinogen took into account 
the fact that 0.5 mL in the vacutainer was sodium citrate and 4.5 mL plasma. 
 
 
Figure 2.13 Standard curve showing clotting times for different dilutions of 
unicalibrator for calibration purposes. 
 
2.4.13 Vitamin D binding protein (VDBP) 
VDBP was measured in the DRISK study at baseline, mid-point and end-point using a 
quantitative sandwich enzyme immunoassay technique and a VDBP kit distributed by 
R&D Systems Europe, Ltd. (19 Barton Lane, Abingdon Science Park, Abingdon, OX14 
3NB, United Kingdom). Blood samples were collected into 5 mL gel separator tubes 
(Becton-Dickinson, Cat no. 367954), left to stand at room temperature for 30 min, and 
centrifuged at 1300 g for 15 min at 4  ̊C. The serum was pipetted into eppendorfs and 
stored in the -80  ̊C freezer until the end of the study when it was sent to KCH for 
analysis. The assay kit contained a monoclonal antibody specific for VDBP already pre-
coated onto a microplate. Standards and samples were pipetted into the wells and any 
VDBP present was bound by the immobilised antibody. After washing away any 
unbound substances, an enzyme-linked monoclonal antibody specific for VDBP was 
added to the wells. Following a wash to remove any unbound antibody-enzyme 
reagent, a substrate solution was added to the wells. Colour developed in proportion 
to the amount of VDBP bound in the initial step. The colour development was stopped 

































and its intensity, proportional to the VDBP concentration, was measured. The inter-
assay CVs were 5.1%, 6.0 and 7.4%, and the intra-assay CVs were 5.7%, 5.8% and 6.2% 
for low, medium and high QCs, respectively. 
 
2.5 Dietary analysis 
In this thesis the aim was to determine vitamin D and calcium intake from the diet. 
Different dietary assessment methods are available, but after consideration of the 
main strengths and limitations related to the required purpose of the studies in this 
thesis (Table 2.8), a food frequency questionnaire (FFQ) was chosen. A FFQ is suitable 
as, although it does not provide valid estimates of absolute intake in individuals, it 
ranks the intake of individuals relative to others in the population and can be used to 
identify changes in diet. It is also affordable, relatively quick and simple for the 
participant to complete and does not require an investigator to be present. 
Furthermore, it assesses diet over a longer period of time than other methods which 
allows for the capture of vitamin D intake, a nutrient present in only a limited number 
of foods such as oily fish, which may not be consumed regularly. However, the 
disadvantage of FFQs is that reported intake is limited to the foods contained in the 
food list which are unlikely to distinguish between, for example, fortified and non-
fortified products. The CRESSIDA study (section 2.6.1), conducted by another study 
group, required a more detailed dietary analysis to assess energy and macronutrient 
intake as well as micronutrients, and so estimated 4-d food diaries were completed 
(section 2.5.2). Advantages of 4-d food diaries are that portion sizes are often well 
described giving a more accurate estimation of the quantity of foods consumed, and 
detailed descriptions of the different foods can be given enabling more accurate 
coding. However, the small number of days of recording can mean that nutrients such 
as vitamin D may not be captured. Furthermore, food diaries are time consuming for 
the participant to complete and the investigator to analyse compared with FFQs. Both 
estimated food diaries and FFQs are subject to under-reporting which can introduce 
bias. In FFQs, respondents may report eating less healthy foods less frequently than 
they actually do, and in food diaries an individual may decide to alter their diet to 
make it simpler to record, or to cover up poor eating habits. Some authors have used a 
pre-defined cut-off for the ratio of reported energy intake to calculated Basal 




1991). This technique is often used to correct for under-reporting energy intake but is 
not appropriate for evaluating FFQs where only a few foods supply most of the intake 
as with calcium and vitamin D. Adjustment for under-reporting of energy would inflate 
values, and excluding participants on the basis of under-reporting energy intake would 
introduce selection bias. Consequently, no adjustments for reported energy intake 
were made, but in line with the EPIC study, it was decided to exclude FFQs that had 
fewer than 70% of the food items checked (Davey et al. 2003). 
 
Table 2.8 Summary of potential dietary assessment methods to use in the D2/D3 






 Relatively simple to 
analyse 
 Does not require literacy 
 Will not provide a valid estimate 
of nutrient intake for nutrients 
which are not consumed every 
day. 




 Quick, easy to administer 
and affordable 
 Can be used to assess diet 
over an extended period 
 Does not provide a valid estimate 
of absolute intake in individuals, 
but is good for ranking individuals 
in terms of their nutrient intake in 
a population 
 Relies on accurate memory of the 
participant 
Food diary  
 Does not rely on memory 
 Several days of food intake 
can be recorded to 
provide valid estimates of 
nutrient intake for 
individuals 
 Time consuming and costly to 
code foods and analyse data 
 High participant burden as time 
consuming 
 The burden of recording all foods 
consumed may influence what is 
consumed i.e. simpler meals may 
be cooked. 
Diet History 
 Good for obtaining 
reasonably accurate  
estimates of nutrient 
intake for individuals  
 Very high investigator and 
participant burden 
 Time consuming and costly to 







2.5.1 Food frequency questionnaire 
A lifestyle questionnaire (Appendix 9) similar to that used in the European Prospective 
Investigation in Cancer (EPIC) study (Bingham et al. 2001), that has been validated for 
vitamin D intake in the UK population (Crowe et al. 2011), was chosen for the D2/D3 
study and DRISK study. The FFQ part of the questionnaire asked about the average 
frequency of consumption of 130 food and beverage items in the preceding 12 months 
with 9 frequency options ranging from never or less than once per month to 6+ times 
per day. The same questionnaire was also used in the CRESSIDA (section 2.6.1) and 
MARINA (section 2.6.2) studies. 
 
2.5.2 4-d food dairy 
A 4-d food dairy was used in the CRESSIDA study (section 2.6.1) to assess dietary intake 
at baseline and 12 wk. Foods entered were coded by a study investigator and the 
vitamin D intake estimated using WISP version 3.0. 
 
2.6 Outline of previous studies on which further analysis of vitamin D status and 
vascular function measures were made 
2.6.1 CRESSIDA 
 Objective 2.6.1.1
The CRESSIDA (Cardiovascular risk REduction Study: Supported by an Integrated 
Dietary Approach) compared effects on CVD risk factors and factors associated with 
the development of CVD of the UK dietary guidelines (DG) and a control based on a 
conventional British dietary pattern. Using a parallel-designed randomised controlled 
trial in 165 healthy non-smoking men and women aged 40-70 y, measurements were 
made of ABP on five occasions, and vascular function and CVD risk factors at baseline 
and after 12 wk, following random assignment to treatment. The primary outcomes 
were changes in 24 h day-time SBP and TC:HDL-C and secondary outcomes were 
changes in FMD, carotid to femoral PWV, hsCRP and a measure of insulin sensitivity 
(RQUICKI). The DG diet had a reduced salt and saturated fatty acid content, an 
increased proportion of wholegrain cereals, at least 5 portions of fruit and 
vegetables/d and advice to consume 1-2 portions of oily fish/wk. Measurements of 




Blood samples were collected at the beginning and end of the intervention and were 
available for vitamin D analysis.  
 
 Dietary intervention 2.6.1.2
The main dietary goals for the control and cardioprotective diet are displayed in Table 
2.9. Both diets were designed to provide 35% energy as fat. The DG diet aimed to 
supply approximately 10% saturated fatty acids (SFA); 16% monounsaturated fatty 
acids (MUFA), 6% polyunsaturated fatty acids (PUFA) and <1 % trans fatty acids (TFA). 
Salt intake was restricted to <6 g/d, and participants were asked to consume 5 portions 
of fruit and vegetables/d, two portions of fish/wk (one of which should be oily) and 
wholegrain cereal accounting for >50 % cereal intake. They were also given restrictions 
on intake of added sugars. The control diet aimed to supply approximately 14% SFA, 
12% MUFA, 6% PUFA and <1% TFA, 3 portions of fruit and vegetables/d, oily fish less 
than 1 serving/month and no restriction on salt intake or added sugars.  No advice was 
given to restrict the intake of food energy. 
 
Table 2.9 Summary of the main dietary goals of the control and UK dietary 
guidelines diets 
 
Diet constituent Control UK dietary guidelines diet (DG)  
Salt Not restricted < 6 g/d 
Saturated fatty acids ~ 13% energy < 10% energy 
Fruit and vegetables 3 serves / d 5 serves/d 
Oily fish <1 serve/ mo 1-2/ wk 
Wholegrain Refined cereals > 50% cereal intake 
Added sugars Not restricted Restricted 
Total fat ~ 35% energy ~ 35% energy 
 
Each group was provided with some foods in order to help them comply with the 
dietary advice they received. For example, to encourage subjects following the DG diet 
to increase their oily fish consumption, they were reimbursed for fresh oily fish that 




diet were provided with tins of tuna and discouraged from consuming oily fish. 
Reinforcement of dietary advice was given throughout the study by a dietician. 
 
 Study design 2.6.1.3
The study was approved by the St Thomas’ Hospital NHS Research Ethics Committee 
(Ref: 10/H0802/24), was formally registered as a randomised controlled trial (ISRCTN 
92382106 http://www.controlled-trials.com/ISRCTN92382106), and received NHS R&D 
approval from the Guy’s and St Thomas’ Hospitals Foundation Trust. The study PIs 
were Professor Tom Sanders, Professor Philip Chowienczyk and Dr Wendy Hall. 
 
A two-arm parallel design was used (Figure 2.14) and participants were randomly 
allocated to the control or DG diet for 12 wk by a computer programme using 
minimisation with age, gender, ethnicity and BMI. Recruitment started in 2010 with 
the first participant randomised in August 2010, and the last participant completing 





Figure 2.14 CRESSIDA study design. LQ, lifestyle and food frequency questionnaire; 




Non-smoking men and women aged 40-70 y were recruited through newspaper and 
magazine advertisements, recruitment databases and an email circular to KCL staff and 
students. A fasting blood sample was taken at the screening appointment to 
determine that the subject’s serum lipids (TC:HDL-C ratio <6.0, triglycerides <5.0 
mmol/L, TC <8.0 mmol/L), liver function, glucose (<7.0 mmol/L) and haematology were 
within prescribed limits, and a urine sample was tested for cotinine, to exclude 
subjects with unreported smoking habit. Exclusion criteria included a reported history 
of angina, myocardial infarction or stroke, clinical history of cancer (excluding basal cell 
carcinoma) in the past 5 y, uncontrolled type 2 diabetes mellitus (fasting plasma 
glucose >7mmol/L), type 1 diabetes mellitus, chronic renal, liver or inflammatory 
bowel disease, history of substance abuse or alcoholism, pregnancy, unwilling to 
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refrain from the use of dietary supplements, unwilling to restrict consumption of oily 
fish, medication for high BP or serum cholesterol, weight change of >3 kg in preceding 
2 months, BMI <20 and >35 kg/m2 and an overall risk of CVD over the next 10 y of 




Figure 2.15 CRESSIDA CONSORT follow diagram 
 
In total, 599 subjects were assessed for eligibility (Figure 2.15), and of these, 165 
eligible subjects agreed to be randomised to the control or DG diet. Drop-out rates 
were very low with only 3 subjects not able to complete the study, leaving complete 
data on 162 subjects for analysis.  
 
ENROLMENT Assessed for eligibility (n=599)
Excluded (n=434)
•Not meeting inclusion 
criteria (n=127)


























 Outcome measurements 2.6.1.5
The first baseline visit took place at the metabolic unit in Franklin-Wilkins Building, KCL. 
ABP procedures were fully explained, including how to fit, start and stop the monitor, 
and the participant was given a monitor, that was later returned in person or by 
courier, which they were asked to wear for the next 25 hours. A 4-d food dairy and 
instructions for completing it were given by a registered Dietician, and the participant 
was asked to complete it before the next appointment. The second baseline and 12 wk 
visits at which vascular measurements were made took place at the CRF at St Thomas’ 
Hospital. Participants wore another ABP monitor for 25 hours at least 2 days before 
these appointments (section 2.2.4). They were requested to avoid alcohol and vigorous 
exercise the day before, and to consume a meal low in fat and salt, provided by the 
study, the night before. They were asked to consume nothing but water after 2200 the 
night before and to arrive at the visits fasted. Measurements of weight, height and 
body composition were made, followed by the collection of a venous blood sample. 
After resting in the supine position for 15 min, supine BP was recorded using an 
automated sphygmomanometer (Omron 70CP or equivalent auto arm BP monitor). Up 
to six measurements were made ensuring that the coefficient of variation was less 
than 5% for 3 measurements in order for the results to be acceptable. Following this, 
the participant walked a short distance to an ultrasound room where they rested in 
the supine position for 30 min, before a trained vascular sonographer measured FMD 
of the brachial artery (the method was the same as that described in section 2.2.1). 
Following the vascular assessments, subjects were given breakfast followed by 
structured advice by a registered Dietician to follow the diet they had been randomly 
allocated to. They were provided with some of the foods and recipes to help with 
compliance, and a 4-d food diary which had been completed prior to the visit was 
checked. TC, HDL-C, LDL-C, triglycerides and hsCRP were amongst the analytes 
measured from the blood samples. Participants were requested to stop taking any 




The MARINA (Modulation of Atherosclerosis Risk by Increasing dose of N-3 fatty Acids) 




(LC-PUFAs) equivalent to the consumption of 1, 2 or 4 portions of oily fish/wk, on 
endothelial function and arterial stiffness (Sanders et al. 2011). The primary outcome 
was endothelial function measured by FMD and the secondary outcomes were 
changes in arterial stiffness measured as carotid-femoral PWV, and 24 h ABP. 
Measurements of dietary intake were made by FFQ. Blood samples collected at 
baseline were available for vitamin D analysis.  
 
 Study design 2.6.2.2
Ethics approval was obtained from the St Thomas’ Hospital NHS Research Ethics 
Committee (Ref: 08/H0802/3). The study was formally registered as a randomised 
controlled trial (ISRCTN66664610 http://www.controlled-trials.com/ISRCTN66664610), 
and received NHS R&D approval from the Guy’s and St Thomas’ Hospitals Foundation 
Trust. Full study details have been published (Sanders et al. 2011), but this thesis used 
only the baseline data from the study, so only the methods relevant to this will be 
included here. The study investigators were Professor Tom Sanders, Dr. Wendy Hall, 
Dr. Fiona Lewis, Dr. Philip Chowienczyk and Dr. Zoitsa Maniou. A parallel design was 
used (Figure 2.16) and participants were randomly allocated to 1 of 4 intervention 
groups by a computer program using minimisation with age, gender and ethnicity. The 
intervention was blends of eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) providing 1.8, 0.9 or 0.45 g EPA + DHA, or placebo containing refined olive oil. 
Each treatment included a run-in period whereby participants took 3 placebo 
capsules/d for 1 month and a 12 month intervention phase (3 capsules/d). In this 
period, participants were also asked to not eat oily fish more than once per month. 







Figure 2.16 MARINA study design. LQ, lifestyle and food frequency questionnaire; 




Non-smoking men and women aged 45-70 y were recruited from advertisements in 
newspapers, the study website, and an email circular to KCL staff and students. A 
fasting blood sample was taken at the screening appointment to determine that their 
serum lipids (TC:HDL-C ratio <6.0, triglycerides <5.0 mmol/L, TC <8.0 mmol/L), liver 
function, glucose (<7.0 mmol/L) and haematology were within prescribed limits. 
Exclusion criteria included a medical history of CVD, an overall risk of cardiovascular 
disease over the next 10 y of >20% assessed according to QRISK2 (www.qrisk.org), 
cancer (excluding basal cell carcinoma) in the previous 5 y, type 1 diabetes mellitus, 
uncontrolled type 2 diabetes (fasting plasma glucose >7mmol/L), chronic renal, liver, 
or inflammatory bowel disease, history of substance abuse of alcoholism, pregnancy, 
weight change of >3kg in preceding 2 months, and BMI <20 and >35 kg/m2. After 475 
screening appointments, 367 subjects were randomly assigned to treatment. In the 
run-in period, a total of 25 participants withdrew from the study, leaving data on 342 




 Outcome measurements 2.6.2.4
Baseline measurements were made after the run-in period and participants were 
asked to avoid strenuous exercise, caffeine, alcohol from 1400 on the previous day up 
until the time of the visit. Participants were also requested to avoid foods high in fat 
and to consume a low-fat frozen meal (<10g fat) before 2200 the day before. They 
were asked to consume nothing but water after 2200 and to arrive at the visit fasted. A 
FFQ and lifestyle questionnaire (Appendix 9) was sent to the participant with the run-
in capsules, completed to assess nutrient intake over the previous 12 months, before 
the run-in period, and returned at the visit. Measurements of weight, height and waist 
circumference were made at the beginning of the visit and a venous blood sample 
collected. After a rest in the supine position for 30 min, a trained vascular sonographer 
measured FMD of the brachial artery (the method was the same as that described in 
section 2.2.1). Subsequently, the participant rested supine for 15 min before having 
their arterial stiffness measured using the SphygmoCor VW apparatus with 
SphygmoCor analysis software (SphygmoCor version 7.01 AtCor Medical Pty) (section 
2.2.2.2) and then Vicorder (Skidmore Medical, Bristol, UK) (section 2.2.2.1). At the end 
of the visit, participants were fitted with an ABP monitor (A & D TM-2430 devices from 
A & D Instruments) that they were asked to wear for the next 25 hours (section 2.2.4). 
TC, HDL-C, LDL-C and triglycerides were measured from the blood sample. Subjects 
























Influences on serum 25-OH-D 
concentrations and vascular outcomes 
 
 










Cross-sectional and prospective cohort studies have found a higher prevalence of CVD 
in people with lower serum concentrations of 25-OH-D (Kendrick et al. 2009; Kim et al. 
2008). It is unknown what mechanisms are responsible for these associations, but 
vitamin D may have effects on CVD risk markers such as arterial stiffness, endothelial 
function, BP, inflammatory markers and lipids. Whilst many cross-sectional studies 
measuring serum 25-OH-D and these indices have been published in recent years, they 
have shown inconsistent results (Al Mheid et al. 2011; Pirro et al. 2012; Chacko et al. 
2011; Gepner et al. 2014; Jablonski et al. 2011; Rezai et al. 2011), and only a limited 
number have measured a range of indices of vascular function and markers of 
inflammation in a large cohort of healthy participants. Furthermore, the majority of 
studies that have measured BP have used a clinic reading, rather than an ambulatory 
24 h measurement which is more accurate (Coats et al. 1992).  
 
Serum 25-OH-D concentrations are strongly influenced by UVB exposure in addition to 
dietary intake. The ability to synthesise 25-OH-D from sunlight is dependent on 
exposure (latitude, time of day, season, duration of exposure), the area of skin 
exposed and skin pigmentation. Vieth et al. (Vieth et al. 2007b) argue that 
recommended dietary intakes are unlikely to maintain optimal serum 25-OH-D 
concentrations and that either UVB exposure, which has the adverse effect of 
increasing risk of skin cancer, or high dose supplementation are required. However, 
there is limited published data on the effect of dietary intakes in line with 
recommendations on serum 25-OH-D concentrations. Whilst there are currently no UK 
recommendations for adults, 10 μg is the amount recommended for those confined 
indoors with little exposure to sunlight (Scientific Advisory Committee on Nutrition 
2007). There is no differentiation between men and women despite differences in 
body weight. Oily fish is the richest source of vitamin D in the diet providing 5-16 
µg/100 g, and the Scientific Advisory Committee on Nutrition (SACN) has previously 
advised that people ‘eat at least two portions of fish, of which one should be oily, 
weekly’ (Scientific Advisory Committee on Nutrition 2004). Despite this, the latest 
National Diet and Nutrition Survey (NDNS) figures from between 2008 and 2010 show 
that the mean consumption of oily fish in the UK was 58 g/wk, which is much lower 




due to only 25% of the population being consumers (Beverley Bates 2011). In the UK, 
margarine and some breakfast cereals, cheeses, yoghurts are fortified with vitamin D 
at around only 0.5-2.5 µg/average portion, but unlike the US, the UK does not fortify 
milk (Expert Group on Vitamins and Minerals 2003a).  
 
An opportunity to assess cross-sectional relationships between serum 25-OH-D and 
indices of vascular function and inflammation was provided by data from the CRESSISA 
and MARINA trials where measurements of vascular function, 24 h ABP and hsCRP had 
been taken. The trials recruited healthy non-smoking participants aged 40-70 y who 
had not had a CVD event. The former study also allowed an assessment of the impact 





Low vitamin D status measured as serum 25-OH-D concentrations is associated with 
higher 24 h BP, increased arterial stiffness measured as PWV and impaired endothelial 
function measured as FMD. 
 
Corollary 
The variability in serum 25-OH-D concentrations is determined by usual dietary vitamin 
D intake as well as UVB exposure and skin pigmentation. 
 
3.2.2 Objective 
To measure 25-OH-D concentrations in the 2 RCTs and estimate the influence of usual 
vitamin D intake on these. To investigate associations between 25-OH-D and factors 
including age, BMI, physical activity, gender and skin pigmentation, and to look for 
associations between vitamin D status and 24 h BP, PWV and FMD adjusting for 
potential confounders. 
 
3.2.3 Study design 
Details of the study design, ethics approval, primary and secondary outcomes, 




Chapter 2 for the two trials; section 2.6.1 for CRESSIDA and section 2.6.2 for MARINA. 
The baseline data from both studies have been used in this chapter to investigate the 
relationship between 25-OH-D concentrations and CVD risk markers. In both studies, 
endothelial function was measured using the FMD technique (section 2.2.1), arterial 
stiffness as PWV by SphygmoCor (ArtCor Medical, Sydney, Australia) (section 2.2.2.2) 
and BP by 24 h ABP monitoring. Anthropometric measurements of weight, height and 
waist circumference were made and a venous blood sample taken to determine TC, 
HDL-C, LDL-C, triglycerides and hsCRP using identical methods to those described in 
Chapter 2. The CRESSIDA study recruited men and women aged 40-70 y and the 
MARINA study men and women aged 45-70 y. The percentage of women who were 
post-menopausal was 53% in the CRESSIDA study and 71% in the MARINA study. The 
CRESSIDA study took place August 2010-July 2012, and the MARINA study May 2008-
July 2009. For the purposes of this chapter, the 25-OH-D content of the serum in both 
trials was determined using a chemiluminescent immunoassay (section 2.4.6.2) by 
KingsPath, a CPA laboratory of the Department of Clinical Biochemistry at KCH, 
London. Serum had been stored at -70  ̊C prior to analysis. 
 
The CRESSIDA study compared effects on CVD risk factors of the UK dietary guidelines 
(DG) to a control based on a conventional British dietary pattern. The DG diet had a 
reduced salt and saturated fatty acid content, an increased proportion of wholegrain 
cereals, at least 5 portions of fruit and vegetables/d and advice to consume 1-2 
portions of oily fish/wk. Additional data from this study at the follow-up (12 wk) 
appointment were used to investigate changes in vitamin D status due to increased 
oily fish consumption. A simplified study design for this RCT is displayed in Figure 3.1. 
Serum 25-OH-D concentrations from the 12 wk appointment were also determined.  
 
Subjects in both studies were asked to not take any supplements, including 





Figure 3.1 CRESSIDA study design. LQ, lifestyle and food frequency questionnaire; 
PWV, pulse wave velocity; FMD, flow mediated dilatation; ABP, 24 h ambulatory blood 
pressure monitoring. 
 
3.2.4 Dietary intake  
Diet was assessed at baseline in the MARINA study by a FFQ contained in a lifestyle 
questionnaire (LQ, section 2.5.1, Appendix 9) which assessed nutrient intake over the 
previous 12 months (before the 1 month run-in period when participants took 3 
placebo capsules/d that did not contain vitamin D). The FFQ data were analysed as 
described in section 4.2.7 to determine nutrient intake per day. In the CRESSIDA study, 
diet was assessed by 4-d food diaries at baseline and 12 wk (section 2.5.2). These were 
coded and analysed using WISP version 3.0 by a CRESSIDA study investigator. The main 
specifics of the DG and control diet are summarised in section 2.6.1.2, but differences 
between the two diets in terms of vitamin D intake are covered here. Participants in 
the DG group were requested to consume two portions of fish/wk (one of which 
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should be oily), whereas participants in the control group were requested to consume 
less than 1 serving/month of oily fish. The DG group was reimbursed for fresh oily fish 
that they purchased and were provided with tinned oily fish (sardines, salmon or 
mackerel). The control group were provided with tins of tuna and discouraged from 
consuming fresh and other tinned oily fish. The guidance for the DG group was to 
consume no more than 3 eggs/wk, but the control group could consume unrestricted 
eggs. The DG group was given non-fortified cereals, and fortified margarine containing 
approximately 0.75 µg/100 g, whereas the control group received fortified cereals 
containing approximately 4 µg/100 g and a spread which was not fortified.  
 
3.2.5 Physical activity 
Physical activity levels were calculated for the CRESSIDA and MARINA studies from 
data collected in the LQ (Appendix 9) which asked questions on how many hours per 
wk the participant spent on housework, DIY, gardening, walking, cycling and other 
physical activities, how many hours this exercise was practiced vigorously, and how 
many stairs the participant climbed per day on average. Physical activity was 
calculated by multiplying the duration of each level of activity by previously 
determined physical activity ratios (Committee on Medical Aspects of Food Policy 
1991), and was expressed as Metabolic Equivalents (MET)/d. A resting metabolic rate 
was assumed to have an MET of 1.  
 
3.2.6 Statistical analysis 
Where values were below the limit of detection, the limit of detection was assigned. 
Statistical analysis of the data was conducted using SPSS for Windows Version 21.0. 
Standard distributional checks were made, and where appropriate, analyses were 
attempted following log transformation. Where variables could not be normalised, 
medians and inter-quartile ranges were determined and non-parametric tests 
performed. In order to test whether the two studies differed at baseline, comparisons 
were made using the independent samples t-test, Mann-Whitney U test or Pearson’s 
chi-squared test for categorical variables. Associations between factors were 
determined using partial correlations. Comparisons between groups were made using 
univariate ANOVA for normally distributed variables or the Mann-Whitney U test or 





3.3.1 Subject characteristics 
In the CRESSIDA study, 599 subjects were assessed for eligibility, and of these 165 
eligible subjects were randomised to the control or DG diet (see section 2.6.1.4). A 
total of 3 subjects dropped out, leaving complete data on 162 subjects; n=82 in the 
control group and n=80 in the DG diet group. In the MARINA study, following 475 
screening appointments, 367 subjects were randomly assigned to treatment (see 
section 2.6.2.3). In the one month run-in period, a total of 25 participants withdrew 
from the study, leaving data on 342 participants at baseline. Baseline characteristics 
for both studies are displayed in Table 3.1. The MARINA subjects were significantly 
older and had a correspondingly higher PWV than the CRESSIDA participants. Waist 
circumference was significantly greater in CRESSIDA participants, but there was no 







Table 3.1 Subject characteristics at baseline for the CRESSIDA (n=165) and MARINA (n=342) studies  
 CRESSIDA (n=165) MARINA (n=342) Combined (n=507) 
Age (y)* 52 (8) 55 (7) 54 (7) 
Gender (M/F) 65/100 131/211 196/311 
Ethnicity    
   White 137 (83.0%) 281 (82.2%) 418 (82.4%) 
   Black 16 (9.7%) 18 (5.3%) 34 (6.7%) 
   Asian 8 (4.8%) 19 (5.6%) 27 (5.3%) 
   Far East 2 (1.2%) 9 (2.6%) 11 (2.2%) 
   Other 2 (1.2%) 15 (4.4%) 17 (3.4%) 
Height (m) 1.66 (0.24) 1.69 (0.10) 1.68 (0.16) 
Weight (kg) 75.0 (13.7) 73.7 (15.8) 74.1 (15.2) 
BMI (kg/m
2
) 26.1 (3.8) 25.6 (4.3) 25.7 (4.2) 
Waist circumference (cm)* 92.7 (11.8) 88.8 (11.5) 90.1 (11.7) 
Total cholesterol (mmol/L) 5.3 (1.0) 5.4 (1.1) 5.4 (1.1) 
HDL-Cholesterol (mmol/L)† 1.5 (0.4) 1.6 (0.5) 1.5 (0.5) 
LDL-Cholesterol (mmol/L) 3.2 (0.8) 3.2 (0.8) 3.2 (0.8) 
Total:HDL cholesterol ratio  3.5 (0.9) 3.5 (1.0) 3.5 (1.0) 
Triglycerides (mmol/L)† 1.2 (0.6) 1.2 (0.7) 1.2 (0.6) 
HsCRP mg/L‡ 1.00 (0.30,2.00) 0.70 (0.30,2.10) 0.80 (0.30,2.00) 
Physical activity (MET/d)‡ 39.7 (37.4,43.5) 41.4 (38.6,45.1) 40.7 (37.9,44.2) 
Pulse Wave Velocity (m/sec)†* 7.4 (1.2) 8.8 (1.8) 8.3 (1.7) 
Flow mediated dilation (%) 5.5 (3.1) 5.4 (3.0) 5.4 (3.0) 
24-h SBP (mm Hg) 122 (12) 124 (13) 123 (13) 
24-h DBP (mm Hg) 74 (7) 75 (7) 74 (7) 
Results as n(%), mean (SD), †geometric mean (approx SD) or ‡median(IQR). HsCRP, high sensitivity C-reactive protein; SBP, systolic blood pressure; DBP, diastolic blood pressure. 
*Significant difference between CRESSIDA and MARINA studies (P<0.001). No other significant differences between studies tested using the independent samples t-test for 
normally-distributed variables, Mann-Whitney U test for not-normally distributed continuous variables, and Pearson’s chi-squared test for categorical variables were found. Data 
were missing for some outcomes; for CRESSIDA, MARINA and both studies combined, the numbers of participants included were 153, 342 and 495 for FMD, 163, 342 and 498 for 




3.3.2 Vitamin D intake and status 
At baseline, mean (SD) concentrations of serum 25-OH-D were 39.3 (24.1) nmol/L in 
men and 35.2 (21.2) nmol/L in women for both studies combined. The percentage of 
participants who had serum 25-OH-D concentrations ≤25 nmol/L and ≤50 nmol/L were 
21.4% and 67.6%, respectively (Figure 3.2). Spearman’s rank correlation coefficients 
between vitamin D intake (µg/d) and serum 25-OH-D concentrations (nmol/L) were 
strongest (ρ = 0.277, P=1.6x10-7) in the CRESSIDA study in which vitamin D intake was 
assessed by 4-d food diaries, but still highly significant in the MARINA study in which a 
FFQ was used to assess intake (ρ = 0.160, P=0.003). Mean vitamin D intakes for 
increasing serum 25-OH-D categories are displayed in Table 3.2 for both studies. A 
significantly greater mean intake was found in the highest (75+ nmol/L) compared to 
the lowest (25-50 nmol/L) 25-OH-D category in the CRESSIDA study and in the 50-75 
nmol/L category compared to the 0-25 nmol/L category in the MARINA study. The non-
significant decrease in the mean intake from 3.9 μg/d in the 50-75 nmol/L category to 
3.3 μg/d in the 75+ nmol/L group in the MARINA study could be a play of chance as 
there were only 10 participants in that category. The other possible difference is that a 
FFQ was used vs. 4-d food diaries in CRESSIDA. However, estimates of vitamin D intake 
from FFQs and 4-d diaries did not differ significantly in the CRESSIDA study (D. 







Figure 3.2 Cumulative number of participants in categories of serum 25-OH-D in 




Table 3.2 Mean vitamin D intake (µg/d) according to vitamin D status (serum 25-
OH-D) in the CRESSIDA and MARINA studies 
 
Vitamin D category (nmol/L) 
P value† 
0-25 25-50 50-75 75+ 
CRESSIDA - 



















Values are mean (95% CI). Vitamin D intake was assessed using 4-d estimated food diaries in 
the CRESSIDA study and FFQs in the MARINA study. †Categories were compared using a 









































3.3.3 Effect of BMI, age, physical activity, gender and skin pigmentation on serum 
25-OH-D concentrations 
A significant difference was found in mean serum 25-OH-D concentrations between 
categories of BMI for both CRESSIDA and MARINA studies combined (P=0.001); people 
in the obese but not overweight category had a lower vitamin D status. There were no 
significant differences in age or physical activity between the categories 0-25, 25-50, 
50-75 and 75+ nmol/L of serum 25-OH-D. However, there were significant differences 
in vitamin D status between males and females (P=0.019) and between people with 
white and melanised skin (P=2.06 x 10-7) (Table 3.3), although these were not due to 
differences in vitamin D intake. 
Table 3.3 Differences in serum 25-OH-D concentrations between BMI categories 
in participants aged 40-70 y 
BMI (kg/m2) 25-OH-D (nmol/L)† 
18.5-25.0 n=238 45 (43, 48) 
25.0-30.0 n=187 43 (40, 47) 
30.0-35.0 n=82 35 (30, 40) 
P value 0.001 
†Marginal means with 95% confidence intervals adjusted for age and gender. P value from 
univariate ANOVA. 
 
Table 3.4  Differences in serum 25-OH-D concentrations between men and 
women and people with white and melanised skin in participants aged 40-70 y 
 Vitamin D intake (µg/d)‡ 25-OH-D (nmol/L)† 
Gender   
Female n=306 2.6 (1.6-4.0) 41 (39, 44) 
Male n=194 2.8 (1.8-3.9) 46 (43, 49) 
P value 0.374 0.019 
   
Skin pigmentation   
White n= 429 2.4 (1.1-4.1) 45 (43, 47) 
Melanised skin n= 71 2.7 (1.1-4.1) 30 (25, 35) 
P value 0.151 2.06 x 10-7 
†Marginal means with 95% confidence intervals adjusted for age and BMI, and also by gender 
for skin pigmentation. ‡Median (IQR). P value from univariate ANOVA for 25-OH-D and Mann-




3.3.4 Seasonal variability in 25-OH-D concentrations  
The CRESSIDA and MARINA studies recruited participants throughout the year in 
different seasons. Figure 3.3 shows that the mean concentrations of serum 25-OH-D 
increased from May to August for both studies combined with the highest 
concentrations occurring in August (53 nmol/L). There was a dip in vitamin D status in 
the winter months, with the lowest concentrations occurring in December (28 nmol/L). 
Univariate ANOVA with age, gender and BMI as covariates showed a significant 
difference in vitamin D status between quarters of the year (P=6.3 x 10-6). Mean 25-
























Figure 3.3 Mean (95% CI) serum 25-OH-D concentrations measured throughout 













































































































3.3.5 Association between serum 25-OH-D and indices of vascular function and 
inflammation 
Table 3.5 shows correlations between serum 25-OH-D, BP, endothelial function, 
arterial stiffness and hsCRP for the combined data from the CRESSIDA and MARINA 
studies. Inverse correlations with serum 25-OH-D concentrations were found for 24 h 
DBP (ρ =-0.10, P=0.03), hsCRP (ρ = -0.11, P=0.01) and PWV (ρ = -0.12, P=0.01). 
 
Table 3.6 presents the results with the participants categorised according to their 
vitamin status adjusted for age, gender, BMI, ethnicity, physical activity and 
seasonality. There was a highly significant difference between serum 25-OH-D 
categories for PWV (P=4.57 x 10-6) with, for example, participants in the 0-25 and 25-
50 nmol/L categories having stiffer arteries compared with those in the 75+ nmol/L 
category. There was also a significant linear trend for PWV across categories (P=1.41 x 
10-6). A significantly greater FMD was found in participants in the 75+ nmol/L category 
compared with the 50-75 nmol/L category suggesting that concentrations above 75+ 
may have beneficial effects. However, FMD decreased between the 0-25 and 50-75 
nmol/L categories and the number of participants (n=36) in the 75+ group was small; 




Table 3.5 Partial correlations between serum 25-OH-D concentrations and 24-h 
systolic (SBP) and diastolic (DBP) blood pressure, carotid to femoral pulse wave 
velocity (PWV), flow mediated dilation of the brachial artery (FMD) and high-
sensitivity C-reactive protein (hsCRP) in 466 healthy men and women aged 40-70 y. 
 r P 
24 h SBP (mm Hg) -0.04 0.37 
24 h DBP (mm Hg) -0.10 0.03 
HsCRP (mg/L) -0.11 0.01 
FMD (%) -0.04 0.33 
PWV (m/sec) -0.12 0.01 
Partial correlation coefficient adjusted for age, gender and study. 
 
Table 3.6 24 h systolic (SBP) and diastolic (DBP) blood pressure, carotid to 
femoral pulse wave velocity (PWV), flow mediated dilation of the brachial artery 
(FMD) and C-reactive protein measured using a high sensitivity assay (hsCRP) in 
healthy men and women aged 40-70 y by category of vitamin D status. 
 
Serum 25-OH-D category (nmol/L) 
P value 
0-25 25-50 50-75 75+ 
 n=101 n=212 n=115 n=36  
























2.3 (1.7,3.0) 2.0 (1.6,2.4) 1.5 (0.9,2.1) 1.1 (0.0,2.2) 0.178 
PWV 
(m/sec) 
9.0 (8.7,9.3) 8.6 (8.4,8.8) 8.1 (7.9,8.4) 7.7 (7.2,8.2) 4.6 x 10-6 
FMD (%) 5.7 (5.2,6.3) 5.3 (4.9,5.6) 4.8 (4.3,5.3) 6.5 (5.6,7.4) 0.005 
Values are mean (95% CI); significance determined by multivariate ANOVA comparison 
between categories adjusted for age, gender, BMI, ethnicity, physical activity and seasonality. 
Significant differences exist between categories where confidence intervals do not overlap. 
‡Median (IQR) and significance calculated using the Kruskal-Wallis test. There is a statistically 




3.3.6 Effect of UK Dietary Guidelines (DG) diet on serum 25-OH-D concentrations 
There were no differences between participants allocated to control and dietary 
guidelines (DG) groups at baseline and the mean 25-OH-D concentrations were 60.3 
and 58 nmol/L respectively. Following the dietary intervention serum 25-OH vitamin D 
increased by 9.2 nmol/L (95% CI 4.2, 14.2; P<0.001) in DG group compared to the 
control group when adjusted for baseline 25-OH-D, age, BMI, gender, ethnicity and 
seasonality (Figure 3.4). The proportion of participants with serum 25-OH-D 
concentrations <50 nmol/L decreased by 11% in the DG group vs a 4% increase in the 
control group. Mean vitamin D intake increased from 3.0 µg/d to 6.6 µg/d in the DG 
group and decreased from 2.9 µg/d to 2.7 µg/d in the control group. Compared with 
the control group, vitamin D intake increased by 3.8 µg/d following the DG diet (95% CI 
2.7, 5.0, P<0.001). Fish consumption was the main contributor to vitamin D intake in 
both groups at baseline (52% of total intake), followed by meat and meat products 
(10%), fats and oils (10%), cereals (10%) and eggs (7%) (Figure 3.5). The contribution of 
fish to vitamin D intake increased to 61% in the DG group at 12 wk. Fats and oils 
(predominantly the fortified study spread) were the next most important contributor 










Figure 3.4 Changes in vitamin D intake and serum 25-OH-D concentrations from baseline to follow-up in the group which followed UK dietary 
guidelines (DG) compared to a control based on a conventional British dietary pattern. Bars are means with SEM. Changes are from univariate 

















































Figure 3.5 Comparison of the percentage contribution of different food groups to 
vitamin D intake at baseline in both groups, and at 12 wk in the group following UK 
dietary guidelines (DG) and the control based on a conventional British dietary 


























































3.4 Discussion and Conclusion 
Of participants aged 40-70 y in the CRESSIDA and MARINA studies, 21.4% and 67.6% 
had serum 25-OH-D concentrations ≤25 nmol/L and ≤50 nmol/L respectively, and 
mean concentrations were 39.3 and 35.2 nmol/L for men and women respectively. The 
percentage of participants who were deficient (<25 nmol/L) is comparable to UK data 
from the most recent 2008-2012 National Diet and Nutrition Survey (NDNS) of 1769 
individuals which found deficiency in 22.8% of adults aged 19-64 y and in 21.0% of 
adults aged 65+ y. However, mean concentrations were higher in the NDNS even 
though a lower percentage of blood samples (54% in adults aged 19-64 y and 47% in 
adults aged 65+ y) were taken in the summer months of April-September compared to 
in the CRESSIDA and MARINA studies (67%). They were 43.5 nmol/L and 47.3 nmol/L in 
men and women aged 19-64 y, and 47.0 nmol/L and 42.5 nmol/L in men and women 
aged 65+ y (Bates et al. 2014), respectively. This may be due to a lower percentage of 
people with melanised skin compared to 17% in the studies analysed here, but data on 
ethnicity has not yet been published for this NDNS survey for comparison. In the 
MARINA and CRESSIDA studies a significantly higher vitamin D status was found in 
whites compared with people with melanised skin, and in men compared to females. 
The finding for skin-type is consistent with the literature which shows a higher vitamin 
D status in whites compared with blacks and South Asians (Scragg et al. 1920; Kift et al. 
2013). Dark skin may lead to a reduced capacity of the body to convert vitamin D to its 
active form as melanin skin pigmentation absorbs UVB photons and competes with 7-
dehydrocholesterol for them (Holick et al. 1981). The higher serum 25-OH-D 
concentrations in men were not due to differences in vitamin D intake between men 
and women and so may be due to differences in UVB exposure, although physical 
activity levels did not differ between the genders, so if this is the case it would not be 
due to a greater level of outdoor sport/working in men. One study has found that an 
age-related decline in serum 25-OH-D concentrations occurred earlier in women than 
in men which could explain these findings as these were older adults aged 40-70 y 
(Maggio et al. 2005).  
 
On examination of the seasonal variability of vitamin D status, the CRESSIDA and 
MARINA studies showed a marked seasonal change in serum 25-OH-D, with the 
highest concentrations measured in the summer months. This was to be expected due 
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to the increase in UVB exposure in the UK summer, and it has been documented 
previously in British cohorts (Hypponen and Power 2007; Zgaga et al. 2011). In addition 
to variability in vitamin D status due to differences in UVB exposure, dietary intake of 
vitamin D was found to be strongly correlated with vitamin D status (P=0.008) over a 
serum 25-OH-D range of 10 to 128 nmol/L, with participants in higher categories of 25-
OH-D having larger dietary intakes of vitamin D. Furthermore, modification of the diet 
to conform to the UK dietary guidelines led to over a doubling of vitamin D intake from 
3.0 µg/d to 6.6 µg/d, and an increase in serum 25-OH-D of 9.2 nmol/L (95% CI 4.2, 
14.2, P<0.001) compared to the control group that was consuming a conventional 
British dietary pattern. No subjects were taking supplements and these findings were 
primarily in response to an increased consumption of oily fish after following the 
recommendations of 1-2 portions per wk compared to less than 1 serving/month in 
the control group. They also occurred despite the DG group being given non-fortified 
cereals whilst the control group received fortified cereals. The increase in 25-OH-D 
concentrations is about a third of that found in a study which gave participants orange 
juice fortified with 25 µg D3/d for 11 wk (Biancuzzo et al. 2010). Although cross-
sectional studies have shown oily fish to be a key contributor to vitamin D intake (Hill 
et al. 2004; Zgaga et al. 2011), to the author’s knowledge there have been no other 
trials published of the effect of increased oily fish intake on vitamin D intake and status 
in the UK.  
 
Cross-sectional analysis looking at the relationship between vitamin D status and CVD-
related factors in the CRESSIDA and MARINA studies found a strong association 
between serum 25-OH-D concentrations and arterial stiffness; participants with a 
higher serum 25-OH-D concentration had a lower, healthier PWV. These findings are in 
agreement with other previously conducted observational studies in healthy 
participants which have shown an inverse association between vitamin D and arterial 
stiffness (Al Mheid et al. 2011; Giallauria et al. 2012; Pirro et al. 2012; Seker et al. 
2013; Webb et al. 2012). The largest of these recruited 1228 healthy adults aged 70 ± 
12 y and measured PWV using the Complior SP device (Artech Medical, Paris, France) 
(Giallauria et al. 2012).  After adjustment for age, gender, race, season of blood draw, 
and PTH levels, PWV remained significantly associated with serum 25-OH-D (β=-0.43, 
P=0.001) (Giallauria et al. 2012). Similarly, after multivariate adjustment for a number 
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of factors including age, race, gender, BMI and lipids, serum 25-OH-D remained 
independently associated with PWV measured using the SphygmoCor device (adjusted 
R2=0.32, β=-0.09, P=0.04) in a study of 554 healthy adults aged 20 to 79 y (Al Mheid et 
al. 2011). Another study in 150 healthy postmenopausal women that also used 
SphygmoCor to measure PWV initially found a significant inverse association with 25-
OH-D concentrations (ρ=-0.23, P=0.006), but this disappeared after controlling for PTH 
(Pirro et al. 2012). Clinical trials of the effect of vitamin D supplementation on PWV are 
few in number, and mostly in participants with diseases including type 2 diabetes (Yiu 
et al. 2013; Breslavsky et al. 2013) and Peripheral Arterial Disease (Stricker et al. 2012). 
They have presented mixed results, although most show no effect (Gepner et al. 2012; 
Stricker et al. 2012; Yiu et al. 2013; Larsen et al. 2012). There is speculation that 
vitamin D may have a positive effect on arterial stiffness via a number of mechanisms 
including inhibition of the renin-angiotensin system (Li et al. 2002; Li 2003), protection 
against vascular calcification (Watson et al. 1997) or suppression of vascular smooth 
muscle cell proliferation (Chen et al. 2010). However, as the data used in the present 
analysis were cross-sectional, the results for PWV do not prove causality and it may be 
that people who go outdoors more often who are exposed to a higher level of UVB 
radiation do more physical activity which may be having favourable effects on arterial 
stiffness (Sugawara et al. 2006). Whilst a significant inverse correlation was found 
between serum 25-OH-D concentrations and 24 h DBP (ρ =-0.10, P=0.03), a 
comparison of 24 h DBP between different categories of vitamin D status did not quite 
reach significance (P=0.06), although there was a trend for it to decrease with 
increasing serum 25-OH-D. Many other previous cross-sectional studies have 
investigated the association between vitamin D status and BP, with most showing an 
inverse association for both SBP and DBP (Judd et al. 2008; Schmitz et al. 2009; Scragg 
et al. 2007; Zhao et al. 2010; Scragg et al. 1920). However, the majority of studies have 
used clinic BP rather than ABP, which is a more accurate measure (Coats et al. 1992). 
Trials investigating the effect of vitamin D supplementation on BP have also been 
conducted and summarised in meta-analyses (Kunutsor et al. 2014; Pittas et al. 2010; 
Elamin et al. 2011; Witham et al. 2009; Wu et al. 2010), but the results are 
inconsistent, and again, all or nearly all studies included have used clinic BP. There is a 
need for well-conducted trials measuring BP using ABP monitors, and PWV to help 
 148 
 
determine whether the associations are causal and vitamin D supplementation can 
improve these measures. 
 
FMD was not significantly correlated with serum 25-OH-D concentrations, but there 
was a significant difference in vitamin D status between participants with serum 25-
OH-D concentrations of 50-75 nmol/L and those with concentrations more than 75 
nmol/L, with participants in the higher category having improved endothelial function. 
Although there were only small numbers in the +75 nmol/L group (n=38), this 
association remained after adjustment for age, gender, BMI, ethnicity, physical activity 
and seasonality. Other cross-sectional studies have mostly shown positive associations 
between 25-OH-D concentrations and FMD (Al Mheid et al. 2011; Jablonski et al. 2011; 
Syal et al. 2012; Yiu et al. 2011). RCTs, however, have shown mixed results but many, 
in accordance with the present study, show no positive relationship between vitamin D 
and FMD (Gepner et al. 2012; Witham et al. 2010; Yiu et al. 2013).  
 
The inflammatory marker hsCRP was inversely correlated with vitamin D status for 
both studies combined (P=0.01) and there was a trend for concentrations to decrease 
as the serum 25-OH-D category increased, although this did not reach significance. In 
the vitamin D deficient group (serum 25-OH-D <25 nmol/L) hsCRP concentrations were 
high at 2.3 mg/L. The literature has mixed findings on the relationship between 25-OH-
D and hsCRP. In agreement with the present study, Amer et al. analysed NHANES data 
from between 2001 to 2006 and showed a significant inverse association between 
serum 25-OH-D concentrations and CRP for 25-OH-D concentrations < 52 nmol/L (n > 
17,000). Interestingly, however, above 52 nmol/L, the relationship was positive (Amer 
and Qayyum 2012). In the present study, serum 25-OH-D concentrations continued to 
decrease between the categories 50-75 nmol/L and 75+ nmol/L for both studies 
combined. Another study by Ngo et al. found an inverse association between hsCRP 
concentrations and serum 25-OH-D3 in 253 adults aged 51-77 y after adjustment for 
age, gender, hypertension and BMI (β=-0.14, P=0.03) (Ngo et al. 2010). However, other 
studies found the initial association between vitamin D and hsCRP to disappear after 
adjustment for adiposity (Hypponen et al. 2010) or BMI (Jorde et al. 2007), or did not 
find any association at all (Michos et al. 2009). Mechanisms as to how vitamin D may 
affect CRP levels and reduce the inflammatory response are uncertain, but 
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experimental studies have shown that treatment with 1,25(OH)2D inhibits the 
production of several other pro-inflammatory cytokines such as interleukin-6 (IL-6) 
(Talmor et al. 2008; Muller et al. 1992) and tumour necrosis factor-α (TNF-α) (Muller et 
al. 1992; Cohen-Lahav et al. 2007).  
 
Strengths of the analyses conducted in this chapter are that they included a large 
number of participants who were healthy without disease-related complications, and a 
range of CVD risk markers. Furthermore, carotid-femoral PWV and ABP were 
measured which are considered to be the ‘gold-standard’ measurements for arterial 
stiffness (Shahin et al. 2013) and BP (National Institute for Health and Clinical 
Excellence 2011), respectively. Additionally, adjustments were made for a number of 
potential confounding factors including age, BMI, gender, seasonality, physical activity 
and ethnicity. A limitation is that the study is cross-sectional and therefore causality 
cannot be assumed.  
 
In conclusion, the above has shown that dietary intake is an important determinant of 
vitamin D status in this UK population, despite status being primarily dependent on the 
skin’s exposure to UVB radiation (Zittermann et al. 2005), and that modifications to 
dietary intake, specifically increases in oily fish consumption, can significantly improve 
vitamin D status in healthy adults. Furthermore, the results strongly support the 
hypothesis that serum 25-OH-D concentrations are associated with arterial stiffness in 
healthy older adults without clinical disease, and provide evidence for potential 
associations with DBP and hsCRP as well. These findings provide a basis for an 
intervention trial to test the hypothesis that vitamin D supplementation improves 
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4 Chapter 4 - Comparison of the effect of low dose D2 and D3 in their capacity to 





The main purpose of this thesis is to determine the effect of dietary vitamin D on CVD 
risk. This can be done by comparing the effects of vitamin D2 with placebo, enabling 
differentiation between the effects of diet and sunlight as D2 increases serum 25-
hydroxyvitamin-D2 (25-OH-D2), rather than 25-hydroxyvitamin D3 (25-OH-D3) which is 
produced in response to UVB exposure. However, it is first necessary to ascertain the 
extent to which D2 increases serum 25-OH-D concentrations in the UK winter months, 
compared with vitamin D3 as there has been some controversy surrounding the 
efficacy of D2 (Houghton and Vieth 2006). 
 
Pharmacopoeias regard D2 and D3 as equivalent and interchangeable with 1 
international unit (IU) being equivalent to 25 ng of D2 or D3 (Medicines Commission 
1980; Committee of Revision 1997). Furthermore, studies have shown the two forms 
to be equally effective in treating hypovitaminosis D in healthy and rachitic infants and 
children (Gordon et al. 2008; Thacher et al. 2010). However, Houghton and Vieth have 
argued that D2 is less effective than D3 at raising serum 25-OH-D concentrations, and 
have recommended that D2 should no longer be regarded as suitable for 
supplementation (Houghton and Vieth 2006). This conclusion is questionable though 
as it was based on studies that did not use specific assays for measuring 25-OH-D 
metabolites (de la Hunty et al. 2010; Romagnoli et al. 2008; Trang et al. 1998; Heaney 
et al. 2011), had flaws in their design and execution (i.e. lacking a placebo treatment) 
(Trang et al. 1998; Romagnoli et al. 2008; Armas et al. 2004), did not control for UVB 
exposure (Binkley et al. 2011), or used very high doses of vitamin D that are not 
relevant to dietary intake (Romagnoli et al. 2008; Armas et al. 2004; Binkley et al. 
2011; Heaney et al. 2011). Consequently, there is a need for a well-controlled, dose-
response trial of food fortified with D2 and D3 using specific assays for 25-OH-D2 and 
25-OH-D3 (O'Donnell et al. 2008). An intake of 5 μg represents the recommended daily 
amount for food labelling purposes in the European Union (European Union 2008), and 
10 μg is the amount recommended in the UK for the house-bound who are unlikely to 




The aim of the present study was to evaluate the effect on serum 25-OH-D metabolites 
of intakes of 5 and 10 μg/d of D2 and D3 (5-D2, 10-D2, 5-D3 and 10-D3), provided in a 
malted milk drink, in the UK winter months when UVB exposure is minimal.  
 
4.2 Methods 
4.2.1 Hypothesis  
Vitamins D2 and D3 provided at doses of 5 or 10 µg/d in a malted milk drink will result 
in meaningful increases in serum 25-OH-D2 and 25-OH-D3 respectively in healthy men 
and women with negligible UVB exposure. 
  
4.2.2 Objective 
To conduct a randomised controlled trial in healthy men and women to compare the 
effects on serum 25-OH-D concentrations of 5 or 10 µg/d D2 or D3 provided in a malted 
milk drink in the winter months in the UK. 
 
Primary outcome: 
Serum 25-OH-D metabolite concentrations. 
 
Secondary outcome:  
Parathyroid hormone (PTH) and serum calcium (Ca2+) concentrations. 
 
4.2.3 Sample size 
Sample size calculations were based on a pilot study conducted in 6 healthy volunteers 
recruited in the month of February in which the mean plasma 25-OH-D concentrations 
as measured by RIA increased from 60 nmol/L, to 70, 78 and 90 nmol/L after 1, 2 and 3 
wk of supplementation with 10 µg D3 in cod-liver oil (2 capsules/d, each containing 5 
µg as specified by the manufacturer, Seven Seas Lt, Hull). Repeated measures on 
unsupplemented participants showed a correlation of 0.91 and the common standard 
deviation (SD) was 17 nmol/L. The power calculation for the present study performed 
in STATA version 9.0 is shown below. Assuming at least two measurements on follow 
up allowed division of the SD by √2 (17/√2 = 12.0). A sample size of 8 per treatment 
group with a minimum of two measures on follow up was estimated to be able to 
detect a 10 nmol/L change, which was deemed to be clinically significant, in serum 
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vitamin D concentrations with α=0.01 (to allow for multiple comparisons) and 90% 
power. Additional power is gained for the comparison of D2 with D3 if both 5 and 10 
μg/d doses are compared with 16/group giving power to detect differences of 5 
nmol/L between the combined groups. 
 
Stata syntax: 
power pairedmeans, corr(0.91) altdiff (10) power (0.9) sd (12) alpha (0.01) 
Stata output: 
Estimated sample size for a two-sample paired-means test 
Paired t test assuming sd1 = sd2 = sd 
Ho: d = d0 versus Ha: d != d0 
Study parameters: alpha = 0.0100, sd = 12.0000, power = 0.9000, corr = 0.9100 
delta = 1.9642, d0 = 0.0000, da = 10.0000 sd_d = 5.0912 
Estimated sample size:  N = 8 
 
4.2.4 Ethical approval and clinical governance 
Ethical approval was obtained from the South East London Research Ethics Committee 
1 (REC reference 10/H0804/91) on 07/02/2011 (Appendix 10). The trial was registered 
at http://www.controlled-trials.com and allocated a clinical trial registration number 
ISRCTN24666304 on 02/08/2011. Written informed consent (Appendix 11) was 
obtained from all participants before commencing the study and phlebotomy was 
conducted by appropriately qualified staff. 
 
4.2.5 Study design 
A placebo controlled double-blind parallel design was used. Participants were 
randomly allocated by computer to one of 5 groups: placebo or 5 or 10 μg of D2 or D3. 
The intervention was administered as a malted milk drink (Horlicks™, GlaxoSmithKline, 
Middlesex, UK). 
 
The study took place from 22/02/2011 – 13/04/2011, a period during which there is 
usually minimal UVB exposure in the UK (Appendix 12). Following screening, eligible 
participants were asked to attend the Metabolic Research Unit (MRU) in the Diabetes 
and Nutritional Sciences Division at KCL for 5 visits (baseline and every week after this 
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for 4 wk). They were also sent a FFQ used in the European Prospective Investigation 
into Cancer and Nutrition (EPIC) to determine their usual vitamin D intake (Appendix 
9). This FFQ has been validated for vitamin D intake in the UK population (Crowe et 
al.). They were requested to fill this in at home and return it at their baseline visit at 
which each participant was given 28 sachets each containing 25 g of malted milk drink. 
They were asked to start drinking a sachet a day, made up with hot water, for 28 days, 
starting on the day of the visit. It was stressed that they should only add hot water, 
and not milk, to try and minimise any changes in calcium intake. At each visit, a blood 
sample was collected by a trained phlebotomist according to the blood collection 
protocol outlined in Appendix 6. The vacutainer method (Becton-Dickinson) was used 
to reduce the risk of spillages. At baseline and visit 4, the blood sample was analysed 
for PTH, Ca, 25-OH-D2 and 25-OH-D3. Blood samples taken at wk 1, 2 and 3 were 





Figure 4.1 Study Design   
 
4.2.6 Recruitment methodology 
Participants (n=40) were recruited from the staff and student population of KCL staff 
and students. They were initially contacted via an ethically approved email circular 
(Appendix 13). Subjects expressing interest were provided with a study information 
sheet (Appendix 14) and asked to complete a telephone/email questionnaire 
(participants had the option as to whether to complete the questionnaire sent by 
email or to ring up and complete it over the telephone) if still interested (Appendix 
15). Those who appeared eligible and willing to participate were invited to attend a 
screening appointment at the Franklin-Wilkins Building in the MRU to further assess 
their suitability for inclusion in the study. BP and anthropometric measurements were 
taken, along with a blood sample to measure plasma PTH, serum Ca2+ and 25-OH-D 








Screening visit.  
Height and weight, 
seated blood 
pressure, blood test 
for serum 25-OH-D, 
Ca2+, PTH, liver 
function and 
haematology,  
Blood sample for 25-OH-D, Ca2+ and PTH. 
At baseline, food frequency 
questionnaire (FFQ) completed and a 
supply of drink powder given to each 
subject. 
Blood sample for 
serum 25-OH-D. 
Randomisation into 5 
groups (8 per group) 0                      1                     2                      3                      4 weeks           
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were within prescribed limits (Appendix 16). A flow chart detailing the process is show 
in Figure 4.2. 
 
Inclusion criteria were healthy males or females aged 18-65 y with normal 
haematology, liver function and plasma glucose. Exclusion criteria were: seated BP 
>160/105 mm Hg, Body Mass Index <18.5 and >35 kg/m2, taking vitamin and mineral 
supplements (including cod-liver oil), or prescription calcium/vitamin D, recent 
exposure to high UVB light since 1 Dec 2010, intolerance to study product (lactose, 
milk protein), chronic renal, liver or inflammatory bowel disease, diabetes, 
unwillingness to restrict consumption of oily fish to no more than 2 portions (98 
g/portion)/wk throughout the study, and unwillingness to abstain from nutritional 





Figure 4.2 Recruitment, screening and randomisation 
 
4.2.7 Habitual dietary intake analysis 
FFQs were analysed using programs created in Microsoft Access and Excel for use in 
previous studies carried out at KCL. These programs had originally been set up to 
determine dietary intake per day for each participant for the macronutrients. In order 
for the program to be able to calculate vitamin D values for each food in the FFQ, 
vitamin D values in µg per 100 g were added to the database. These values were 
determined from supermarket websites (for example, for specific cereals), McCance 
and Widdowson's “The Composition of Foods: Summary Edition (6th Edition)” 
Recruitment email circular (Appendix 9)
Respondents  given information sheet (Appendix 10) 
and interviewed by telephone or email using study 
questionnaire (Appendix 11) to assess eligibility
NOT SUITABLE – reason recordedSUITABLE
Screening appointment booked at the 
MRU at KCL. Participant asked to fast 
for 3hr before the appointment 
Screening appointment
• Participant given a paper copy of information 
sheet and an opportunity to ask questions.
• Informed consent obtained (Appendix 7).
• 3 hr fasted blood sample taken.
•Blood pressure and anthropometric 
measurements taken (height and weight)
Blood sample sent to KCH for processing 
same day as appointment. Full blood count, 
glucose, liver function, PTH, Ca2+, 25-OH-D2
and 25-OH-D3 measured
• Lab results checked and signed off 
by a medical doctor if necessary. 
•Checked if participant eligible based 
on exclusion criteria
SUITABLE NOT SUITABLE – reason recorded
Subject allocated the next sequential screening 
number in the format starting S001, S002 etc. 
Screening Log updated
Participant randomly assigned to 
treatment group and ID number 





(McCance and Widdowson 2002), and the USDA National Nutrient Database for 
Standard Reference (USDA 2014). The FFQ asked about the average frequency of 
consumption of 130 food and beverage items in the preceding 12 months with 9 
frequency options (Appendix 9). If a participant had changed their diet in the last few 
months, they were asked to answer the FFQ questions based on their most recent diet. 
Average portion sizes had previously been derived for each of the food and beverage 
items based on those used originally in the EPIC questionnaire, values in “Food Portion 
Sizes” by the Ministry of Agriculture, Fisheries and Food (Crawley 1994), and “A 
Photographic Atlas of Food Portion Sizes” by the Ministry of Agriculture, Fisheries and 
Food (Nelson 1997). Portion fractions had also previously been decided for each of the 
frequency options. Nutrient intake per day was calculated based on the intake of the 
130 food and beverage items recorded by each participant. The database was set up to 
calculate macronutrients based on a default cereal (Cornflakes). In order to obtain 
accurate vitamin D estimates for cereal consumption, the vitamin D content of the 
specific cereals entered was determined separately and added on to the total vitamin 
D intake per day for each participant where relevant. Calculations were also performed 
to determine the macronutrient (energy, fat, carbohydrate and protein) and vitamin D 
contribution from extra foods for the participants who had entered these, and values 
were added to the total intakes per day. 
 
4.2.8 Sample analysis 
Table 4.1 shows the methods used and where the analyses were conducted, and gives 










Table 4.1 Biochemical measurements of study day samples 
Analyte Method Section where 




PTH Immunoassay 2.4.7 KingsPath 
Calcium Colourimetric assay 2.4.5 KingsPath 
25-OH-D2 and  
25-OH-D3 
uHPLC-MS/MS 2.4.6.1 LGC/HFL Sport 
Science 
PTH, parathyroid hormone; KingsPath, King’s College Hospital; LGC, LGC Testing (Formerly HFL 
Sports Science, Cambridgeshire); uHPLC-MS/MS, ultra high pressure liquid chromatography 
tandem mass spectrometry. 
 
4.2.9 Composition of malted milk drink 
Each 25 g sachet provided: 92 kcal, 2.4 g protein, 18.9 g carbohydrate (of which sugars, 
9 g), 0.8 g fat (of which saturates, 0.3 g) and 100 mg sodium. Prior to the start of the 
study, the D2 and D3 content of the malted milk drink was analysed by International 
Food Network (IFL) using an accredited method based on 100°C + KOH extraction, solid 
phase extraction to remove interfering components, and HPLC (Appendix 17). The 
limit of detection for this method was 0.5 µg/100 g. This analysis confirmed no vitamin 
D2 or D3 in the placebo sample. The vitamin D3 levels were found to be within 0% and 
10% of the target amounts of 5 µg and 10 µg respectively (5.2 µg for the 5 µg sachets 
and 10 µg for the 10 µg sachets). However, the analysis showed an insufficient amount 
of D2 in the samples and therefore an additional analysis was requested from the 
Laboratory of Government Chemists PLC (Teddington, UK). This could have been due 
to inherent analysis uncertainties which are +/- 20% and +/- 10% respectively. It could 
also be due to the lab not being able to extract all of the vitamin D2 from the food 
matrix (the extraction phase sometimes causes issues in products that are 
encapsulated, as the vitamin D2 was). The analysis at LGC (Appendix 17) used the same 
method as described above, with a limit of detection of 0.1 µg/100 g, and found much 
improved values for vitamin D2 (4.8 µg for the 5 µg sachets and 7.5 µg for the 10 µg 
sachets). However, the values for vitamin D3 were about half of what they should have 
been. It is possible that this could be due to a sampling error as a sample was taken 
from a pool of 3 samples. Vitamin D is microencapsulated in the powder so it is 
possible for the distribution not to be uniform in a small sample taken for analysis. 
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4.2.10 Statistical analyses 
Statistical analysis of the data was conducted using SPSS for Windows Version 20.0. 
Where values for 25-OH-D2 were below the limit of detection (2.4 nmol/L), a value of 
2.4 nmol/L was assigned. Standard distributional checks were made, and where 
appropriate, analyses were attempted following log transformation. Data were 
analysed on an intention to treat basis by repeated measures analysis of variance (4 
time points) with the baseline value as a covariate and treatment group as the 
between-subjects factor. Repeated measures contrasts were performed on the data to 
test for a dose response and compare the 5 and 10 µg groups in the changes in 25-OH-
D metabolite concentrations from baseline to post-intervention. The incremental area 
under the curve (iAUC) was calculated using the trapezoid rule. Comparison of the 
iAUC and changes at wk 4 from baseline were compared by one-way analysis of 
variance and Dunnett’s test was used to indicate a significant difference compared 
with placebo. All values in the text are mean ± SD unless otherwise stated. 
 
4.3 Results 
4.3.1 Participant details 
Forty participants (n = 16 males, n = 24 females) were randomly and equally allocated 
into the 5 treatment groups and the flow of participants through the study is detailed 





Figure 4.3 Flow of participants through the study 
 
One female disliked the test drink and withdrew from the study.  Data were available for 
analysis on 39 participants, who reported consuming all 28 sachets. Baseline 
characteristics are displayed in Table 4.2. There were no significant differences across 
treatment groups in age, height, weight, BP, vitamin D intake as assessed by FFQ, 25-
OH-D concentrations, PTH levels, or Ca2+ concentrations. The BMI in participants in the 
5-D3 group was slightly higher than in the 5-D2 group. Mean baseline concentrations of 
25-OH-D2, 25-OH-D3 and total 25-OH-D were 3, 38 and 42 nmol/L, respectively. A total 
of 27.5, 67.5 and 90.0% of participants were classified as being below the cut-offs of 25 
nmol/L, 50 nmol/L and 75 nmol/L, respectively. 
Responded to email (n=242)
Completed telephone 
interview (n=58)
Attended  a screening 
appointment (n=50)
Randomised (n=40)
No longer able to take 
part in study (n=2)
Subject numbers already 
fulfilled (n=6)
Did not meet inclusion 
criteria (n=2)
Subject numbers already 
fulfilled (n=1)




































1Values are means ± SD. 5-D2, 5 µg ergocalciferol/d; 5-D3, 5 µg cholecalciferol/d; 10-D2, 10 µg ergocalciferol/d; 10-D3, 10 µg cholecalciferol/d; PTH, 
parathyroid hormone. 
2Includes both D2 (ergocalciferol) and D3 (cholecalciferol) from fortified foods. 
3Values are geometric means ± SD. 
4No statistically significant differences between groups at baseline assessed by chi-squared test, Kruskall-Wallis test, or one-way analysis of variance except 
for BMI which was significantly greater in participants in the 5-D3 group compared to those in the 5-D2 and in the 10-D3 group compared with the 5-D2 group 
(Bonferroni Multiple comparison P<0.05) 
Characteristics Placebo 5-D2 5-D3 10-D2 10-D3 
Male: female  2:6 3:5 3:5 3:5 5:3 
Age, y 24.1 ± 1.8 24.4 ± 4.7 30.5 ± 11.0 24.4 ± 3.9 30.6 ± 10.6 
White: non-white 6:2 6:2 6:2 8:0 5:3 
Height, cm 170.1 ± 7.3  175.8 ± 8.1 171.9 ± 9.4 170.1 ± 7.9 169.5 ± 10.7 
Weight, kg 61.8 ± 9.8 63.0 ± 7.3 74.7 ± 11.6 66.7 ± 11.3 71.9 ± 17.1 
BMI, kg/m2 21.3 ±2.1 20.4 ±1.5 25.7 ±2.8 22.9 ±2.7 24.8 ±3.9 
Systolic/diastolic BP (mm Hg) 113/71 ± 11/5 118/77 ± 6/8 119/77 ± 12/4 116/74 ± 9/4 127/78 ± 17/10 
Vitamin D intake,2,µg/d 2.4 ± 1.6 2.6 ± 1.3 2.4 ± 1.3 3.2 ± 1.3 2.6 ± 1.2 
Calcium intake, mg/d 902 ±346 806 ±223 880 ± 249 1000 ±220 1019 ± 279 
Serum 25-OH-D2, nmol/L 3.4 ± 1.2 5.9 ± 8.2 2.7 ±0.7 2.8 ± 0.6 2.5 ± 0.1 
Serum 25-OH-D3, nmol/L 32.3 ± 13.7 49.4 ± 27.6 34.4 ± 22.1 41.3 ± 14.1 34.9 ± 29.1 
Total serum 25-OH-D, nmol/L 35.6 ± 13.3 55.3 ± 26.6 37.1 ± 22.1 44.0 ± 14.1 37.3 ± 29.1 
Serum Ca2+,3 mmol/L 2.25 ± 0.07 2.31 ± 0.05 2.28 ± 0.05 2.27 ± 0.07 2.25 ± 0.07 




Raw data is displayed in Appendix 18. Serum vitamin D metabolite concentrations 
remained low and unchanged in the placebo group. The 25-OH metabolite 
concentrations rose steadily in the first three weeks of supplementation and appeared 
to have reached a plateau at 4 wk as there was no evidence of further increases 
between weeks 3 and 4 (Figure 4.4). There was a significant dose-response 
relationship between the changes in plasma analyte concentrations. Repeated 
measures contrasts showed greater increases in 25-OH-D2 over the 4 wk in the 10-D2 
group compared to the 5-D2 group (P = 0.007). Similarly, the increase in 25-OH-D3 in 
the 10-D3 group was greater than that in the 5-D3 group (P = 0.003) and the increase in 
total 25-OH-D in the two 10 μg/d groups was greater than that in the two 5 μg/d 
groups (P=0.01). Vitamin D2 did not affect the concentration of 25-OH-D3, nor did D3 
affect that of 25-OH-D2. Significant differences versus placebo were found in total 25-
OH-D for 5-D2, 10-D2, 5-D3 and 10-D3 treatment groups (P≤0.001). Compared with 
placebo, the increment in serum 25-OH-D2 from baseline to post-intervention was 
greater in the 5-D2 and 10-D2 groups (both P<0.01), as was the increase in 25-OH-D3 
greater in the 5-D3 and 10-D3 groups (P<0.05 and P<0.01) (Table 4.3). The increase in 
25-OH-D2 in the D2 groups was not significantly different to the increase in 25-OH-D3 
for the D3 groups (iAUC 24 ± 11, 45 ± 26, 23 ± 13 and 49 ± 25 nmol·L
-1·wk for 5-D2, 10-
D2, 5-D3 and 10-D3). Furthermore, the increment in serum total 25-OH-D did not differ 
between D2 and D3 supplement groups (P=0.945) (Figure 4.4) and the iAUCs for total 
25-OH-D in the D2 groups tended to be lower but did not differ significantly from those 
in the D3 groups (iAUC 15 ± 15, 35 ± 27, 23 ± 14 and 49 ± 24 nmol·L
-1·wk for 5-D2, 10-
D2, 5-D3 and 10-D3 respectively).  
 
The analyses were also conducted adjusting for gender, age and BMI. There were no 
significant gender or BMI effects or interactions, but there was a significant age x time 





Figure 4.4 Serum concentrations of 25-OH-D2 (panel A), 25-OH-D3 (panel B) and 
total 25-OH-D (panel C) in healthy men and women not exposed to UVB following 
placebo (n=8), 5 µg ergocalciferol/d (5-D2), n=8; 5 µg cholecalciferol/d (5-D3), n=7; 10 
µg ergocalciferol/d (10-D2), n=8 and 10 µg cholecalciferol/d (10-D3), n=8 for 4 wk in 
the winter months. Values are means with 95% CI. Data were analysed by repeated 
measures analysis of variance (4 time points) with the baseline value as a covariate and 
treatment group as the between-subjects factor. Repeated measures contrasts were 
performed to test for a dose response effect. 





























Treatment x time interaction P<0.001
 5-D2 vs 10-D2 P=0.007
  D2 vs D3 effect P<0.001





























Treatment x time interaction P<0.001
       5-D3 vs 10-D3 P=0.003































Treatment x time interaction P=0.009
       5 g vs 10 g/d P=0.01




Table 4.3 Changes (Δ) in serum 25-OH-D metabolite, serum calcium and plasma parathyroid hormone (PTH) concentrations after 4 wk of 
consuming a drink providing a daily intake of 5 µg or 10 µg of ergocalciferol (D2) or cholecalciferol (D3) or placebo in participants not exposed to 
UVB1. 
 
1 Values are mean changes from baseline with 95% CI, n=8 for every group apart from the 5-D3 group for which n=7.  5-D2, 5 µg ergocalciferol/d; 5-D3, 
5 µg cholecalciferol/d; 10-D2, 10 µg ergocalciferol/d; 10-D3, 10 µg cholecalciferol/d; PTH, parathyroid hormone. 
2 Probability from oneway ANOVA of the changes from baseline between treatment groups. 
*P<0.05, **P<0.01 compared with placebo; Dunnett’s test.
Analyte Placebo 5-D2 5-D3 10-D2 10-D3 P value
2 
Δ25-OH-D2, nmol/L  -0.2 (-1.0, 0.5)  9.2 (5.5, 12.9)** -0.1 (-0.2, 0.1) 17.6 (9.2, 25.9)** - 0 (-0.1, 0.1) <0.0001 
Δ25-OH-D3, nmol/L  -3.1 (-8.0, 1.7) -3.8 (-10.3, 2.8) 12.0 (2.7, 21.2)* -2.9 (-9.3, 3.4) 19.8 (9.4, 30.2)**  <0.0001 
ΔTotal 25-OH-D, nmol/L  -3.4 (-8.2, 1.5) 4.9 (-2.3, 12.7) 11.9 (2.7, 21.2)* 13.6 (4.1, 23.0)** 19.7 (9.4, 30.1)**  0.001 
ΔCa2+, μmol/L  -23 (-54, 99) -39 (-145, 67) -17 (-87, 57) -15 (-85, 123) -21 (-85, 124)  0.728 




There was no significant difference in the change in serum Ca2+ concentrations from 
baseline to post-intervention between treatment groups (Table 4.3). 
 
4.3.4 PTH 
Although there was a decrease in PTH of 13 ng/L (95% CI: -21, -3) in the 10 µg/d groups 
compared to baseline, this change was not significantly different from the change in 
the placebo group (Table 4.3). 
 
4.4 Discussion and conclusion 
This study set out to compare the effects of intakes of 5 or 10 μg/d D2 or D3, as might 
be provided by fortified foods, on serum vitamin D metabolite concentrations. It 
addresses an important question regarding the efficacy of fortified foods in helping 
maintain normal serum 25-OH-D concentrations. At baseline, 67.5% of participants had 
a 25-OH-D concentration below 50 nmol/L. This level is currently generally regarded as 
representing the lower limit of adequacy in vitamin D status. After a month of 5 or 10 
µg/d of D2 or D3, only 35% of participants in the treatment groups still had values 
below 50 nmol/L. The study is particularly relevant to the UK because of the relatively 
large population of vegetarians, particularly those of South Asian origin. D2 is derived 
from fungi and is acceptable to people unwilling to consume animal products, whereas 
D3 is derived from animal products. This study was conducted at a time of year when 
UVB exposure is extremely limited in the UK. The precaution of excluding participants 
who had recent high exposure to UVB was also taken. Most participants did not 
consume any D2. However, in one participant, high (>25 nmol/L) serum concentrations 
of 25-OH-D2 were found at baseline that were later found to be derived from regular 
consumption of fortified soya milk. Nevertheless, a very clear dose response 
relationship between D2 intake and serum 25-OH-D2 was shown, and there was 
considerably less variability in this analyte than that of 25-OH-D3 which is influenced by 
UVB exposure as well as dietary intake. There was no evidence of any change in 25-
OH-D3 concentrations in the participants allocated to placebo or the D2 groups 
confirming that the results were not confounded by variations in exposure to UVB 
during the study. 
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Both forms of vitamin D resulted in significant increments in their respective 25-OH-D 
metabolites compared with placebo, but the size of the increment did not differ 
between D2 and D3 treatments. There was a trend for the increment in 25-OH-D3 to be 
greater than that of 25-OH-D2, but there was greater variability in this compared to 25-
OH-D2, as shown by the larger confidence intervals. Furthermore, the increment in 25-
OH-D2 was reduced by the use of the limit of detection. Although four measurements 
were obtained on treatment for every participant compared to the minimum of 2 on 
follow-up required for the sample size calculation, and the comparison between D2 
and D3 included 16 participants in each group, rather than 8; both factors which allow 
for the detection of a smaller difference than 10 nmol/L, the sample size used in this 
study may be insufficient to detect more subtle differences between D2 and D3.  Before 
any definitive conclusion can be drawn on the equivalence of D2 and D3, a larger 
sample size with a more diverse population would be required, particularly including 
those with an elevated BMI (>30 kg/m2).  
 
Much of the uncertainty regarding the ability of the two forms to increase vitamin D 
status has arisen because of the use of non-specific assays. Several previous studies 
have concluded that D2 is less effective than D3 at increasing serum 25-OH-D 
concentrations (Armas et al. 2004; Trang et al. 1998; Romagnoli et al. 2008; Binkley et 
al. 2011; Heaney et al. 2011), but these were all uncontrolled, and three used an assay 
that was not able to measure 25-OH-D2 and 25-OH-D3 separately (Heaney et al. 2011; 
Romagnoli et al. 2008; Trang et al. 1998). All of the studies, apart from the study by 
Binkley et al. (Binkley et al. 2011), which gave participants 40 µg/d or 1250 µg/wk, also 
used supplements providing more than 100 µg. Two gave very large single doses of 
vitamin D at 7500 µg (Romagnoli et al. 2008) or 1250 µg (Armas et al. 2004). It is not 
possible to extrapolate from such high doses to the low amounts provided in fortified 
foods.  
 
A strength of this study is that a highly sensitive UPLC-MS/MS assay was used which 
separated the two vitamin D metabolites. This assay only uses 0.1 mL of serum but has 
sensitivity over the range 2.4 to 363.5 nmol/L for 25-OH-D2, and 7.5 to 374.4 nmol/L 
for 25-OH-D3, with accuracies of between 0.5% and 6.6% for both metabolites. This 
study compares the two forms of vitamin D at an intake within the dietary range and in 
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line with recommendations in healthy adults. The findings are broadly in agreement 
with a study by Holick et al. (Holick et al. 2008) in which healthy adults were randomly 
allocated to receive 25 µg of D3 (n=20), 25 µg of D2 (n=16), 12.5 µg of each of D3 and D2 
(n=18), or placebo once a day for 11 wk. Their measurements were conducted using 
LC-MS/MS; the detection limit for the assay was 10 nmol/L and the interassay 
coefficient of variation was about 10%. They found both 25-OH-D2 and 25-OH-D3 to be 
equally effective. In our study, serum 25-OH metabolite concentrations appeared to 
plateau at 4 wk whereas in the study by Holick et al. it was suggested that the plateau 
was reached after 6 wk (Holick et al. 2008). However, closer inspection of their data 
suggests that later values fell back closer to the 4 wk value. A recent study by 
Biancuzzo et al. gave participants 25 µg/d of D2 or D3 in orange juice for 11 wk at the 
end of winter in the US. They similarly showed that a plateau in 25-OH-D2 and 25-OH-
D3 was reached after 4-5 wk of supplementation, and that both D2 and D3 were equally 
effective at raising and maintaining 25-OH-D concentrations (Biancuzzo et al. 2010).  
 
The mean absolute increases in the present study compared with placebo for 25-OH-
D2 were 9.4±2.5 and 17.8±2.4 nmol/L following 5-D2/d and 10-D2/d, and for 25-OH-D3 
were 15.1±4.7 and 22.9±4.6 nmol/L following 5-D3/d and 10-D3/d. This would suggest 
that for every 1 μg D2 or D3 there is about a 2 nmol/L increase in the 25-OH-D 
metabolite. For comparison, Holick et al. (Holick et al. 2008) found that 
supplementation with 25 µg/d led to serum 25-OH-D increases of 24.7 nmol/L in the D2 
group (n=16) and 23.2 nmol/L in the D3 group (n=20) over 11 wk; equivalent to 
increases in serum 25-OH-D of approximately 1 nmol/L per µg vitamin D which is about 
half the value observed in the present study. It is possible that higher intakes become 
less effective at raising 25-OH-D concentrations because they increase the catabolic 
rate of the vitamin. However, the mean baseline 25-OH-D value in Holick’s study was 
47.0 nmol/L (Holick et al. 2008), compared to the mean of 42.0 nmol/L at baseline in 
this study and it may be that a greater treatment response is seen in participants who 
start with a lower serum 25-OH-D concentration.  
 
Supplementation with D2 did not influence serum concentrations of 25-OH-D3. 
Previously, Armas et al. (Armas et al. 2004) and Thacher et al. (Thacher et al. 2010) 
have reported that a single 1.25 mg oral dose of vitamin D2 led to a fall in 25-OH-D3 in 
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adult men and healthy and rachitic Nigerian children, respectively. This may be due to 
competition for the 25-hydroxylase by D2, an increased catabolism of 25-OH-D3 and/or 
competitive displacement of 25-OH-D3 from the VDBP by 25-OH-D2. However, the 
findings in the current study support those of Holick et al. (Holick et al. 2008), and 
provide no evidence to suggest that D2 influences the catabolism of D3 or its 
metabolites. It may be only very high doses of vitamin D2 that lead to strong enough 
effects on the factors listed above to cause a decrease in serum 25-OH-D3 
concentrations. 
 
There was some tentative evidence for a decline in PTH concentrations with 10 μg/d of 
vitamin D but this was not significantly different compared with placebo. However as 
there is high variability between participants in PTH, it would be necessary to study a 
much larger number of participants to confirm this effect. It is also possible that due to 
the adequate calcium intakes at baseline, higher concentrations of serum 25-OH-D 
may not decrease PTH concentrations any further. 
 
The strengths of this study are that it was conducted in the winter months using a 
physiologically relevant dose of vitamin D, and a highly sensitive and specific assay to 
measure 25-OH-D2 and 25-OH-D3. The food matrix used was a drink which may have 
facilitated absorption of the vitamin and so the results cannot necessarily be 
extrapolated to other foods i.e. breakfast cereals.  A limitation of the study is that the 
participants were in good health and not obese. With increasing age and obesity there 
may be an increase in the rate of turnover of vitamin D resulting in lower serum 
concentrations (MacLaughlin and Holick 1985; Wortsman et al. 2000). There were 
some differences in BMI between groups at baseline owing to the small sample size. 
However adjusting for BMI in the analyses did not alter the conclusions, and in view of 
the findings in Chapter 3, the effects of BMI seem most pronounced in those with a 
BMI>30kg/m2. 
 
In conclusion, the present study shows that consumption of a malted milk drink 
fortified with a low dose of either D2 or D3 leads to significant improvements in serum 
25-OH-D concentrations. It therefore can be concluded that dietary vitamin D2
 could be 
used at levels likely to be consumed in the diet to test whether supplementation 
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influences cardiovascular risk markers. The results indicate that a daily intake of 10 μg 
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5 Chapter 5 - The effect of low dose vitamin D2, provided in a fortified malted milk 




Marked seasonal variations in serum 25-OH vitamin D (25-OH-D) concentrations occur 
which result in 55-70% and 17-39% of the UK population having values below 50 
nmol/L and 25 nmol/L respectively in the winter months (Ruston 2004; Bates et al. 
2014). Vitamin D insufficiency, as well as affecting bone health, may also increase risk 
of cardiovascular disease (CVD) (Wang et al. 2012a). Some evidence from long-term 
randomised controlled trials suggests that vitamin D supplementation (often in 
combination with calcium) reduces total mortality (Zheng et al. 2013; Bjelakovic et al. 
2014; Chowdhury et al. 2014) but there is no clear evidence to support a beneficial 
effect on CVD incidence and mortality.  
 
Vitamin D insufficiency might affect risk of CVD by altering vascular function and 
inflammation. There is some evidence from cross-sectional studies showing that low 
25-OH-D concentrations are associated with higher BP (Judd et al. 2008; Scragg et al. 
2007) endothelial dysfunction (Al Mheid et al. 2011; Jablonski et al. 2011), arterial 
stiffness (Al Mheid et al. 2011; Giallauria et al. 2012) and elevated levels of MMP-9 and 
C-reactive protein (Ngo et al. 2010; Timms et al. 2002). However, these associations 
may not be causal and could be confounded by associations with physical activity level 
(Al-Othman et al. 2012) and chronic disease. Some trials (Tarcin et al. 2009; Sugden et 
al. 2008; Harris et al. 2011) report improvements in vascular function and 
inflammation but others (Yiu et al. 2013; Witham et al. 2013a; Gepner et al. 2012) find 
no such effects. A few trials have produced un-interpretable results because they 
either have not controlled for sunlight exposure (Breslavsky et al. 2013; Gepner et al. 
2012) or were poorly designed (lacking a placebo treatment) (Tarcin et al. 2009; Dong 
et al. 2010). Furthermore, most trials to date have used doses of vitamin D in the range 
of 63-125 µg/d (Gepner et al. 2012; Yiu et al. 2013), or a single dose of around 2500 – 
7500 µg (Harris et al. 2011; Tarcin et al. 2009; Witham et al. 2010) and so are 
pharmacological rather than nutritional comparisons as the amounts are much greater 
that can be achieved through dietary intake. A need for a well-designed study in 
healthy older people is long overdue. 
 
The aim of the study presented here was to ask the question “Does an intake of 
vitamin D that can be achieved through diet in the winter months improve endothelial 
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function and thus lower BP?”. The decision to use ergocalciferol (D2) was taken in 
order to exclude any possible effect of sunlight exposure; the dose level of 10 µg/d was 
selected on the basis of the trial described in Chapter 4. Flow mediated dilation of the 
brachial artery was chosen as the best measure of endothelial function as it is a well 
validated method of measuring the capacity of the vascular endothelium to produce 
the vasodilator nitric oxide (NO) (Green et al. 2014). BP is subject to substantial 
measurement error and observed bias. In order to overcome this, 24 h ABP monitoring 
was used. To exclude the known adverse effects of smoking on vascular function only 
non-smoking participants were invited. However, as age is a major predictor of future 




Dietary vitamin D2 provided in a malted milk drink in the winter months will lower BP 
and improve endothelial function in healthy older men and women. 
 
Corollary: Dietary vitamin D2 provided in a malted milk drink in the winter months will 
reduce chronic inflammation and slow arterial stiffening. 
 
5.2.2 Objective 
To conduct a randomised placebo controlled trial of an intake equivalent to 10 µg 
vitamin D2/d, provided in a malted milk drink, in healthy men and post-menopausal 
women (50-70 y) during the winter months.  
 
Primary outcome:  




1) Indices of inflammation (hsCRP, MMP-9, and fibrinogen). 
2) Lipid profile (TC, HDL-C and triglycerides) with TC:HDL-C as the major indicator 
of risk. 




Plasma renin concentrations, factor VII coagulant activity (FVIIc), insulin sensitivity and 
β cell function assessed using the homeostatic model assessment (HOMA-2). 
 
Markers of compliance to the intervention 
The metabolites 25-OH-D2, 25-OH-D3, Ca
2+, and parathyroid hormone (PTH) were 
measured along with body weight. Any unused sachets of intervention product were 
returned and a tally of the number consumed recorded. Serum free vitamin D 
concentrations were estimated post hoc using published equations after determining 
VDBP and albumin concentrations. 
 
5.2.3 Sample size 
Sample size calculations were based on being able to detect a 1 unit SD change in FMD 
over the 12 wk intervention period. Assuming a mean FMD of 6.8% for healthy 
subjects, with an SD of 2.0, a sample size of 16 per group would be required to detect a 
1.4% change in FMD with α = 0.05 and 80% power, assuming two measurements are 
made on treatment. For 24 h ABP, a within-subject SD of 7 mm was estimated, and 
two measures at baseline and two on treatment would give power to detect a 5 mm 
change. Allowing for drop-outs, a target of recruiting 40 participants was set. 
 
5.2.4 Ethical approval, clinical governance and R&D approval 
Ethical approval was obtained from the London-Westminster Research Ethics 
Committee 1 (REC reference 11/LO/1626) on 06/12/2011 (Appendix 19). The trial was 
registered at http://www.controlled-trials.com and allocated a clinical trial registration 
number ISRCTN45316882 on 07/09/2012.  Approval from the Guy’s and St Thomas’ 
Department of Research and Development (R&D) was obtained on 14/12/2011 (Trust 
R&D registration number RJ111/N332) (Appendix 20) and additional consent was 
given for analysis of VDBP. Participants gave written informed consent (Appendix 21) 
and received a small remuneration for taking part in the study. 
 
5.2.5 Study design 
A parallel design randomised placebo-controlled trial was selected as the seasonal 
nature of the study would make a cross-over design unsuitable. Participants were 
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randomly allocated to treatment using minimisation for gender and ethnicity on the 
MinimPy Program 0.3. The treatment allocation was done by a member of KCL staff 
who was unconnected with the study. The member of staff had the treatment 
allocation (A or B) for each of the subject codes, but was blinded to the identity of A or 
B in terms of whether it was active or placebo treatment. The allocation of treatment 
(A or B) was held by a code-breaker who was a member of GlaxoSmithKline staff 
unrelated to the study and was concealed until the study was completed and data for 
the primary and secondary outcomes had been entered into the statistical database 
(29/11/2013). 
 
Measurements were made at baseline and after 6 and 12 wk of intervention; in the 
case of 24 h ABP a further baseline measurement was made following the screening 
visit (Figure 5.1). The study took place between 20/01/2012 and 03/05/2012, and 
between 04/01/2013 and 30/04/2013, both periods when UVB exposure was low in 





Figure 5.1  Study design. 
Screening blood samples tested for glucose, lipids, liver function, 25-OH-D and haematology. ABP, Ambulatory blood pressure monitoring; FMD, flow-mediated 
dilation; PWV, Pulse Wave Velocity; Anthropometric measurements including height, weight, BMI and waist circumference taken at every visit, including 
screening; Blood metabolites at baseline, mid-point and end of study tested for vitamin D binding protein, 25-OH-D2 and 25-OH-D3, Ca
2+, PTH, glucose, C-peptide, 
high sensitivity C-reactive protein, MMP-9, lipids (total cholesterol, HDL cholesterol and triglycerides), renin, fibrinogen and factor VII coagulant activity. Lifestyle 








• 24 h ABP after the 
visit






















5.2.6 Test materials 
A malted milk drink (Horlicks™, GlaxoSmithKline, Middlesex, UK) was used as a vehicle 
to supply the vitamin D, and the placebo treatment was an identical drink without 
added vitamin D. Participants were asked to consume three drinks/wk. The material to 
constitute the drink was provided in single serves in plain silver sachets: for the active 
treatment each sachet provided 24 µg vitamin D2/serving. Participants were given a 
supply of 42 sachets at the start of the intervention and requested to return any 
unused sachets at the end of the study. They were provided with instructions to make 
the drinks up with hot water and not to add milk. Each 25 g sachet provided: 96 kcal, 
2.4 g protein, 19.3 g carbohydrate (of which sugars, 8.8 g), 0.8 g fat (of which 
saturates, 0.3 g) and 0.1 mg sodium. The ingredients list was: wheat flour, malted 
barley, dried whey, calcium carbonate, sugar, vegetable fat, dried skimmed milk, salt, 
acidity regulator (potassium bicarbonate).  
 
5.2.7 Recruitment of participants 
The study aimed to recruit healthy men or post-menopausal women aged 50-70 y. 
Exclusion criteria were: a reported history of angina pectoris, MI, stroke, peripheral 
vascular disease, arterial fibrillation, congenital heart defects or congenital heart 
disease, ABP >150/95 mm Hg (assessed by ABP monitoring), current use of medication 
for lowering blood cholesterol (statins) or BP, type 1 or type 2 diabetes mellitus 
(fasting blood glucose >7.0 mmol/L), chronic renal, liver or inflammatory bowel 
disease, current cigarette smoker, underweight or morbidly obese (Body Mass Index 
<18.5 and >35 kg/m2), an overall risk of CVD over the next 10 y of >20% assessed 
according to QRISK2 (ClinRisk Ltd 2013), prolonged exposure to high UVB light since 
Nov 2011 (or since Nov 2012 for the second cohort), going to a lower latitude country, 
or using a tanning sun-bed during the study period, serum 25-OH-D at screening 
>65nmol/L, intolerance to study product (lactose, milk protein), taking vitamin and 
mineral supplements (including cod-liver oil) or prescription calcium/vitamin D, 
unwillingness to restrict consumption of oily fish to no more than 2 portions per wk, 





Participants were recruited via an email sent to the staff and student population at KCL 
(Appendix 22), posters at KCL (Appendix 23), and a London Metro newspaper 
advertisement (Appendix 24). Subjects expressing interest were provided with a study 
information sheet (Appendix 25) and asked to complete a telephone/email 
questionnaire (participants had the option as to whether to complete the 
questionnaire sent by email or to ring up and complete it over the telephone) if still 
interested (Appendix 26). Those who appeared eligible and willing to participate were 
invited to attend a screening appointment either at the MRU in Franklin-Wilkins 
Building at KCL, or in the Clinical Research Facility (CRF) at St Thomas’ Hospital to 
further assess their suitability for inclusion in the study. BP and anthropometric 
measurements were taken, along with a blood sample to ascertain that haematology, 
liver function, lipid profile, plasma glucose and 25-OH-D concentrations were within 
prescribed limits (Appendix 16). The subject was fitted with an ABP monitor at the end 
of the visit and asked to wear it for the next 25 hours. They were also asked to bring in 
a completed lifestyle questionnaire containing a FFQ (Appendix 9), which they had 
been sent prior to their appointment to determine their usual dietary intake of vitamin 








Figure 5.2 Flow diagram of participants through the study. KCL, King’s College 
London; MRU, Metabolic Research Unit; ABP, Ambulatory blood pressure monitoring. 
 
5.2.8 Dietary intakes and physical activity 
Prior to the intervention (screening or baseline) and during the study (6 wk visit), 
participants completed a validated physical activity questionnaire (PAQ) (Appendix 27) 
(Craig et al. 2003) and a lifestyle questionnaire (Appendix 9) similar to that used in the 
Recruitment email circular (Appendix 18), recruitment posters (Appendix 19), 
and London Metro newspaper advertisement (Appendix 20).
Respondents  given information sheet (Appendix 
21) and interviewed by telephone or email using 
study questionnaire (Appendix 22) to assess 
eligibility
NOT SUITABLE – reason recordedSUITABLE
Screening appointment booked at the CRF at 
St Thomas’ or MRU at KCL. Participant asked 
to fast for 3hr before the appointment. 
Lifestyle questionnaire sent by post.
Screening appointment
• Participant given a paper copy of information 
sheet and an opportunity to ask questions.
• Informed consent obtained (Appendix 17).
• 3 hr fasted blood sample taken.
•Blood pressure and anthropometric 
measurements taken (height, weight and waist 
circumference).
•24hr ABPM given to participant along with 
instructions and diary card (Appendix 1 and 2).
•Completed lifestyle questionnaire returned.
Blood sample sent to KCH for processing same 
day as appointment. Glucose, haematology, 
liver function, total and HDL cholesterol, 
triglycerides and total 25-OH-D measured
SUITABLE NOT SUITABLE – reason recorded
Participant randomly assigned to 
treatment group and allocated 
the next sequential participant 
code in the format starting 001, 
002. Dispensing log updated. 
Subject allocated the next sequential 
screening number in the format starting 
S001, S002 etc. Screening Log updated.
• Lab results checked and signed off by a 
medical doctor if necessary. 
• ABP monitors returned  and data analysed.
•QRISK2 score calculated.




European Prospective Investigation in Cancer (EPIC) study (Bingham et al. 2001) which 
included an FFQ validated for vitamin D intake in the UK population (Crowe et al. 
2011), and asked about their medical history, previous smoking habits and educational 
attainment. Section 4.2.7 described how the lifestyle questionnaire data were analysed 
and habitual dietary intake determined. Physical activity data were analysed using the 
International Physical Activity Questionnaire (IPAQ) scoring protocol to determine 
median metabolic equivalents (MET) – min/wk. 
 
5.2.9 Ambulatory blood pressure monitoring 
Measurements of 24 h ABP were made following screening, baseline, 6 wk and 12 wk 
visits using A&D TM-2430 (A & D Instruments, 24-26 Blacklands Way,  
Abingdon Business Park, Abingdon Oxfordshire, OX14 1DY) devices (graded AA by the 
British Hypertension Society) (Williams et al. 2004) in accordance with UK guidelines 
(O'Brien et al. 2005). Further details are provided in section 2.2.4. The ABP monitor 
was programmed to take measurements every 30 min during the day (0700-2200) and 
hourly at night (2200-0700). At the end of the screening visit, participants were 
instructed how to use the monitor and were fitted with it. They were given a brief 
instruction card (Appendix 4) and diary card (Appendix 5) with their monitor. In a 
small number of cases, it was inconvenient for the participant to wear the monitor 
immediately after the visit (but not after the screening visit). If this occurred, it was 
checked that the participant had a friend or relative who could fit the monitor for 
them when convenient with the help of the instruction card. The trained researcher 
also went over with the participant the important points to remember in fitting the 
monitor correctly, and demonstrated this at the end of the visit to remind them. 
During readings taken by the monitor the participant was instructed to stop what they 
were doing and relax their arm. They were asked to complete the diary card following 
each measurement to report what they were doing immediately prior to the 
measurement (lying down, sitting, standing or walking plus any other details or 
problems that may have occurred) and to record when they went to bed and woke up. 
After fitting the monitor, the researcher recorded details of the monitor number, 
where and when (date and time) the monitor could be collected and the contact 
information of the participant. A courier was booked and the monitor was returned 
directly to the researcher at KCL. Monitors were usually collected within a day or two 
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of the measurements being taken. The data were downloaded onto a computer, 
analysed using TM-2430-13 Doctor-Pro Software, and the first 3 readings obtained 
were discarded, leaving the remaining readings to be checked by the author. If it was 
considered that there were insufficient accurate measurements (at least 22 awake 
measurements and 6 asleep measurements), or the equipment had failed to work, the 
participant was requested to wear the monitor again for 24 h as soon as possible.  
 
5.2.10 Vascular function and measurements made on blood samples 
Before each clinic visit at baseline, 6 wk and 12 wk, participants were asked to avoid 
strenuous physical activity, foods high in fat, caffeine and alcohol on the day prior to 
the visit and to fast overnight from 22:00 drinking nothing but water until attending 
the CRF at St Thomas’ Hopsital the following morning. Each visit began with a short 
questionnaire in the ward to check that the participant was not taking any nutritional 
supplements, and to ask whether they had started taking any medication or had 
experienced prolonged sun exposure since the last visit. Measurements of weight, 
waist circumference and seated BP were then taken and a blood sample collected 
using the vacutainer method (Becton-Dickinson, Oxford). For all but one participant, 
blood samples were collected in the seated position. Both serum (after being left to 
stand at room temperature for 30 min) and plasma were centrifuged for 15 min at 
1300 g then separated from the gel section/haematocrit and stored pending analysis 
at -70°C. The following analytes were determined at baseline, 6 wk and 12 wk: 25-OH-
D2 and 25-OH-D3 by uHPLC/MS/MS, VDBP, serum Ca
2+, PTH, C-peptide, glucose, hs-
CRP, renin, fibrinogen, FVIIc, MMP-9, TC, HDL-C and triglycerides. Table 5.1 shows the 
methods used and where the analyses were conducted, and gives reference to the 
appropriate section in Chapter 2 where the methods are described in detail. Care was 
taken to ensure that the PTH sample was stored at -70°C within two hours of 
collection. Details on the specific vacutainers used and blood handling methods 
including centrifuge speed and time and temperature the sample was spun at can be 
found in Appendix 7. Following the blood sample, participants were asked to rest in 
the supine position on a ward bed for at least 10 min and measurements of supine BP 
and arterial stiffness (see section 2.2.2) were made. The participant then walked to the 
ultrasound room and rested for a further 15 min prior to a measurement of flow 
mediated dilatation (FMD) of the brachial artery (section 2.2.1). Measurements of FMD 
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were usually made on the right arm and blood was generally taken from the left arm, 
ensuring that FMD measurements were not in the arm from which blood had been 
taken earlier. Following the measurements, participants were fitted with an ABP 
monitor to wear over the next 25 h (section 5.2.9). They were then offered a breakfast 
of tea/coffee, cereal and bread with butter and jam, marmite or peanut butter. 
 
 
Table 5.1 Summary of the biochemical measurements and methods. 
Analyte Method Section where 









Calcium Colourimetric assay 2.4.5 KingsPath 
hsCRP Immunoturbidimetry 2.4.9 KingsPath 




25-OH-D2 and D3 uHPLC-MS/MS 2.4.6.1 LGC 
Total 25-OH-D Chemiluminescent immunoassay 2.4.6.2 KingsPath 
VDBP ELISA 2.4.12 KingsPath 
Fibrinogen Clotting time assay 2.4.11 KCL 
FVIIc Clotting time assay 2.4.11.1 KCL 
Glucose Enzymatic assay 2.4.1 KingsPath 
Cholesterol Enzymatic assay 2.4.4.1 KingsPath 
HDL cholesterol Enzymatic assay 2.4.4.2 KingsPath 
Triglycerides Enzymatic assay 2.4.4.3 KingsPath 
PTH, parathyroid hormone; hsCRP, high sensitivity C-reactive protein; MMP-9, matrix-
metalloproteinase 9; VDBP, vitamin D binding protein; FVIIc, Factor VII coagulant activity; 
KingsPath, King’s College Hospital; KCL, King’s College London. LGC, LGC Testing (Formerly HFL 
Sports Science), Cambridgeshire. ELISA, enzyme-linked immunosorbent assay; uHPLC-MS/MS, 
ultra-high pressure liquid chromatography tandem mass spectrometry. 
 
5.2.11 Calculation of free 25-OH-D 
Free vitamin D was defined as circulating 25-OH-D not bound to albumin or VDBP. It 
was calculated using the method described by Powe et al (Powe et al. 2013) using 
known affinity-binding constants for albumin and VDBP: Directly measured and 






5.2.12 Statistical analyses 
Statistical analysis of the data was conducted using SPSS for Windows Version 21.0. 
Standard distributional checks were made, and where appropriate, analyses were 
attempted following loge transformation. Where values were below the limit of 
detection, the limit of detection was assigned. In order to test whether the two 
treatment groups differed at baseline, comparisons were made using the independent 
samples t-test, Mann-Whitney U test or a Fisher’s exact test for categorical variables. 
The treatment effect was defined as the difference compared to placebo. It was 
decided in the final statistical analysis plan to focus on 24 h SBP and FMD as the two 
primary outcomes to avoid penalties associated with multiple comparisons for day-
time and night-time values as well as DBP. Data were analysed on an intention to treat 
basis using the SPSS General Linear Model (GLM) with the mean treatment as the 
dependent variable, the treatment allocation as the predictor factor, age, gender and 
BMI as covariates, and the mean baseline value as an offset variable. A main effects 
model was used, and pairwise contrasts were performed between treatment groups. 
The SPSS syntax is shown below: 
 
GENLIN MeanTreatment24hSBP BY TreatmentGrp (ORDER=ASCENDING) WITH Age 
A_BMI Sex  
  /MODEL TreatmentGrp Age A_BMI Sex INTERCEPT=YES OFFSET=meanblspbl  
 DISTRIBUTION=NORMAL LINK=IDENTITY  
  /CRITERIA SCALE=MLE COVB=MODEL PCONVERGE=1E-006(ABSOLUTE) SINGULAR=1E-
012 ANALYSISTYPE=3(WALD) CILEVEL=95 CITYPE=WALD LIKELIHOOD=FULL  
  /EMMEANS TABLES=TreatmentGrp SCALE=ORIGINAL COMPARE=TreatmentGrp 
CONTRAST=PAIRWISE PADJUST=LSD  
  /MISSING CLASSMISSING=EXCLUDE  
  /PRINT CPS DESCRIPTIVES MODELINFO FIT SUMMARY SOLUTION. 
 
Where variables could not be normalised by log transformation, medians and inter-
quartile ranges were determined and non-parametric tests performed, including the 
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Mann-Whitney U test to compare changes in the outcomes from baseline to post-
intervention between groups. 
 
5.3 Results 
5.3.1 Participant details 
There were 179 respondents to the advertisement, 133 completed the initial 
questionnaire, 53 attended a screening visit and 41 were randomly allocated to 
treatment. Two participants in the placebo group withdrew their consent from the 
study for personal reasons; one following a dog-bite and the other owing to an 
unrelated medical condition that required pain-killing medication. Data were available 
for analysis on the primary outcome for 18 and 21 participants in the placebo and 
vitamin D2 groups. The CONSORT diagram is displayed in Figure 5.3 and the details of 
the participants by randomised treatment are shown in Table 5.2. The mean age was 
60 y, 46% were in paid employment and 32% were retired. Generally a high proportion 
had completed higher education. Although the mean BMI was in the normal range, the 
average waist circumference indicated a fairly high prevalence of central adiposity. The 
participants were predominantly normotensive, but had moderately elevated serum 
cholesterol (>5.0 mmol/L) and a total cholesterol:HDL cholesterol ratio >3.0.  Their 10 y 
risks of CVD estimated by QRISK2 were typical of adults of their age in the UK, being 
higher in men (10%) than women (6.7%). At screening, the mean (SD) 25-OH-D 











•Did not meet inclusion criteria (n=73)
•No longer able to take part due to 
personal reasons (n=7)
Attended a screening 
appointment (n=53)
Excluded (n=12)
•Did not meet inclusion criteria (n=8)
•No longer able to take part due to 
personal reasons (n=4)
Randomised (n=41)




6 wk visit: 21/21 (100%) 6 wk visit: 18/20 (90%)
12 wk visit: 21/21 (100%) 12 wk visit: 18/20 (90%)



































Number of subjects (%) or mean values (SD) or †geometric mean (approx SD) or ‡median (IQR). 
Comparisons between groups show no significant differences using independent samples t-test, Mann-
Whitney U test, or Fisher’s exact test as appropriate; QRISK-2, 10 year risk of cardiovascular disease. 
ALP, alkaline phosphatase; AST, aspartate transaminase; GGT, gamma glutamyl  transferase. 
             Men         Women 
  Placebo Vitamin D Placebo Vitamin D 
 (n=10) (n=10) (n=10) (n=11) 
Age (y) 57 (6) 61 (4) 60 (5) 59 (6) 
Ethnicity         
   White 8 (80%) 9 (90%) 9 (90%) 11 (100%) 
   Black 0 (0%) 1 (10%) 0 (0%) 0 (0%) 
   Asian 2 (20%) 0 (0%) 0 (0%) 0 (0%) 
   Far East 0 (0%) 0 (0%) 1 (10%) 0 (0%) 
   Other 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Height (m) 1.77 (0.07) 1.77 (0.04) 1.64 (0.08) 1.63 (0.04) 
Weight (kg) 76.8 (13.7) 78.7 (11.4) 62.4 (9.1) 65.1 (9.0) 
BMI (kg/m2) 24.3 (3.5) 25.0 (3.2) 23.3 (3.3) 24.5 (3.2) 
Waist circumference (cm) 91.3 (12.1) 92.8 (11.2) 80.7 (6.8) 83.3 (11.3) 
Seated SBP (mm Hg) 122 (9) 128 (11) 120 (17) 118 (13) 
Seated DBP (mm Hg) 81 (8) 81 (9) 75 (12) 73 (7) 
QRISK-2 (%) 9.6 (5.1) 10.9 (3.6) 7.4 (4.1) 5.9 (3.6) 
Glucose (mmol/L) 4.9 (0.6) 5.2 (0.5) 5.0 (0.6) 5.4 (0.5) 
Total cholesterol (mmol/L) 5.5 (1.0) 4.9 (1.0) 6.0 (1.0) 5.4 (0.7) 
HDL-C (mmol/L)†  1.4 (0.4) 1.5 (0.3) 1.9 (0.5) 1.7 (0.5) 
LDL-C (mmol/L) 3.4 (0.8) 3.0 (0.7) 3.5 (0.9) 3.3 (0.7) 
TC:HDL-C ratio 3.88 (1.02) 3.35 (0.76) 3.43 (1.02) 3.36 (0.98) 
Haemoglobin (g/dL) 14.2 (1.0) 14.7 (1.1) 13.4 (0.7) 13.4 (0.8) 
WBC (giga/L) 5.24 (0.79) 5.52 (0.99) 5.99 (0.99) 5.71 (1.22) 
RBC (tera/L) 4.74 (0.45) 4.96 (0.28) 4.43 (0.30) 4.61 (0.47) 
Total protein (g/L) 71 (2) 71 (3) 70 (3) 69 (3) 
Albumin (g/L) 44 (2) 44 (1) 44 (2) 43 (1) 
Bilirubin (µmol/L)‡ 11 (8-11) 12 (11-14) 9 (8-10) 8 (6-9) 
ALP (IU/L) 65 (14) 57 (8) 68 (16) 73 (20) 
AST (IU/L) 25 (7) 24 (6) 22 (3) 21 (5) 
GGT (IU/L)†  20.3 (9.59) 20.20 (7.96) 18.0 (14.5) 13.14 (5.4) 
Total 25-OH-D (nmol/L) 31.3 (14.4) 37.2 (12.4) 40.0 (12.1) 39.3 (9.3) 
Education (highest achieved)         
  GCE/O-level 0 (0%) 2 (20%) 2 (20%) 2 (18.2%) 
  A-level 1 (10%) 1 (10%) 1 (10%) 4 (36.4%) 
  HND, Diploma 3 (30%) 2 (20%) 1 (10%) 2 (18.2%) 
  Degree 5 (50%) 5 (50%) 4 (40%) 3 (27.3%) 
  None of these/other 1 (10%) 0 (0%) 2 (20%) 0 (0%) 
Employment status         
  In paid employment 5 (50%) 4 (40%) 6 (60%) 4 (36.4%) 
  Unemployed 1 (10%) 2 (20%) 0 (0%) 0 (0.0%) 
  Retired 3 (30%) 3 (30%) 3 (30%) 4 (36.4%) 
  Housewife/husband 0 (0%) 0 (0.0%) 1 (10%) 2 (18.2%) 
  Other 1 (10%) 1 (10%) 0 (0%) 1 (9.1%) 
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5.3.2 Body weight, waist circumference, dietary intake of vitamin D and calcium, 
and physical activity during the study. 
Table 5.3 details the body weight, waist circumference, vitamin D and calcium intake, 
and total physical activity of participants during the study, which did not change 
significantly. Participants were given 42 sachets of the intervention product and 
returned approximately six indicating that they had consumed 3 sachet/wk for 12 wk. 




























Table 5.3 Changes in body weight, waist circumference, dietary intake and physical 
activity 





Effect (95% CI) 
P  
value 
Body weight (kg)       
Baseline 69.6 (13.3) 71.4 (11.8)   
Midpoint 70.5 (13.0) 71.5 (12.1)   
Endpoint 70.3 (13.0) 71.5 (12.5)   
Mean treatment 70.4 (13.0) 71.5 (12.3) 0.29 (-0.35, 0.93)  0.36 
     
Waist circumference 
(cm)† 
      
Baseline 85.5 (9.9) 88.7 (12.5)   
Midpoint 84.6 (9.3) 87.8 (12.8)   
Endpoint 85.8 (9.7) 87.6 (12.5)   
Mean treatment 85.2 (9.3) 87.7 (12.5) -0.1% (-1.8, 1.6)  0.93 
     
Number of Sachets out of 
42 returned 
5.7 (2.0)   5.3 (1.9) -0.3 (-1.6, 0.9)  0.60‡ 
     
Dietary vitamin D intake 
(µg/d)† 
    
Baseline 3.2 (2.2) 2.4 (1.7)   
Treatment 2.8 (1.2) 2.4 (1.3) -4.0% (-21.3, 17.1) 0.68 
Treatment + intervention 2.8 (1.2) 12.6 (1.3)   
     
Calcium intake (mg/d)     
Baseline 929 (281) 932 (272)   
Treatment 976 (289) 964 (332) -21.5 (-195, 152) 0.85 
     
Physical activity (MET – 
min/wk) ¶ 
    
Baseline 261 (127, 440) 297 (146, 594)   
Treatment 419 (240, 494) 366 (185, 524) -6.0% (-55.0, 42.9) 0.44 
Values are mean (SD); †Geometric mean (approx SD) and treatment effect calculated as percentage 
using log transformed data. Treatment effects and probability from Generalised Linear Model with 
baseline value as offset adjusted for age and gender (physical activity also adjusted for BMI); ‡two 
sample t-test. ¶ median (IQR) and Mann Whitney test used to calculate probability; MET, Metabolic 














5.3.3 Vitamin D status 
The mean serum concentrations of 25-OH-D2, 25-OH-D3 and total 25-OH-D at baseline 
were 2.8, 39.8 and 42.6 nmol/L respectively, with 18% <25 nmol/L and 72% <50 nmol/L 
(Table 5.4). Serum vitamin D metabolite concentrations remained low and unchanged 
in the placebo group. In the D2 group, the median 25-OH-D2 metabolite concentrations 
increased from 2.4 (IQR 2.4, 2.4) to 25.9 (IQR 18.6, 33.4) nmol/L, appearing to plateau 
between 6 and 12 wk of supplementation (Figure 5.4). The change in total 25-OH-D in 
the D2 group (16.2, 95% CI 10.4, 22.0) was significantly greater (P<0.001) than that in 
the placebo group (-3.3, 95% CI -9.6, 3.0). There was a non-significant trend for 25-OH-
D3 to fall in both groups compared with the baseline measurement. After 12 wk of D2 
supplementation, total 25-OH-D concentrations had increased from 40.8 nmol/L at 
baseline to 59.2 nmol/L such that none of the participants had 25-OH-D values <25 
nmol/L, but 24% still remained <50 nmol/L. Individual results are presented in 
Appendix 28. There was a trend (P=0.104) for VDBP to fall in the D2 group compared 
with placebo. Levels of free 25-OH-D rose significantly in the D2 group compared with 
placebo (P<0.001). There were no significant treatment effects for serum Ca2+ or 
plasma PTH concentrations (Table 5.5). However, a Mann-Whitney U test on the 




Table 5.4 Effects of an intake equivalent to 10 μg vitamin D2/d vs. placebo on 25-OH-
D metabolites, vitamin D binding protein and free 25-OH-D concentrations in healthy 
men and women aged 50-70 y. 
  Placebo  
(n=18) 
Vitamin D2  
(n=21) 
Treatment 
effect (95% CI) 
P value 
25-OH-D2 (nmol/L) †       
Baseline 2.4 (2.4, 3.0) 2.4 (2.4, 2.4)   
6 wk 2.4 (2.4, 3.2) 22.9 (16.3, 30.1)   
12 wk 2.7 (2.4, 5.0) 25.9 (18.6, 33.4)   
Mean on treatment 2.7 (2.4, 3.7) 22.3 (19.6, 30.9)   
Change 10.7% (-19.0, 40.4) 199% (169, 221)   
Adjusted change  15% (-13.0, 43.4) 195% (169, 221) 180% (141, 218) 1.22E-07 
     
25-OH-D3 (nmol/L)‡       
Baseline 35.2 (25.4) 35.08 (14.7)   
Midpoint 31.0 (24.8) 31.40 (10.4)   
Endpoint 33.1 (21.4) 32.59 (8.7)   
Mean on treatment 33.5 (24.1) 33.41 (12.0)   
Change  -5.1% (-10.3, 0.5) -4.8% (-9.7, 0.4)   
Adjusted change -5.4% (-10.4, -0.3) -4.8% (-9.5, 0.1) 0.6% (-6.4, 7.6) 0.868 
     
25-OH-D (nmol/L)       
Baseline 44.8 (26.2) 40.8 (14.4)   
Midpoint 40.2 (24.9) 55.2 (15.7)   
Endpoint 42.3 (21.2) 59.2 (12.6)   
Mean on treatment 41.2 (22.6) 57.2 (13.5)   
Change -3.6 (-10.4, 3.2) 16.5 (10.2, 22.8)   
Adjusted change  -3.3 (-9.6, 3.0) 16.2 (10.4, 22.0) 19.5 (10.8, 28.2) 1.10E-05 
     
VDBP (mg/L)     
Baseline 355.3 (157) 382.3 (188.9)   
Midpoint 380.12 (189.3) 366.0 (178.2)   
Endpoint 359.6 (191.3) 373.9 (199.9)   
Mean on treatment 369.9 (188.8) 370.0 (186.9)   
Change 14.6 (-9.3, 38.5) -12.3 (-34.5, 9.8)   
Adjusted change 13.9 (-8.6, 36.4) -11.8 (-32.6, 9.0) -25.7 (-56.7, 5.3) 0.104 
     
Free 25-OH-D 
(pmol/L)‡ 
    
Baseline 6.23 (3.93) 5.98 (7.11)   
Midpoint 5.31 (4.12) 8.67 (7.38)   
Endpoint 6.23 (4.14) 9.49 (8.20)   
Mean on treatment 5.87 (3.91) 9.12 (7.74)   
Change -6% (-21, 12) 52% (30, 78)   
Adjusted change -6% (-22, 10) 42% (28, 56) 48% (27, 69) 1.09E-05 
Values are mean (SD); Treatment effect and probability from Generalised Linear Model with baseline 
value as offset and age, BMI and gender as covariates, adjusted changes are the marginal means 
adjusted for covariates; †Median (IQR), treatment effect calculated as percentage using log transformed 
data and probability calculated using Mann-Whitney U test; ‡Geometric mean (approx SD) and 
treatment effect calculated as percentage using log transformed data. VDBP, vitamin D binding protein.   
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Table 5.5 Effects of an intake equivalent to 10 μg vitamin D2/d vs. placebo on serum 









Ca2+ (mmol/L)       
Baseline 2.26 (0.09) 2.23 (0.08)   
6 wk 2.25 (0.09) 2.22 (0.06)   
12 wk 2.24 (0.10) 2.24 (0.07)   
Treatment  2.25 (0.09) 2.23 (0.06)   
Change -0.02 (-0.04, 0.01) 0.01 (-0.02, 0.03)   
Change adjusted -0.00 (-0.04, 0.01) 0.00 (-0.02, 0.03) 0.02 (-0.02, 0.05) 0.381 
     
PTH (ng/L)†       
Baseline 38.9 (18.2) 39.9 (15.6)   
6 wk 38.6 (23.4) 36.1 (16.6)   
12 wk  40.6 (25.2) 34.1 (19.3)   
Treatment  39.8 (23.5) 35.5 (16.4)   
Change (%) 2.1 (-12.4, 19.0) -10.8 (-22.8, 2.8)   
Change adjusted (%) 2.6 (-12.1, 17.1) -11.8 (-25.3, 1.7) -14.3 (-34.4, 5.8) 0.163 
Mean values (SD); †Geometric mean (approx SD) and treatment effect calculated as percentage using 
log transformed data. Treatment effect from Generalised Linear Model with baseline value as offset, 
covariates age, BMI and gender. Adjusted changes are the marginal means adjusted for covariates. 
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Figure 5.4 Serum concentrations of 25-OH-D2 (panel A) and 25-OH-D3 (panel B) in healthy men and women not exposed to UVB following 
placebo (n=18) or an intake equivalent to 10 µg vitamin D2/d (n=21) for 12 wk in the winter months. Values are geometric means with 95% CI.  














































5.3.4 Blood pressure, flow mediated dilation and arterial stiffness  
Table 5.6 shows the changes in BP measured by 24 h ABP monitoring. Both SBP and 
DBP fell on D2 treatment compared with placebo: mean differences (95% CI) in mm Hg, 
adjusted for age, gender and BMI were -4.3 (-7.3, -1.2; P=0.007) and -2.8 (-5.4, -0.2, 
P=0.032), respectively. There was no evidence to indicate that the lower BP was 
related to changes in heart rate. The mean differences in day-time and night-time SBP 
in mm Hg were -3.3 (95% CI -6.7, 0; P=0.05) and -4.7 (95% C -7.7, -1.7; P=0.002) 
respectively (Figure 5.5) (Appendix 29). Table 5.7 shows the results for plasma renin, 
which remained unchanged during the study. 
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Table 5.6 Effects of an intake equivalent to 10 μg vitamin D2/d vs. placebo on 24 h 
systolic and diastolic BP and heart rate in healthy men and women aged 50-70 y. 
Mean values (SD); Treatment effect from Generalised Linear Model with baseline value as offset. 
Adjusted changes are the marginal means adjusted for the covariates age, BMI and gender.  
 
 Placebo 
(n = 18) 
Vitamin  D2  
(n = 21) 
Treatment  
effect  (95% CI) 
P  value 
SBP (mm Hg)       
Baseline 1 119 (11) 120 (12)     
Baseline 2 118 (14) 119 (10)     
Baseline mean 119 (12) 120 (10)     
6 wk 121 (11) 118 (11)     
12 wk 122 (11) 118 (8)     
Treatment mean 121 (10) 118 (9)   
Change  2.39 (-0.05, 4.83) -2.07 (-4.33, 0.19) -4.5 (-7.6, -1.3) 0.005 
Adjusted change  2.27 (0.04, 4.51) -1.97 (-4.04, 0.09) -4.3 (-7.3, -1.2) 0.007 
          
DBP (mm Hg)       
Baseline 1 73 (7) 73 (8)     
Baseline 2 71 (7) 73 (7)     
Baseline mean 72 (6) 73 (7)     
6 wk 75 (7) 72 (8)     
12 wk 73 (8) 72 (7)     
Treatment mean 74 (7) 72 (7)   
Change 2.36 (0.18, 4.55) -0.76 (-2.79, 1.26) -3.1 (-5.9, -0.3) 0.029 
Adjusted change 2.18 (0.33, 4.04) -0.61 (-2.33, 1.11) -2.8 (-5.4, -0.2) 0.032 
     
24 h heart rate (bpm)       
Baseline 1 72 (6) 68 (8)     
Baseline 2 71 (8) 69 (8)     
Baseline mean 72 (7) 69 (7)     
6 wk 72 (6) 67 (8)     
12 wk 73 (6) 71 (7)     
Treatment mean 72 (6) 69 (7)   
Change 0.97 (-0.95, 2.89) -0.21 (-1.99, 1.56) -1.2 (-3.6, 1.3) 0.345 




Figure 5.5 Mean changes (95% CI) in day-time and night-time systolic (SBP) and 
diastolic (DBP) BP in 21 and 18 participants allocated to an intake equivalent to 10 μg 
vitamin D2/d or placebo respectively.  Data were analysed using the SPSS Generalised 
Linear Model using the mean value on treatment regressed against treatment 































Table 5.7 Effects of an intake equivalent to 10 μg vitamin D2/d vs. placebo on 
plasma renin concentrations in healthy men and women aged 50-70 y. 
  Placebo 
(n = 18) 
Vitamin  D2        
(n = 21) 
Treatment effect  P value 
Renin (MIU/L)      
Baseline 13.5 (8.5, 18.2) 16.4 (9.9, 20.5)    
6 wk 12.1 (7.7, 17.6) 11.2 (7.4, 16.9)    
12 wk 11.1 (8.9, 19.4) 10.6 (8.6, 19.4)     
Treatment mean 12.8 (7.7, 18.5) 10.7 (8.8, 16.4) -9.8% (-39.5, 19.9) 0.360 
Median values (IQR). Treatment effect (95% CI) from the Generalised Linear Model using the logged 
mean value on treatment regressed against treatment allocation, age, BMI and gender with mean 




Table 5.8 shows the changes in FMD (%) and PWV (m/sec) over the 12 wk study 
period. The mean value among participants (3.8%) was lower than reported in 
previous studies from our laboratory where values are typically in the range of 6%, 
indicating some impairment of endothelial function among the participants. A total of 
56% of participants had an FMD below 4% at baseline. There were no significant 
changes over the treatment period and the average FMD at each time point differed 
by less than 1% FMD unit between groups. The mean treatment effect on FMD with 
95% CI was -0.17% (-1.62, 1.28; P=0.815). PWV remained unchanged in the placebo 
group but fell slightly in the vitamin D2 group by -0.30 m/sec (95 CI -0.60, -0.002). 
However, the difference between treatments of -0.30 m/sec (-0.74, 0.14; P=0.184) did 
not achieve statistical significance.  
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Table 5.8 Effects of an intake equivalent to 10 µg/d vitamin D2 vs. placebo on 
brachial artery diameter (BAD), flow mediated dilation (FMD) and carotid to femoral 
pulse wave velocity (PWVc-f)  








BAD (mm)       
Baseline 3.60 (0.75) 3.56 (0.72)     
Midpoint 3.50 (0.76) 3.71 (0.66)     
Endpoint 3.52 (0.75) 3.69 (0.73)     
Mean on 
treatment 
3.51 (0.74) 3.70 (0.66)   
Change -0.08 (-0.29, 0.13) 0.14 (-0.06, 0.33) 0.23 (-0.06, 0.51) 0.118 
Adjusted change -0.10 (-0.30, 0.11) 0.15 (-0.04, 0.34) 0.24 (-0.04, 0.52) 0.094 
          
FMD (%)         
Baseline 4.00 (2.51) 3.72 (2.63)     
Midpoint 5.56 (2.82) 4.46 (3.28)     
Endpoint 4.30 (2.53) 4.12 (2.19)   
Mean treatment 4.93 (2.10) 4.29 (2.33)   
Change 0.93 (-0.30, 2.16) 0.57 (-0.57, 1.71) -0.36 (-1.94, 1.21) 0.650 
Adjusted change 0.83 (-0.22, 1.88) 0.66 (-0.32, 1.63) -0.17 (-1.62, 1.28) 0.815 
     
PWVc-f (m/sec)       
Baseline 7.79 (1.15) 7.55 (0.98)     
Midpoint 7.81 (1.32) 7.30 (1.14)     
Endpoint 7.71 (1.30) 7.24 (1.14)   
Mean treatment 7.76 (1.28) 7.27 (1.12)   
Change -0.03 (-0.37, 0.32) -0.28 (-0.59, 0.04) -0.25 (-0.69, 0.19) 0.264 
Adjusted change 0.00 (-0.32, 0.32) -0.30 (-0.60, -0.002) -0.30 (-0.74, 0.14) 0.184 
Mean values (SD). Treatment effect (95% CI) from Generalised Linear Model with baseline value as 























5.3.5 Haemostatic and inflammatory risk factors and serum lipids 
Table 5.9 shows the changes in haemostatic and inflammatory variables over the 12 
wk study period. There were no significant treatment effects on hsCRP, fibrinogen or 
FVIIc. MMP-9 fell by 19.6% (-37.8, -1.4, P=0.035) in the D2 group compared to placebo. 
Table 5.10 presents the results for fasting lipids. HDL-C, LDL-C and TC increased in the 
D2 group compared to placebo; differences in marginal means (95% CI) in mmol/L or as 
a percentage, were 6.9% (95% CI 0.8, 12.9; P=0.026), 0.2 (0.0, 0.5; P=0.038) and 0.3 













Table 5.9  Effects of an intake equivalent to 10 μg vitamin D2/d vs. placebo on fibrinogen, factor VII coagulant activity (FVIIc), high sensitivity C-
reactive protein (hsCRP) and matrix metalloproteinase-9 (MMP-9).  
  
Baseline 6 wk 12 wk Treatment 
mean 
Treatment effect  P value 
Fibrinogen (g/L) ‡ 
      
Placebo n=18 3.59 (3.28-4.08) 4.01 (3.44-4.40) 3.68 (3.44-3.93) 3.85 (3.56-4.20) 
  
Vitamin D2
 n=21 3.76 (3.33-3.98) 3.57 (3.24-3.91) 3.62 (3.32-4.01) 3.63 (3.33-3.78) -7.2% (-18.2, 3.8) 0.185 
       
FVIIc (%)  
      
Placebo n=18 126 (31) 133 (29) 129 (31) 131 (29) 
  
Vitamin D2
 n=21 143 (37) 143 (49) 144 (50) 143 (45) -5.0 (-20.7, 10.6) 0.528 
       
HsCRP (mg/L) ‡ 
      
Placebo n=14 0.70 (0.50-1.20) 0.90 (0.38-1.40) 0.63 (0.30-1.20) 0.65 (0.35-1.35) 
  
Vitamin D2
 n=19 0.75 (0.32-1.45) 0.70 (0.30-1.54) 0.76 (0.32-1.35) 0.84 (0.29-1.30) -2.8% (-32.4, 26.9) 0.827 
       
MMP-9 (µg/L)† 
      
Placebo n=18 216 (89) 238 (127) 223 (132) 233 (117) 
  
Vitamin D2
 n=21 264 (84) 235 (108) 226 (88) 233 (90) -19.6% (-37.8, -1.4) 0.035 
Mean values (SD); †Geometric mean (approximate SD) and treatment effect calculated as percentage using log transformed data; ‡ median (IQR) and treatment effect calculated 
as percentage using log transformed data.  Treatment effects were derived from SPSS Generalised Linear Model regressed against age, BMI, gender with baseline value as offset. 






Table 5.10 Effects of an intake equivalent to 10 μg vitamin D2/d vs. placebo on serum lipids  
  Baseline 6 wk 12 wk Treatment mean Treatment effect  
(95% CI) 
P value 
TC: HDL-C ratio        
Placebo n=18 3.5 (0.7) 3.6 (0.8) 3.5 (0.8) 3.51 (0.79)   
Vitamin D2
 n=21 3.2 (0.6) 3.2 (0.7) 3.2 (0.6) 3.21 (0.63) -0.0 (-0.2, 0.1) 0.581 
       
Total cholesterol (mmol/L)        
Placebo n=18 5.4 (0.9) 5.2 (0.9) 5.4 (1.0) 5.32 (0.89)   
Vitamin D2
 n=21 4.9 (0.6) 5.0 (0.7) 5.2 (0.7) 5.15 (0.71) 0.3 (-0.02, 0.6) 0.035 
       
HDL-C (mmol/L)†        
Placebo n=18 1.6 (0.4) 1.5 (0.4) 1.6 (0.4) 1.54 (0.38)   
Vitamin D2
 n=21 1.6 (0.3) 1.6 (0.4) 1.7 (0.3) 1.63 (0.35) 6.9% (0.8, 12.9) 0.026 
       
LDL-C (mmol/L)       
Placebo n=18 3.3 (0.7) 3.1 (0.7) 3.2 (0.7) 3.16 (0.72)   
Vitamin D2
 n=21 2.9 (0.5) 3.0 (0.6) 3.2 (0.7) 3.07 (0.63) 0.2 (0.0, 0.5) 0.038 
       
Triglycerides (mmol/L)†       
Placebo n=18 1.1 (0.6) 1.1 (0.6) 1.2 (0.6) 1.15 (0.58)   
Vitamin D2
 n=21 0.9 (0.3) 0.9 (0.3) 0.8 (0.2) 0.89 (0.26) -2.7% (-16.1, 10.7) 0.689 
Values are mean (SD); †Geometric mean (approximate SD) with treatment effect calculated as percentage from log transformed data; Treatment effects (95% CI) derived from  




5.3.6 Fasting glucose and indices of insulin secretion and sensitivity 
Table 5.11 shows the changes in plasma glucose, C-peptide (as a marker of insulin 
secretion), β cell function and insulin sensitivity. The participants were 
normoglycaemic and estimates of insulin secretion and sensitivity were normal. There 
were no significant differences between treatment groups. 
 
Table 5.11  Changes in plasma glucose, C-peptide and estimates of β cell function 
and insulin sensitivity following an intake equivalent to 10 µg/d vitamin D2 vs. 
placebo for 12 wk. 
  Placebo 
(n = 18) 
Vitamin  D2        
(n = 21) 
Treatment effect  P value 
Glucose (mmol/L)      
Baseline 4.8 (0.5) 5.3 (0.6)    
6 wk 4.9 (0.4) 5.2 (0.6)    
12 wk 4.8 (0.5) 5.2 (0.6)    
Mean on treatment 4.81 (0.40) 5.21 (0.52) -0.01 (-0.20, 0.19) 0.932 
     
C-Peptide† (nmol/L)      
Baseline 0.47 (0.20) 0.55 (0.19)    
6 wk 0.47 (0.24) 0.52 (0.18)    
12 wk 0.49 (0.26) 0.53 (0.22)    
Mean on treatment 0.48 (0.24) 0.53 (0.19) -6.4% (-16.6, 3.8) 0.386 
     
β cell function (%)†      
Baseline 105 (26) 99 (26)    
6 wk 104 (33) 99 (32)    
12 wk 113 (26) 97 (27)    
Mean on treatment 109 (27) 99 (27) -4.2% (-12.1, 3.6) 0.287 
Insulin sensitivity (%S)      
Baseline 106 (38) 87 (28)    
6 wk 108 (46) 90 (24)    
12 wk  102 (40) 89 (27)    
Mean on treatment 105 (42) 90 (23) 3.4 (-5.9, 12.6) 0.473 
Values mean (SD); †Geometric mean (approx SD) and treatment effect calculated as percentage using 
log transformed data; Treatment effect  from Generalised Linear Model with covariates age, BMI, 








5.4 Discussion and conclusion 
This study adds to the current evidence that vitamin D insufficiency is prevalent during 
the winter in healthy British men and women in the age range 50-70 y. It shows that 
moderate supplementary intakes (10 µg/d) of vitamin D2 from a fortified drink improve 
vitamin D status. The proportion of participants with plasma 25-OH-D <50 nmol/L fell 
from 71% to 24% with the vitamin D2 intervention. However, free 25-OH-D may be a 
better indicator of physiological bioactivity in extra-renal tissues compared with total 
25-OH-D (Glendenning et al. 2013). In young adults, free 25-OH-D concentrations are 
more strongly correlated with bone mineral density than total 25-OH-D concentrations 
(Powe et al. 2011). It is notable, therefore, that free 25-OH-D increased by 48.0% (95% 
CI 26.6, 69.3) with D2 administration vs. placebo. The increment in free 25-OH-D is 
comparable to that reported in a study in which hip fracture patients were 
supplemented with either D3 or D2 at 25 µg/d for 3 months; the increases were 46% 
and 36% after D3 and D2 respectively (Glendenning et al. 2013). The findings of the 
present study indicate that an additional 10 µg/d was sufficient to improve vitamin D 
status both in terms of total 25-OH-D but also the proportion in the free fraction. 
 
The salient finding was a -4.3 mm Hg treatment effect in 24 h SBP determined by 
ambulatory monitoring. Two primary outcomes (FMD and 24 h SBP) were specified 
and the probability was P=0.007 which is less than the critical value of P=0.025. 
However, the change in BP was slightly less than the 5 mm Hg for which the study was 
powered; the observed power for the change was 78%. Therefore a type 1 error may 
have occurred and the findings may be due to chance. BP increased in the placebo 
group whereas it fell in the vitamin D2 group. It is well documented that BP increases 
between winter and spring (Modesti et al. 2013) but the reasons have been hitherto 
unexplained. The results presented here indicate that this may be due to vitamin D 
status. Whilst a few studies report that vitamin D supplementation lowers BP (Judd et 
al. 2010; Forman et al. 2013; Sugden et al. 2008), meta-analyses (Pittas et al. 2010; 
Kunutsor et al. 2014; Elamin et al. 2011; Witham et al. 2009; Wu et al. 2010) are 
equivocal. Most meta-analyses have concluded that there is no significant effect of 
vitamin D on BP (Pittas et al. 2010; Elamin et al. 2011; Kunutsor et al. 2014), but one 
found a significant decrease in DBP (-3.1 mm Hg, 95% CIs –5.5 to -0.6) (Witham et al. 
2009) and another observed a decrease in SBP of 2.44 mm Hg (Weighted mean 
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difference -2.44, 95% CI -4.86, -0.02) (Wu et al. 2010). However, the meta-analysis by 
Witham et al. included one study which used UV radiation rather than giving a dose of 
vitamin D. Furthermore, the majority of studies included in all of the meta-analyses 
have measured clinic BP rather than using repeat 24 h ABP monitoring which is more 
reliable and less subject to bias (Mancia et al. 2007; Staessen et al. 1999). As a 20 mm 
Hg difference in usual SBP is associated with a doubling of risk CVD mortality 
(Lewington et al. 2002), the 4 mm Hg difference in SBP found in the present study may 
reduce risk of CVD mortality by 20%.  
 
This change in SBP was not accompanied by changes in FMD which suggests that the 
BP lowering effect does not involve a change in the capacity of the vascular 
endothelium to synthesise nitric oxide. This lack of effect on FMD is in agreement with 
3 recent studies showing no significant change in FMD after 62.5 µg vitamin D3 daily 
for 4 months (Gepner et al. 2012), 125 µg vitamin D3/d for 12 wk (Yiu et al. 2013), or a 
single oral dose of D3 at 2500 µg or 5000 µg (Witham et al. 2010). However, FMD was 
more variable than anticipated and this may have reduced the power to detect a 
change. A few studies have claimed a positive effect of supplementation on FMD 
(Harris et al. 2011; Witham et al. 2012; Sugden et al. 2008; Tarcin et al. 2009), but all 
used very high doses of vitamin D; 1500 µg monthly D3 (Harris et al. 2011), a single oral 
dose of 2500 µg D2 (Witham et al. 2012; Sugden et al. 2008) or 7500 µg intra-
muscularly monthly (Tarcin et al. 2009). Furthermore, three of these studies were 
conducted in groups with compromised health including stroke patients (Witham et al. 
2012), overweight adults (Harris et al. 2011) and adults with type 2 diabetes (Sugden et 
al. 2008).  
 
It would appear unlikely that the BP lowering effect can be explained by a change in 
renin secretion (Li 2003) as plasma renin concentrations remained unchanged in 
agreement with a report by Sugden et al. (Sugden et al. 2008).  The BP lowering effect 
could be mediated by PTH. Associations between PTH and BP (Jorde et al. 2000; He et 
al. 2011) have been reported, and experimental studies have shown that PTH infusion 
leads to an increase in BP (Hulter et al. 1986).  However, although there was a trend 
for PTH to fall on the active treatment, an effect mediated by PTH seems unlikely. The 
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BP lowering effect of vitamin D may be via direct modulatory effects on vascular 
smooth muscle cells or other pathways to yet be defined. 
 
Few RCTs have measured arterial stiffness in response to vitamin D supplementation, 
and in agreement with the present study, most showed no change (Gepner et al. 2012; 
Larsen et al. 2012; Stricker et al. 2012; Yiu et al. 2013). In contrast, a trial in healthy 
black youth (Dong et al. 2010) did show an improvement in carotid-femoral PWV, 
measured using applanation tonometry and SphygmoCor software, from 5.41 ± 0.73 
m/sec at baseline to 5.33 ± 0.79 m/sec post-test after 50 µg/d D3 for 16 wk (P = 0.031). 
However, the size effect was small and this result could have arisen by play of chance. 
Furthermore, the study was only investigator-blinded, and was not placebo controlled 
(Dong et al. 2010). In the present study there was a trend for PWV to fall in the vitamin 
D2 group (although not significantly different from placebo) which would be consistent 
with a fall in BP improving PWV (Nye 1964). PWV changes slowly over many years 
rather than over months, and a longer period of intervention may be required to show 
significant effects. 
 
Some reports show that vitamin D supplementation decreases hsCRP (Timms et al. 
2002; Asemi et al. 2013b; Witham et al. 2013b), but most find no effect (Belenchia et 
al. 2013; Jorde et al. 2010b; Muldowney et al. 2012; Pittas et al. 2007a; von Hurst et al. 
2010; Wood et al. 2012; Yiu et al. 2013; Zittermann et al. 2009), as in the present 
study. Fibrinogen is also an acute phase protein and an independent risk factor for CVD 
that promotes thrombosis (Meade 1997). There is sparse data on fibrinogen’s 
relationship with vitamin D. Cross-sectional studies show mixed results (Parikh et al. 
2012; Shea et al. 2008) but a clinical trial in which 218 long-term hospital inpatients 
aged over 65 y were randomised to receive a similar dosage of 10 µg/d D3, 30 µg/d D3, 
or placebo for 6 months also showed no significant changes in fibrinogen (Bjorkman et 
al. 2009). Cross-sectional studies have found 25-OH-D to be inversely and 
independently associated with MMP-9 (Baker et al. 2014; Timms et al. 2002; Wasse et 
al. 2011). Expression of MMPs in atherosclerotic plaques by inflammatory cells may 
enhance the matrix breakdown in fibrous caps leading to an increased likelihood of cap 
rupture (Agewall 2006). In the present study, MMP-9 fell in the D2 group compared to 
placebo (-19.6%, 95% CI -37.8, -1.4, P = 0.035). Although this was a secondary outcome 
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and there were multiple primary outcomes which increases the probability of this 
occurring at P=0.05 by chance, the finding is in agreement with a study by Timms et al. 
that reported reductions in MMP-9 of -57.84% and -64.68% when participants were 
supplemented for 1 y with three monthly injections of 1250 µg D3 or 12.5 µg D3, 
respectively (Timms et al. 2002).  Another trial comparing 25 µg D3 vs. placebo for 12 
wk in participants with type 2 diabetes reported a significant difference in the change 
in MMP-9 on treatment (-2.3 ± 3.7) vs. control (0.44 ± 7.1), P=0.02 (Shab-Bidar et al. 
2011). In contrast, Muldowney et al. failed to show a significant change in MMP-9 after 
5, 10, or 15 µg/d of vitamin D3 for 22 wk in 394 subjects (Muldowney et al. 2012). It is 
unknown as to what the mechanisms for a potential association between vitamin D 
and MMP-9 may be, although in vitro studies have indicated that vitamin D in its active 
form 1,25(OH)2D down-regulates and suppresses MMP-9 production (Bahar-Shany et 
al. 2010; Anand and Selvaraj 2009; Coussens et al. 2009).  
 
There were significant increases in TC, LDL-C and HDL-C in the D2 group compared to 
placebo; mean differences between treatments were 5.6%, 6.3% and 6.9% 
respectively. However, there was no effect on the TC:HDL-C which is regarded as the 
most robust lipid metric of risk (Lewington et al. 2007), and lipid profile was a 
secondary outcome therefore significance may have occurred by chance. A meta-
analysis of 10 RCTs suggested that vitamin D supplementation increased LDL-C by 
0.084 mmol/L (95% CI, 0.014, 0.15), but there were no effects on other lipids (Wang et 
al. 2012a). In contrast, analysis of data from 600 postmenopausal women in the 
Women’s Health Initiative (WHI) RCT which gave 1000 mg calcium and 10 µg D3/d 
found a 0.12 mmol/L decrease in LDL-C (95% CI, 0.011, 0.22) compared with placebo (P 
= 0.03) (Schnatz et al. 2014).   
 
No effect of D2 supplementation on insulin sensitivity or β cell function was observed, 
consistent with a meta-analysis of 15 vitamin D supplementation RCTs (George et al. 
2012). 
 
Strengths and weakness. 
The strength of the present study is that it was conducted double-blind in an older age 
group during the winter months and it used vitamin D2 which meant that the findings 
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were not confounded by changes in vitamin D status due to sunlight exposure. 
Additional strengths were the use of repeated ABP monitoring and demonstration of 
compliance to the intervention using uHPLC tandem mass-spectroscopy. The short-
term nature of the study is, however, a limitation. Furthermore, the participants who 
were predominantly white only showed mild vitamin D insufficiency compared to 
people with melanised skin and this limits the extent to which the findings can be 
generalised to the wider population. More marked effects may be found in individuals 
exhibiting a greater vitamin D insufficiency.   
 
In conclusion, this study shows that an additional intake of 10 µg/d vitamin D2 lowers 
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6.1 Introduction  
It has been observed that low serum 25-hydroxyvitamin D (25-OH-D) concentrations 
are associated with impairment of cognitive function (van der Schaft et al. 2013; 
Annweiler et al. 2013; Balion et al. 2012). However, many studies have not adjusted 
for important confounders such as gender, age, BMI, seasonality and education (van 
der Schaft et al. 2013). Furthermore, causality cannot be proven, and it may be that 
adults with cognitive decline have a lower vitamin D status owing to pre-existing 
disorders or less time exposed to sunlight. Despite this, there are reasons to believe 
that vitamin D may have a role in the brain; the enzyme 1α-hydroxylase which 
converts vitamin D to the active form, 1,25(OH)2D, and the VDR for 1,25(OH)2D are 
widely distributed in the human brain in neurons and glial cells (Eyles et al. 2005). 
Furthermore, 1,25(OH)2D has been found to have a number of roles in the brain 
including modulating calcium binding proteins which have neuroprotective roles 
(Alexianu et al. 1998), modulating the production of nerve growth factor (Neveu et al. 
1994) and nitric oxide synthase (Garcion et al. 1998), and stimulating neurogenesis and 
some of its target gene products (McCann et al. 2008; Grant 2009).   
 
The few vitamin D supplementation trials that have been conducted with cognitive 
function as an outcome have shown mixed results and were either not randomised or 
placebo-controlled (Annweiler et al. 2012; Przybelski et al. 2008) or had short follow-
up periods of 6 wk or less which is unlikely to be long enough to see an effect (Dean et 
al. 2011; Przybelski et al. 2008). Trials assessing mood have also shown inconsistent 
results (Lansdowne and Provost 1998; Harris and Dawson-Hughes 1993; Jorde et al. 
2008). Consequently, there is a need for a longer term, well-conducted, randomised, 
placebo-controlled trial to examine the effect of vitamin D supplementation in adults 
with lower 25-OH-D concentrations at baseline on mood and cognition (Annweiler et 
al. 2013). It was decided therefore to measure cognitive function in the participants 
who were enrolled in the vitamin D2 supplementation trial described in Chapter 5. 
  
6.2 Hypothesis 
Vitamin D2, provided in a malted milk drink in the winter months, will improve 





To measure cognitive function in participants enrolled into a randomised placebo 
controlled trial of an intake equivalent to 10 µg vitamin D2/d, provided in a malted milk 




This study was conducted as part of the study described in Chapter 5. See section 5.2 
for details of ethical approval, clinical governance and R & D approval, sample size, 
inclusion and exclusion criteria, recruitment and screening methodology, sample 
analysis and composition of malted milk drink.  
 
6.4.1 Study design 
The parts of the study that are relevant to this chapter are shown in Figure 6.1. 
Subjects were asked to complete a computerised cognitive function test (about 25 
























6.4.2 Cognitive function test 
Cognitive function was assessed with the Computerised Mental Performance 
Assessment System (COMPASS) (Northumbria University) which has previously shown 
sensitivity to interventions of other nutrients (Kennedy et al. 2010). The battery of 
tests consisted of a series of tasks to assess mood and cognition (including episodic 
memory, working memory and attention) which are described in sections 6.4.2.1 to 
6.2.2.2, and took approximately 25 min to administer. The test was conducted under 
controlled conditions. Before the baseline and 12 wk clinic visits, participants were 
asked to avoid strenuous physical activity, foods high in fat, caffeine and alcohol on the 
day prior to the visit and to fast overnight from 22:00 drinking nothing but water until 
after their appointment. Tests always took place between 0900 and 1200. Participants 
were taken to a temperature controlled room, free from noise and disturbance, and 
left alone to complete the cognitive function test undisturbed. All tests were 
completed on the same laptop computer with the same mouse and Cedrus RB-530 
response pad (this had buttons representing yes/no, left/right, blue/green/yellow/red 
and a central reaction time button) (Figure 6.2). Prior to the assessment, participants 
were instructed on how to use the response pad and were given a short 5 min training 





Figure 6.2 Cedrus RB-530 response pad which participants used in addition to the 
mouse for completing the cognitive function test. 
 
 Assessing mood 6.4.2.1
6.4.2.1.1 Bond Lader 
Displayed on the screen was a line representing a scale, which had an adjective 
describing two generally opposing moods on each side. Using a mouse, participants 
were asked to click at a point on the scale which represented how they were feeling at 
that time. Each scale was scored out of 100 and in total there were 16 scales. Scores 
were split into those describing feelings of ‘Alert’, ‘Calm’ and ‘Content’, added 
together into 3 composite scores. 
 
 Assessing cognition 6.4.2.2
6.4.2.2.1 Simple reaction time (SRT) 
This test consisted of an upwards pointing arrow appearing on the computer screen at 
irregular intervals. Participants were asked to respond by pressing the central white 
button on the response pad as quickly as they could once the arrow was displayed. The 






6.4.2.2.2 Telephone number working memory 
A nine-digit telephone number was displayed on the screen for 5 seconds which the 
participant was required to memorise. After a further 5 seconds during which the 
screen was blank, a number pad appeared on the screen and participants had to enter 
as much of the number as they could remember using the mouse to select numbers on 
screen. Numbers could not be deleted or re-entered. The outcome for this task was 
the % accuracy overall and the overall reaction time in msec. 
 
6.4.2.2.3 Stroop 
This task involved a series of colour names (RED, YELLOW, GREEN, BLUE) being 
displayed on the screen. Each name was written in a red, yellow, green or blue 
coloured font. Participants were required to press on the response pad the button 
which corresponded with the colour of the font, not the colour the word depicted. 
Both congruent and incongruent stimuli were displayed. The outcome for this task was 
the % accuracy overall and the overall reaction time in msec. 
 
6.4.2.2.4 Corsi blocks 
The computer displayed 9 blue squares on a black background for this task. In a 
sequence, some of the blue squares changed to red and back to blue. The participants 
were required to remember this sequence and once it had finished to click on the blue 
squares that had changed colour, in the exact sequence that they had changed. The 
task started with only 4 blocks changing colour, and at each level was repeated 5 
times. A block was added for each level after this until the participant was unable to 
remember 3 or more sequences at one level accurately. The score for this task was 
calculated as the average of the last 3 correctly completed trials. For example, if the 
participant correctly responded to all 5 level 4 trials and only 1 level 5 trial, their span 
score would be 4.3 [(4+4+5)]/3]. 
 
6.4.2.2.5 Peg and ball  
This test consisted of two configurations displayed on the screen which each showed a 
series of 3 pegs containing 3 coloured balls (red, blue, green). The goal configuration 
was the one displayed at the top of the screen and the participant was required to 
arrange the balls on the bottom configuration to match with the position of those on 
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the goal configuration. They were asked to do this in as few moves as possible. 
Average thinking and completion times were calculated from 18 peg and ball 
presentations, discounting the first 2 practice trials. Total errors were calculated as the 
total number of moves in excess of the total number required to complete all 18 trials 
i.e. total number of moves in excess of 72.  
 
6.4.2.2.6 Word presentation 
Near the beginning of the cognitive function test a list of words was displayed on the 
screen, one word at a time. A total of 15 words were displayed with a 1 sec 
presentation time and a 1 sec inter-stimulus time. 
 
6.4.2.2.7 Word recognition 
This task involved a display on the screen, one at a time, of all target words that were 
shown during the word presentation in addition to an equal number of decoy words. 
Participants were required to indicate whether they had seen the word earlier or not 
by pressing on the middle button of the response pad. The outcome for this task was 
the % accuracy overall and the overall reaction time in msec. 
 
6.4.3 Statistical analysis 
Statistical analysis of the data was conducted using SPSS for Windows Version 21.0 on 
all participants for whom baseline and 12 wk data were available. Standard 
distributional checks were made, and where appropriate, analyses were attempted 
following log transformation. In order to test whether the two treatment groups 
differed in their cognitive function test scores at baseline, comparisons were made 
using the independent samples t-test, Mann-Whitney U test or a Fisher’s exact test for 
categorical variables. Spearman’s rank correlation was used to determine associations 
between baseline serum 25-OH-D and the cognitive function outcomes. Changes in 
each outcome from baseline to 12 wk in the D2 group compared with placebo were 
assessed using a univariate analysis of covariance on the final scores adjusted for 





A total of 41 participants were recruited and there were 2 drop-outs after the baseline 
visit (section 5.3.1). For one female participant, the laptop screen froze at baseline and 
the problem could not be fixed at the time. Therefore, the final analysis was conducted 
in 38 participants (n=21 in the D2 group and n=17 in the placebo group) for whom data 
was available at baseline and 12 wk. There were 6 occasions over the 2 time points 
where the word recognition task did not display and therefore data is missing. Baseline 
characteristics are summarised in section 5.3.1 and Table 5.2. There were no 
significant correlations between baseline serum 25-OH-D concentrations and the 
mood or cognitive function outcomes. There were no differences in test scores at 
baseline between the D2 and placebo groups. At baseline, males scored more highly 
than females on the Corsi Block Span test [mean difference (95% CIs), 1.5 (0.2, 2.9), 
P=0.026]. There were no other significant differences in scores between males and 
females. When age was split into two groups, one 50 to 60 years and the other 60 to 
70 y, the younger group had a significantly higher Corsi Block Span score at baseline 
(P=0.010) and a significantly lower telephone overall reaction time score (P=0.032). 
 
6.5.1 Effects of D2 supplementation on mood 
There were no significant treatment effects on mood assessed using the Bond Lader 
test (Table 6.1). 
Table 6.1 Effects of an intake equivalent to 10 μg/d vitamin D2 vs. placebo on 
mood 
 Placebo Vitamin D2 Treatment effect 
(95% CI) 
P value 
Bond lader ‘Alert’ (n=38)     
Baseline 60.3 (15.7) 63.9 (17.7)   
Endpoint 61.6 (13.6) 61.7 (19.8) -1.9 (-11.5, 7.6) 0.686 
     
Bond lader ‘Content’ (n=38)     
Baseline 66.5 (14.5) 72.0 (17.8)   
Endpoint 69.0 (14.1) 71.6 (16.3) -2.9 (-11.8, 6.0) 0.505 
     
Bond lader ‘Calm’ (n=38)     
Baseline 63.0 (17.7) 63.8 (19.5)   
Endpoint 67.6 (17.6) 64.3 (20.7) -5.9 (-18.1, 6.2) 0.325 
Values mean (SD). Between group comparison by univariate ANCOVA adjusted for baseline value, age, 
gender, BMI and education.  
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6.5.2 Effects of D2 supplementation on cognition 
Table 6.2 Effects of an intake equivalent to 10 μg/d vitamin D2 vs. placebo on 
cognition 




SRT Overall RT† 
(n=38) (msec)   
  
Baseline 323 (273, 398) 282 (271, 373)   
Endpoint 287 (252, 371) 300 (262, 330) -1.9% (24.9, 28.1) 0.736 
   
  
Tel % Correct (n=38) 
  
  
Baseline 36.8 (30.8) 26.7 (22.3)   
Endpoint 44.5 (34.5) 29.5 (29.3) -5.7 (-20.5, 9.0) 0.434 
   
  
Tel Overall RT‡ 
(n=38) (msec)   
  
Baseline 9414 (5487) 11159 (4955)   
Endpoint 8434 (1628) 10615 (7179) 13.9% (-8.2, 41.2) 0.227 
   
  
Stroop % Correct† 
(n=38)   
  
Baseline 99.2 (98.3, 100) 99.2 (98, 100)   
Endpoint 99.2 (98.8, 100) 99.6 (98, 100) 2.7% (-10.2, 17.4) 0.831 
   
  
Stroop Overall RT ‡ 
(n=38) (msec) 
    
Baseline 944 (165) 1012 (282)   
Endpoint 846 (116) 973 (339) 7.9% (-5.9, 23.6) 0.265 
   
  
Corsi Block Span 
Score† (n=38)  
    
Baseline 5.7 (4.7, 6.0) 5.3 (2.7, 5.7)   
Endpoint 5.7 (5.5, 6.3) 5.0 (4.3, 5.7) -9.2% (-27.3, 13.2) 0.976 
     
P&B Average RT 
Thinking‡ (n=38) 
(msec)   
  
Baseline 5378 (2368) 5378 (2695)   
Endpoint 3944 (2419) 4024 (1502) 7.0% (-13.6, 32.6) 0.525 
   
  
P&B Average RT 
Complete‡ (n=38) 
(msec)   
  
Baseline 18958 (6548)  15678 (8300)   
Endpoint 13630 (3636) 11968 (4183) 7.2% (-6.1%, 22.5%) 0.293 
   
  
P&B Total Errors† 
(n=38)   
  
Baseline 2 (1,4) 7 (3,10)   
Endpoint 3 (1,7) 5 (2,11) -36.6% (-75.8%, 65.8%) 0.638 
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 Placebo Vitamin D2 Treatment effect 
(95% CI) 
P value 
Word recognition % 
Correct‡ (n=32)   
  
Baseline 79.8 (10.2) 79.8 (13.0)   
Endpoint 82.3 (9.7) 80.6 (10.8) -1.2% (-8.1%, 6.2%) 0.732 
   
  
Word recognition 
Overall RT‡ (n=32) 
(msec)   
  
Baseline 1202 (338) 1327 (436)   
Endpoint 1133 (435) 1317 (411) 6.6% (-14.0%, 32.1%) 0.544 
Values mean (SD); †Median (IQR), treatment effect calculated as percentage using log transformed data 
and probability calculated using Mann-Whitney U test; ‡Geometric mean (approx SD) and treatment 
effect calculated as percentage using log transformed data; Between group comparison by univariate 
ANCOVA adjusted for baseline, age, gender, BMI and education. SRT, simple reaction time; RT, reaction 
time; Tel, telephone; P&B, Peg and Ball. 
 
There were no significant treatment effects on any of the cognitive function outcomes 
(Table 6.2). The Peg & Ball scores for average reaction time thinking and average 
reaction time complete significantly improved at 12 wk compare with baseline (P = 
0.005 and P = 0.0003, respectively). There were no other significant differences 
between baseline and follow-up scores. 
 
6.6 Discussion and conclusion 
This study could find no effect of vitamin D2 supplementation equivalent to 10 µg/d on 
measures of mood or cognition in healthy older adults in the winter months. 
Compared to norms and minimal performance levels (Appendix 30) from the Brain 
Performance and Nutrition Research Centre (BPNRC) where the COMPASS battery of 
tests was created, participants in this study scored close to or just below the norms for 
accuracy (% correct) in tests, but their reaction times were often below the minimal 
performance levels. For example, for the word recognition test, average overall 
reaction time scores at baseline and 12 wk were 1255 and 1229, respectively and the 
minimal performance level is 1104. This may be due to some of the participants being 
unfamiliar with using computers. For most tests, participants achieved higher scores 
on follow up compared to baseline as was expected due to an increased familiarity 
with the test, although this difference was only significant for the peg and ball task 
reaction times (Hausknecht et al. 2007). The peg and ball task is more complex than 
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some of the other tasks, and it required quite a lot of mouse use which some 
participants were not familiar with. 
 
The findings of this study are in agreement with those from two other vitamin D 
supplementation trials (Dean et al. 2011; Przybelski et al. 2008) and a vitamin D and 
calcium trial (Rossom et al. 2012) which found no effect on cognitive function and are 
summarised in Table 6.3. The vitamin D and calcium RCT was conducted as part of the 
Women’s Health Initiative in the US. A total of 2034 women were randomised to 
treatment (100 mg calcium carbonate and 10 µg vitamin D3), and 2109 to placebo. 
Following enrolment onto the study between 1994 and 1999, participants completed 
annual cognitive assessments up until 2007. Global and domain-specific cognitive 
function were assessed using the Modified Mini-Mental State Examination (2MSE) and 
WHI Study of Cognitive Aging (WHISCA) cognitive battery, respectively (Rossom et al. 
2012), but no significant changes occurred in the treatment group compared with 
placebo. There is evidence though that higher calcium concentrations are associated 
with poorer global cognitive function and cognitive decline (Schram et al. 2007) and 
therefore it is possible that any positive effect of vitamin D was masked by the 
negative effect of calcium. However, Dean et al. conducted a RCT giving only vitamin 
D3 in capsules at an intake of 125 µg/d for 6 wk to 127 healthy younger adults with a 
mean age of 21.8 y. Participants were asked to complete a number of tests designed to 
assess working memory, response inhibition and cognitive flexibility, but no changes 
were found in any of the outcomes in the vitamin D group compared with placebo 
(Dean et al. 2011). Similarly, Przybelski et al. showed no effect of 1250 µg D2 taken 3 
times/wk for 4 wk on cognition in nursing home residents, although this study had no 
placebo group and so the results are questionable (Przybelski et al. 2008). A trial by 
Annweiler et al. did find improvements in cognitive performance, particularly in 
executive function, in older outpatients visiting a memory clinic who took 20 µg/d or 
2500 µg/month of oral vitamin D3 for 16 months. It is possible that longer term 
supplementation is needed to see an effect, although this trial was not randomised or 





The finding of no effect of vitamin D supplementation on mood in the present study is 
consistent with the findings of other trials showing no effect on ratings of depression, 
anxiety or anger in younger adults (Dean et al. 2011), mental health scores of 
psychological well-being in elderly women (Dumville et al. 2006), or mood scores in 
250 women aged 43 to 72 y who were in good general health (Harris and Dawson-
Hughes 1993). In contrast, studies have shown a positive effect of 10 µg and 20 µg 
vitamin D3 on mood in 44 healthy adults compared to placebo (Lansdowne and Provost 
1998) and of 15 µg/d and 100 µg/d on wellbeing scores in endocrine outpatients (Vieth 
et al. 2004b). However, one of these trials did not have a placebo group (Vieth et al. 
2004b) and both did not adjust for potential confounders (Vieth et al. 2004b; 
Lansdowne and Provost 1998). 
 
Strengths and weakness. 
Strengths of the present study are that it was a well-conducted placebo-controlled RCT 
with good compliance to the intervention, and it was conducted in a healthy, older age 
group with low baseline 25-OH-D levels during the winter months. Also, the results 
were adjusted for age, gender, BMI and education to rule out a confounding effect of 
these variables. The main weakness of the study is that it was not powered to detect a 
change in mood or cognitive function. It is possible that a larger sample size and longer 
intervention length may be needed to see an effect. In addition, the participants were 
all healthy with no known cognitive impairments and therefore the results may not be 
generalisable to other groups in the population. 
 
In conclusion, this study has shown that an increased intake of vitamin D2 of 10 µg/d 
on top of usual dietary vitamin D intake (3-4 µg/d) does not influence cognitive 
function or mood in healthy older adults. 
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Table 6.3 Summary of clinical trials investigating the effect vitamin D on cognitive function, including the trial described in this chapter. 
†Mean; ¶ Median  
Study Population 
Characteristics 




age y  
Duration 
of study 
Baseline and follow-up 
25-OH-D (nmol/L)† 






Healthy adults Placebo or an intake 
equivalent to 10 μg/d D2 
39 59 12 wk 41 to 59  44 to 42  Mood and cognition None 








and anger  
None 




Control group with serum 
25-OH-D >62 nmol/L took 
nothing (n=38) and 
another group (n=25) with 
serum 25-OH-D <62 nmol/L 
took 1250 µg  D2 3x/wk 




(Rossom et al. 
2012) 
Adult women 1000 mg calcium 
carbonate with 10 µg D3/d 
or placebo 
4143 71 Mean 
follow-up 
of 7.8 y 








A D3 group receiving 20 
µg/d or 2500 µg/mo, and a 
control group receiving no 
vitamin D 


























This thesis set out to investigate the effects of low intakes of vitamin D, as may be 
obtained in the diet, on vascular function and markers of inflammation. In order to 
overcome confounding by UVB exposure, the experimental studies were conducted in 
the winter months and vitamin D was provided as vitamin D2. The ability of D2 to raise 
serum 25-OH-D concentrations as effectively as D3 has been questioned by Houghton 
and Vieth (Houghton and Vieth 2006) based on studies using pharmacological doses of 
the two forms, and a meta-analysis of RCTs (Tripkovic et al. 2012) concluded that D3 
was more efficacious. However, in the meta-analysis, the comparison between D2 and 
D3 for daily supplementation as opposed to bolus administration did not achieve 
statistical significance, and some studies included (Heaney et al. 2011, Romagnoli et al. 
2008, Trang et al. 1998) used assays such as immunoassays that are unable to measure 
25-OH-D2 and 25-OH-D3 separately, and may underestimate 25-OH-D2 (Carter et al. 
2007). The work described in this thesis used a ‘gold-standard’ uHPLC-MS/MS method 
with high precision and accuracy. The first RCT conducted gave 5 or 10 µg/d of D2 or D3 
for 4 wk and increments from baseline compared with placebo following 5 and 10 μg/d 
of D2 were (mean ± SEM) 9.4 ± 2.5 and 17.8 ± 2.4 nmol/L for 25-OH-D2 and following 5 
and 10 μg/d of D3 were 15.1 ± 4.7 and 22.9 ± 4.6 nmol/L for 25-OH-D3, respectively. 
The increment in 25-OH-D2 following the dose equivalent to 10 µg/d vs. placebo in the 
second trial was 22.8 ± 2.0 nmol/L which is consistent with the findings of the first 
study and reaffirms the reliability of the results. The findings of the first study are 
displayed in Figure 7.1 with previous placebo-controlled trials that have compared the 
ability of vitamin D2 and D3 to increase serum 25-OH-D concentrations at doses in the 
nutritional range (5-25 μg/d) in healthy adults (Biancuzzo et al. 2010; Holick et al. 
2008). A study by Glendenning et al. which reports changes in 25-OH-D2 and 25-OH-D3 
following 25 µg/d is excluded from the figure because it was in a group of very old 
women (aged 83 ± 8 y) who had sustained a hip fracture and it was uncontrolled 
having no placebo group (Glendenning et al. 2013). Logan et al. found 25 µg/d D3 
taken for 25 wk to be more effective than 25 µg/d D2 at maintaining autumn and 
winter serum 25-OH-D concentrations (Logan et al. 2013). However, there were many 
drop-outs in the study and a large number of participants were excluded from the 
analysis on the basis of non-compliance as the data are reported on a per protocol 
basis rather than on an intention-to-treat basis which increases the risk of bias (Logan 
et al. 2013). Only 13/31 participants randomised to D2 were included in the analysis 
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compared with 23/32 randomised to D3; this puts the study at high risk of bias. In 
contrast to the findings of Logan et al., Biancuzzo et al. (Biancuzzo et al. 2010), Holick 
et al. (Holick et al. 2008) and the present study (Fisk et al. 2012) all showed no 
difference between D2 and D3. These studies differ from the conclusions of the meta-
analysis (Tripkovic et al. 2012). However, the meta-analysis as discussed included 
assessments using immunoassays that systematically underestimate 25-OH-D2 as 
pointed out by Glendenning et al. (2013). A definitive answer as to whether there are 
meaningful differences between D2 and D3 in their capacity to raise 25-OH-D 
concentrations would need a much larger trial with a sample that is more 
representative of the general population.  
 
 
Figure 7.1 Placebo-controlled trials (Biancuzzo et al. 2010; Holick et al. 2008; Fisk 
et al. 2012; Logan et al. 2013) comparing the effect of vitamins D2 and D3 at doses 
ranging from 5-25 μg/d (numbers on right hand side) on total 25-OH-D 
concentrations measured by HPLC/tandem mass spectrometry. A negative effect size 
favours vitamin D3.  
 
It is notable that the increment in 25-OH-D of approximately 2 nmol/L for each μg 
consumed of D2 or D3 in the studies reported in this thesis is greater than the 1.2 
nmol/L per µg vitamin D consumed (95% CI 0.72, 1.68) reported in a meta-analysis of 
16 RCTs of vitamin D-fortified foods (Black et al. 2012). However, the studies included 
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in the meta-analysis had a high level of heterogeneity including baseline serum 25-OH-
D concentrations ranging from 24-84 nmol/L and daily doses of between 3 and 25 μg 
provided by the foods, therefore results need to be interpreted with caution.  
 
7.1 Associations of vitamin D status with measures of vascular function, 
inflammation and established CVD risk factors  
 
7.1.1 Arterial stiffness 
A strongly significant linear trend for decreasing PWV measured using SphygmoCor 
with increasing serum 25-OH-D categories was found in the MARINA and CRESSIDA 
studies in Chapter 3 (P=1.41 x 10-6). This significant association between vitamin D 
status and arterial stiffness is in agreement with other cross-sectional studies (Al 
Mheid et al. 2011; Giallauria et al. 2012; Lee et al. 2012; Pirro et al. 2012; Seker et al. 
2013; Webb et al. 2012; Zagura et al. 2011; Mayer et al. 2012; Kuloglu et al. 2013), for 
example, Mayer et al. measured PWV using the Sphygmocor device in 560 subjects 
and found a significantly higher PWV in subjects in the bottom quartile (9.04 m/s) of 
serum 25-OH-D compared to subjects in the 2nd-4th quartiles (8.07 m/s, 7.93 m/s and 
7.70 m/s, respectively) (Mayer et al. 2012). A meta-analysis has suggested that even a 
1 m/s difference in PWV translates into a 15% difference in CVD risk (Vlachopoulos et 
al. 2010). The results of the present study are summarised with other studies providing 
a comparison between a higher and lower vitamin D status in Figure 7.2. All studies 
showed a significantly greater PWV at lower concentrations of serum 25-OH-D. 
Although the finding in Chapter 3 does not prove causation, a variety of mechanisms 
have been proposed to explain why vitamin D should favourably effect arterial 
stiffness and these include inhibition of the renin-angiotensin system (Li et al. 2002; Li 
2003), protection against vascular calcification (Watson et al. 1997) or suppression of 





Figure 7.2 Cross-sectional studies comparing participants with higher serum 25-
OH-D concentrations to those with lower concentrations. A negative size effect 
indicates a lower PWV. 
 
PWV measured using the Vicorder device decreased over the 12 wk in the D2 group 
compared to baseline in Chapter 5, whereas there was no evidence of a fall in the 
placebo group. However the difference in the D2 group compared with placebo did not 
achieve statistical significance. It seems likely that some of the change in PWV may 
reflect changes in systolic BP on the D2 intervention. However, if vitamin D as 
1,25(OH)2D prevents the age-related increase in arterial stiffness (Benetos et al. 2002) 
due to inhibition of vascular calcification (Watson et al. 1997; de Boer et al. 2009), it is 
likely that a longer term study would be needed to see a change. The few RCTs that 
have measured arterial stiffness in response to vitamin D supplementation have also 
all been of a relatively short duration, with the longest lasting 20 wk (Larsen et al. 
2012). In agreement with the present study, most of these showed no change in PWV 
(Gepner et al. 2012; Larsen et al. 2012; Yiu et al. 2013). The placebo-controlled studies 




Figure 7.3 Placebo-controlled trials comparing the effect on PWV of daily doses 
of 62.5 μg D3 (Gepner et al. 2012), 75 μg D3 (Larsen et al. 2012), 125 μg D3 (Yiu et al. 
2013) and 10 μg D2 (current study). A negative size effect indicates a reduction in 
PWV compared with placebo. 
 
7.1.2 Blood pressure 
The most salient finding of the vitamin D2 intervention was the 4.3 mm Hg lower SBP 
measured using ambulatory monitoring (P=0.007). As a 20 mm Hg difference in usual 
SBP is associated with a doubling of risk in CVD mortality (Lewington et al. 2002), a 4 
mm Hg difference in SBP would be predicted to reduce the risk of CVD mortality by 
20%. Whilst some meta-analyses of RCTS have concluded that there is no significant 
effect of vitamin D on SBP and DBP (Pittas et al. 2010; Elamin et al. 2011; Kunutsor et 
al. 2014), these have predominantly included studies that have measured BP as seated 
BP. Only a few vitamin D supplementation trials have measured BP using ABP monitors 
(Judd et al. 2010; Larsen et al. 2012; Witham et al. 2012; Witham et al. 2013c; Witham 
et al. 2014). These were conducted in participants who had hypertension (Larsen et al. 
2012; Judd et al. 2010; Witham et al. 2013c; Witham et al. 2014) or had previously 
suffered from a stroke (Witham et al. 2012), and none showed a significant change in 
BP. The finding in the present study of no change in heart rate after vitamin D 
supplementation suggests that vitamin D may be having an effect on systemic vascular 
resistance (SVR). There was no treatment effect on FMD implying that the change in BP 
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was not due to changes in NO production, and there was no change in renin 
concentrations, suggesting that the effects are independent of the renin-angiotensin 
system. There is the possibility that changes occurred due to a decrease in PTH 
concentrations, but the change in PTH was not significant. Therefore, it is most likely 
that vitamin D was having either a direct effect on vascular smooth muscle cells or an 
indirect on the central nervous system (CNS) leading to changes in sympathetic 
stimulation and tone.  
 
Despite the reduced BP after short-term D2 supplementation in older adults in the RCT 
conducted as part of this thesis, it cannot be assumed that the findings can be 
extrapolated to other populations including younger adults and different ethnicities. 
Older people, for example are more likely to have a high BP (National Institute for 
Health and Clinical Excellence 2011) and therefore might have a different response to 
younger adults who have a more healthy BP. Furthermore, different ethnicities in the 
UK, particularly South Asians have much lower 25-OH-D concentrations compared to 
the white population (Kift et al. 2013), and also a higher risk of hypertension (Whitty et 
al. 1999), so may show an even greater improvement in BP with vitamin D 
supplementation. It is also not known what effect longer-term, chronic 
supplementation would have and whether D3 supplementation would have a similar 
effect to D2. A follow-on RCT is needed to determine whether the finding of a 
reduction in 24 h BP can be replicated in other populations and different ethnicities. 
This study would be of a larger size and a longer duration of a few years to investigate 
whether the effect is sustained and also whether arterial stiffness is reduced over a 
longer period of time. 
 
7.1.3 Indices of inflammation and thrombotic risk 
HsCRP and fibrinogen concentrations did not change with vitamin D2 supplementation, 
but MMP-9 fell by 19.6% (P=0.035) in the D2 group compared with placebo. Although 
MMP-9 was a secondary outcome and there were multiple primary outcomes which 
increases the probability of this occurring at P=0.05 by chance, this is consistent with 
the findings of another RCT which randomly allocated 100 type 2 diabetes patients to 
receive a plain yoghurt drink containing 170 mg calcium and no vitamin D/250 mL or a 
vitamin D3-fortified yoghurt drink containing 170 mg calcium and 12.5 µg D3/250 mL 
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twice a day for 12 wk and found a significantly greater decrease (P=0.005) in MMP-9 
concentrations in the D3 group (-2.3 ± 3.7 ng/mL) compared with placebo (0.44 ± 7.1 
ng/mL) (Shab-Bidar et al. 2011). There are however few vitamin D supplementation 
trials that have measured MMP-9 and further research is needed in larger, well-
conducted RCTs in order to confirm this finding, although in vitro studies have 
indicated that vitamin D in its active form 1,25(OH)2D down-regulates and suppresses 
MMP-9 production (Bahar-Shany et al. 2010; Anand and Selvaraj 2009; Coussens et al. 
2009). MMPs provide a continuous source of extracellular matrix degradation within 
atherosclerotic lesions, contributing to the disruption of the fibrous cap which may 
lead to plaque rupture. Therefore, if vitamin D supplementation does lead to a 
decrease in MMP-9 concentrations, it may help prevent the progression of 
atherosclerosis and plaque rupture (Ferroni et al. 2003). MMP-9 might also lead to 
increased arterial stiffening over time via degradation of elastin (Yasmin et al. 2005) 
and vitamin D supplementation may influence CVD risk by helping to reduce this 
undesirable effect. 
 
The RCT did not find any significant effects on FVIIc. This is consistent with a cross-
sectional study which found no significant association between FVIIc and either serum 
25-OH-D or 1,25(OH)2D concentrations (Jorde et al. 2007). 
 
7.1.4 Serum lipids, fasting glucose and indices of insulin secretion and sensitivity 
Changes in lipid concentrations were observed in the RCT after D2 supplementation; 
HDL-C, LDL-C and TC all increased significantly compared with placebo. However, there 
was no effect on the TC:HDL-C ratio which is regarded as the most robust lipid marker 
of risk (Lewington et al. 2007). The LDL-C elevating effect is in agreement with a meta-
analysis of 10 vitamin D RCTs which found LDL-C to increase following 
supplementation (Wang et al. 2012a), although the size effect was very small (0.08 
mmol/L (95% CI, 0.01, 0.15). The meta-analysis observed no effect for TC and HDL-C 
apart from in studies lasting longer than 1 y for which there was a significant change in 
HDL-C concentrations, although this was in the opposite direction to the present study 




The participants in the present study were predominantly normoglycemic, and vitamin 
D supplementation did not affect β cell function and insulin sensitivity in agreement 
with a meta-analysis of 15 vitamin D supplementation (George et al. 2012). 
 
7.2 Vitamin D and cognitive function 
This thesis found no effect of vitamin D2 supplementation in 50-70 y olds on measures 
of mood or cognition. This finding is in agreement with other trials that have measured 
mood-related outcomes (Dean et al. 2011; Dumville et al. 2006; Harris and Dawson-
Hughes 1993) and cognition (Dean et al. 2011; Przybelski et al. 2008) and it suggests 
that there is unlikely to be any benefit on cognitive function of supplementation in the 
general population. However, studies are needed to investigate whether there is any 
effect in older adults over 70 years who may have experienced greater cognitive 
decline. 
 
7.3 Risks and benefits of obtaining vitamin D from food, fortified foods, dietary 
supplements and sunlight/UVB irradiation 
Whilst exposure to UVB irradiation is the most effective means of increasing vitamin D 
status, it is associated with a major risk of skin cancer (Ashwell et al. 2010). Many 
authorities now advise restricting exposure to sunlight and promote the use of UVB 
filters in cosmetics and sun lotions which decrease the capacity to synthesise vitamin D 
(Matsuoka et al. 1987). In older age, there is a decreased ability of the skin to produce 
vitamin D in response to UVB exposure (MacLaughlin and Holick 1985), and older 
people may be less likely to spend time outdoors due to a lower mobility. Clothing and 
headscarves block UVB radiation, and UVB exposure is low in the UK winter months. 
Therefore dietary intake is important for maintaining an adequate vitamin D status in 
certain at-risk groups and during the winter months. 
Dietary intake of vitamin D was low in the studies reported in this thesis; median 
values (IQR) were 2.3 (1.8-3.8) µg/d in the D2/D3 study, 2.6 (2.2-3.7) µg/d in the older 
population in the second RCT, and 2.7 μg/d for the CRESSIDA and MARINA studies 
combined. These values are consistent with the most recent NDNS findings from food 
sources of only of 2.5 µg/d in men (n=1126) and 2.1 µg/d (n=1571) in women aged 19-
64 y (Bates et al. 2014). Although there are currently no dietary recommendations for 
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vitamin D in adults, those confined indoors have a RNI of 10 µg/d (Scientific Advisory 
Committee on Nutrition 2007). It has been suggested that intakes of 9 µg and 28 µg 
vitamin D/d would be needed to maintain winter 25-OH-D concentrations in 97.5% of 
the population above 25 nmol/L or 50 nmol/L respectively, in 97.5% of the population 
(Cashman et al. 2008; Cashman et al. 2009). Such intakes are only likely to be achieved 
through fortification or supplementation. 
 
Strong correlations between serum 25-OH-D concentrations and dietary intake 
assessed using 4-d food diaries and FFQs were found in the cross-sectional analyses in 
Chapter 3 and the data presented in this thesis have shown that increasing oily fish 
intake can significantly increase vitamin D status. In the CRESSIDA study, a group 
following UK dietary guidelines (DG) including advice to consume 1-2 portions of oily 
fish/wk for 12 wk were compared to a control group based on a conventional British 
dietary pattern which included less than 1 serving/month of oily fish. Mean vitamin D 
intake increased from 3.0 µg/d to 6.6 µg/d in the DG group and the percentage of 
participants with serum 25-OH-D concentrations >50 nmol/L increased from 60 to 71% 
over the 12 wk period; concentrations at 12 wk vs control were 9.2 nmol/L (95% CI 4.2, 
14.2, P<0.001) greater. However, diet alone may be insufficient to meet needs in all 
people and consideration needs to be given to supplementation and fortification of 
foods. 
 
Supplementation requires remembering to take the supplement on a regular basis or 
having it regularly administered, but it can be an effective targeted intervention that is 
possible to adapt to an individual’s needs. Massive dosage typically by intramuscular 
injection can also be a remedy for low vitamin D status in at-risk groups although it 
does require medical personnel to administer the injection. One possibility is that it 
could be done at the same time as the influenza vaccination which is offered to older 
people in the UK and other high risk groups. Fortification of food can be a very 
effective means of delivering vitamin D providing the food is consumed regularly by a 
large proportion of the population. Whilst it may not result in a sufficient status (> 75 
nmol/L), the RCT in Chapter 4 has shown that even low dose vitamin D provided in a 
fortified malted milk drink at 5 or 10 μg/d is able to significantly increase serum 25-OH-
D concentrations. However, the potential hazards of inducing toxicity in a small 
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minority has to be considered when fortifying foods. Although an upper level has not 
yet been established in the UK due to a lack of data, 25 µg/d has been considered as 
safe and unlikely to cause adverse effects in the general population (Bassuk and 
Manson 2009). This is low though compared with the tolerable upper intake level of 50 
µg/d in North America and Europe (IOM 1997; European Commission Health Consumer 
Protection Directorate-General 2002). One approach to assess the risks and benefits of 
fortification is to use that employed by the EU Benefit-Risk Analysis of Foods (BRAFO) 
project which included an estimation of the risk and benefits of universal folic acid 
fortification of flour/bread (Verhagen et al. 2012). 
 
At present, foods are fortified with either D2 or D3, although most often D3 is used. As 
the forms seem to be equipotent at low doses, D2 is likely to be important for 
widespread fortification as it is more acceptable to vegetarians, vegans and religious 
groups who may not consume D3 due to it being from animal sources (Excellence 
2014). In the UK, foods tend to be fortified with small quantities based on the serving 
size, for example, breakfast cereals contain approximately 1.3 µg per 30 g portion and 
margarine 0.75 µg for every 2 tsp. In the US, vitamin D is added to milk at 10 μg per 
quart (1 quart = 946.4 mL) (PMO 2007). Based on the results of the RCT, these 
amounts are unlikely to have much effect on vitamin D status unless the foods are 
consumed in large quantities. Whilst the current levels of fortification in the UK do 
make a difference to vitamin D status as shown in the most recent NDNS in adults aged 
19-64 where 19% of vitamin D in the diet was coming from fat spreads and 13% from 
cereals and cereal products, fortification at higher levels and in a product which is 
consumed widely in a high proportion of the population may be needed to help bring a 
greater proportion of the population to an adequate vitamin D status. The present 
study demonstrated that a malted milk drink is an effective vehicle for vitamin D, but a 
product such as milk which is consumed extensively may be more effective. Many 
brands of soya milk currently fortify with around 0.75 μg vitamin D/100g. However, 
data is lacking on the bioavailability of vitamin D2 and D3 in different matrices and 







One of the main findings of this thesis is that poor vitamin D status is associated with 
arterial stiffness in healthy older people; this would be predicted to lower CVD 
mortality risk by 18%.  However, it was not possible to show significant changes in 
arterial stiffness in a short-term trial of vitamin D supplementation; a longer period of 
intervention is probably necessary to demonstrate major changes in arterial stiffness.  
The work presented in this thesis also shows that dietary intake has a significant 
impact on vitamin D status, especially the consumption of oily fish. A dietary 
intervention with 10 μg D2/d in the winter months lowered systolic BP by 4.3 mm Hg in 
older predominantly normotensive adults in the UK winter months, and this change if 
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Lower serum 25-hydroxy vitamin D (25-OH-D) concentrations are associated with a greater risk 
of CVD mortality, coronary heart disease and stroke (1). Besides dietary intake of vitamin D, 
serum 25-OH-D is also influenced by UVB exposure and vitamin D binding protein 
concentration. Randomised controlled trials (RCT) have yet to show any clear benefit of 
vitamin D supplementation on CVD risk or mortality (2, 3), but vitamin D might influence 
vascular function and inflammation. Vieth et al (4) argue that recommended dietary intakes for 
vitamin D are unlikely to maintain optimal serum 25-OH-D concentrations and that UVB 
exposure, which increases risk of skin cancer, or high dose supplementation are needed. Most 
published trials testing the effects on CVD risk factors have used pharmacological doses of 
vitamin D (5). 
We investigated the effect of low dose vitamin D2 supplementation on CVD risk factors in 
the winter months, when UVB exposure is minimal. In the first RCT, we showed that both D2 
and D3 fortified drinks (at two dose levels of 5 or 10 μg/d), taken for 4 wk, resulted in 
significant dose dependent (P<0.001) increases in their respective 25-OH metabolites, measured 
by ultra-HPLC tandem mass spectrometry; mean increments ± SED from baseline, compared 
with the placebo group, following 5 and 10 μg D2/d were 9.4 ± 2.5 and 17.8 ± 2.4 nmol/L for 
25-OH-D2, and following 5 and 10 μg D3/d were 15.1 ± 4.7 and 22.9 ± 4.6 nmol/L for 25-OH-
D3 (6). In a second placebo-controlled RCT, which compared effects on CVD risk factors, 41 
predominantly normotensive men and post-menopausal women (50-70 y) consumed drinks 
providing an intake equivalent to 10 µg/d D2, for 12 weeks in the winter months. The primary 
outcome was endothelial function measured as flow mediated dilation of the brachial artery; 
secondary outcomes were 24-h ambulatory blood pressure (BP), arterial stiffness and 
inflammatory markers; compliance to treatment was determined by measuring vitamin D status. 
Mean differences ± SED from baseline vs. placebo were 20.6 ± 2.9 nmol/L (P<0.001) for 25-
OH-D2 but there were no differences between treatments in 25-OH-D3. Both 24 h systolic and 
diastolic BP fell on D2 treatment compared with placebo: mean differences (95% CI) in mm Hg 
were -4.2 (-7.3, -1.2; P=0.008) and -2.5 (-5.2, 0.1; P=0.061) respectively. No significant 
differences in flow mediated dilation, arterial stiffness or inflammatory markers were found. In 
conclusion, our data suggest that D2 and D3 are equipotent in increasing 25-OH-D, and that a 
dose of 10 µg/d D2 for 12 weeks has favourable effects on BP compared with placebo in healthy 
men and women with negligible UV-B exposure. 
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APPENDIX 6 D2/D3 study blood handling protocol at screening and on study visits 
SAMPLE TUBES ICE/RT CENTRIFUGE SEPARATION‡ ANALYTES STORAGE TRANSPORT  





Room temperature 15 min x 1300 
g @ 4  ̊C 
Separate plasma 
into 2 x 0.4 mL 
aliquots 
Glucose Freeze 1 aliquot and send the 
other fresh to KCH 









Room temperature No None FBC Room temperature Same day to KCH at room 
temperature 





Ice 15 min x 1300 
g @ 4  ̊C 
Separate plasma 
into 2 x 0.4 mL 
aliquots within 2h 
PTH Freeze both aliquots and 
store at -80°C 
Store and transport later in 
batches to KCH in dry ice 






Stand for 30 min at 
room temperature 
before centrifuging 
15 min x 1300 
g @ 4  ̊C 
Separate into 1 x 1 





Freeze both 0.5mLaliquots 
and send the 1mL fresh to 
KCH. Keep the vit D sample to 
send to HFL at the end of the 
study. 
Same day to KCH at room 
temperature (for LFT and 
Calcium). Transport vit D samples 
to HFL Sport Science in dry ice at 
end of the study. 
Baseline and 
Visit 4 (7mL) 





Ice 15 min x 1300 
g @ 4  ̊C 
Separate plasma 
into 2 x 0.4 mL 
aliquots within 2h 
PTH Freeze both aliquots and 
store at -80°C 
Store and transport later in 










Stand for 30 min at 
room temperature 
before centrifuging 
15 min x 1300 
g @ 4  ̊C 
Separate into 1 x 1 






Freeze all aliquots and store 
at -80° 
Keep vitamin D samples – send 
all together to HFL Sport Science 
at the end of the study. Store 
Ca/Albumin sample at -80° and 
transport later in batches. 








Stand for 30 min at 
room temperature 
before centrifuging 
15 min x 1300 
g @ 4  ̊C 




Freeze all aliquots and store 
at -80° 
Keep vitamin D samples – send 
all together to HFL Sport Science 
at the end of the study. 
All analysis done at King’s College Hospital (KCH), apart from vitamin D for screening and all study days. BD (Becton-Dickinson, Oxford Science Park, OX4 4DQ). FBC, full blood count; LFT, liver function 






APPENDIX 7 DRISK study blood handling protocol at screening and on study days 
VISIT TUBES ICE/RT CENTRIFUGE SEPARATION‡ ANALYTES STORAGE TRANSPORT  







15 min x 1300 
g @ 4  ̊C 
Separate 
plasma into 2 x 
0.4 mL aliquots 
Glucose Freeze 1 aliquot at -
80° and send the 
other fresh to KCH 











No None FBC Room temperature Same day to KCH at room 
temperature 





Stand for 30 




15 min x 1300 
g @ 4  ̊C 
Separate into 2 
x 1 mL aliquots 
LFT, FLIP and 25-OH-D Freeze one 1mL 
aliquot and send 
the other 1mL fresh 
to KCH.  
Same day to KCH at room 
temperature 
Baseline, 
6 wk and 12 
wk 
visits (18 mL 
per visit) 







15 min x 1300 
g @ room 
temperature 
Separate 
plasma into 2 x 
0.5 mL aliquots 
and 1 x 0.6 mL 
within 2h 
PTH and renin Freeze both 
aliquots (within 2 
h). Store both at -
80°C. 
Store and transport later in 









Stand for 30 




15 min x 1300 
g @ room 
temperature 
Separate into 3 
x 0.5 mL and 2 x 
1.0 mL aliquots 
1
st













 1.0 mL aliquots – 
spares. 
Freeze all aliquots 
and store at -80° 
Keep vitamin D samples – these 
will be sent all together to HFL 
Sport Science at the end of the 
study in dry ice. Store and 
transport other samples later in 









15 min x 1300 
g @ room 
temperature 
Separate into 2 
x 1.0 mL 
aliquots 
Fibrinogen and FVIIc Freeze both 
aliquots and store 
at -80° 
Store and transport later in 
batches to KCH in dry ice. 
 







15 min x 1300 
g @ room 
temperature 
Separate 
plasma into 2 x 
0.4 mL aliquots 
Glucose Freeze both aliquot 
at -80°  
Store and transport later in 
batches to KCH in dry ice. 
All analysis apart from 25-OH-D2, 25-OH-D3, fibrinogen and FVIIc for visits 1, 2 and 3 done at King’s College Hospital (KCH). 25-OH-D2 and 25-OH-D3 measured at HFL Sport Science. BD (Becton-
Dickinson, Oxford Science Park, OX4 4DQ). FBC; full blood count; LFT, liver function test; PTH, parathyroid hormone; FLIP, full lipid profile; MMP-9, matrix metalloproteinase-9; hsCRP, high sensitivity 
C-reactive protein; ‡2 mL Eppendorf tubes used. 
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APPENDIX 8 DEQAS Proficiency Certificate for the Department of Clinical 






APPENDIX 9 Lifestyle questionnaire used in DRISK, CRESSIDA and MARINA studies. 









































































































APPENDIX 10 Letter of favourable opinion for D2/D3 study from the South East 




































APPENDIX 12 Data from Public Health England in Chilton, near Oxford (the closest 
measurement station to London) showing that UV radiation was low during the 
study periods for the D2/D3 study (22/02/2011 – 13/04/2011) and the DRISK study 
(20/01/2012 - 03/05/2012 and 04/01/2013 - 30/04/2013) 
Data used in this appendix is erythemally effective irradiance (UVReff). This is solar 
ultraviolet radiation (UVR) data that has been biologically weighted for the erythema 
(redness of the skin) action spectrum. As shown in Figure A, the action spectrum for 
human erythema and the action spectrum for the synthesis of pre-vitamin D are fairly 
similar in the UVB part of the solar spectrum (290-315 nm), and therefore this data is 
reasonable to use as a measure of UVB exposure with the potential to produce pre-
vitamin D.  
 
Figure A Commission Internationale de l’Éclairage (CIE) (1) action spectra for 
human erythema and the synthesis of previtamin D taken from (2). 
 
Figure B demonstrates how UVReff changes over the course of a year with much 
higher values in the summer compared with the winter months (data shown are for 
2011 when the D2/D3 comparison study was conducted). Figure C shows the changes in 
UVReff over each of the study periods. Values increased at the end of each study 
period, but remained low on average with means (SD) of 3.4 x 105 mW/m2.s (5.2 x 105) 
for the D2/D3 comparison study and 6.1 x 10
5 mW/m2.s (5.0 x 105) between 
20/01/2012 and 03/05/2012 and 6.5 x 105 mW/m2.s (6.9 x 105) between 04/01/2013 - 
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30/04/2013 for the DRISK study. Although UVReff values were quite high at the end of 
the 2013 study period, 25-OH-D3 concentrations for participants taking part in the 
study during 2013 decreased overall from baseline to 12 wk from 33.9 to 31.8 nmol/L 
in the D2 group and from 44.3 to 42.4 nmol/L in the placebo group. 
 
 
Figure B Mean (SD) erythemally effective irradiance (UVReff) in Chilton during 
2011 
 
Figure C Mean (SD) erythemally effective irradiance (UVReff) in Chilton during 


















































































1. Bouillon, R.,  Eisman, J., Garabedian et al. (2006). Action spectrum for production of 
previtamin D3 in human skin. CIE Technical Report 174, Commission Internationale de 
l’Eclairage (CIE) Central Bureau, Vienna, Austria.  
 
2. Springbett, P., Buglass, S. & Young, A.R. (2010). Photoreception and vitamin D status. J 
















































APPENDIX 13 Recruitment email for D2/D3 study 
 
Circular e-mail for use for recruitment of volunteers for study ref 10/H0804/91, approved by 
the South East London Research Ethics Committee 1. This project contributes to the College's 
role in conducting research, and teaching research methods. You are under no obligation to 
reply to this email, however if you choose to, participation in this research is voluntary and you 
may withdraw at any time. 
 
Title of Project: Comparison of the efficacy of vitamin D2 and D3 at raising vitamin D status. 
 
There is a substantial body of evidence to suggest that there are likely to be health benefits of 
adequate vitamin D status in relation to a wide range of medical conditions such as 
osteomalacia, cardiovascular disease, muscle weakness, autoimmune diseases, and cancer. 
Levels of vitamin D insufficiency are high in the UK, particularly during the winter months. It is 
known that supplementation with vitamin D as either ergocalciferol (vitamin D2) or 
cholecalciferol (vitamin D3) can help improve vitamin D status. However, the evidence 
concerning the equivalence of these two forms in terms of their effectiveness at raising 
vitamin D levels is uncertain.  
 
We require volunteers to help us investigate how effective different levels and types of vitamin 
D are at improving vitamin D status. If you are healthy, male or female, and are aged between 
18 and 65 years, then you may be able to help us. You will be provided with an information 
sheet and given the opportunity to ask any questions you may have before proceeding. You 
will be asked to consume a malted milk drink every day for 4 weeks. You will be randomly 
allocated into one of 5 groups; malted milk drink not fortified with vitamin D (control), or 
malted milk drink fortified with 5mcg or 10mcg of either vitamin D2 or vitamin D3.  We will ask 
you to come to the metabolic unit in the Franklin-Wilkins Building, which is at the Waterloo 
Campus of King's College London, on 6 occasions over a 5-6 week period. At each of these 
visits we will ask you to have a 2-3 tsp (10-15 mL) blood sample taken. This will be taken by a 
trained medical professional.  
  
Exclusion factors are: 
- Blood pressure >160/105 mm Hg 
- Body Mass Index <18.5 and >35 kg/m2 
- Anyone taking vitamin and mineral supplements (including cod-liver oil), or 
prescription calcium/vitamin D 
- Recent exposure to high UV-b light since 1 Dec 2010 
- Intolerance to study product (lactose, milk protein) 
- Chronic renal, liver or inflammatory bowel disease 
- Diabetes 
- Unwilling to restrict consumption of oily fish to no more than 2 portions of oily fish per 
week. 
 
This study will take place between February and April 2011 and you will be paid £50 on 
completion of the study as compensation for time spent on the study. You will also be 
reimbursed for travel expenses. If you are interested or have any questions relating to the 






























































APPENDIX 16 Reference ranges for assays 
Screening assays 
Males 
Plasma glucose:       Normal ≤ 6 mmol/L 
 
Liver function test 
Total protein:        60-80 g/L 
Albumin:        35-50 g/L 
Total Bilirubin:       3-20 µmol/L 
Alkaline Phosphatase (ALP):      30-130 IU/L 
Aspartate transaminase (AST):     10-50 IU/L 
Gamma GT:        1-55 IU/L 
Globulin:        25-35 g/L 
 
Full blood count 
White blood cells (WBC):      4.00-11.00 10ˆ9/L 
Red blood cells (RBC):      4.5-5.8 10ˆ12/L 
Haemoglobin(Hb):       13.0-16.5 g/dL 
Packed cell volume (PCV):      0.400-0.540 L/L 
Mean corpuscular volume (MCV):     77-95 fL 
Mean corpuscular haemoglobin (MCH):   25-34 pg 
Mean corpuscular haemoglobin concentration (MCHC):  33.0-37.0 g/dL 
Red cell distribution width (RDW):    11.0-15.0 % 
Platelet count (PLT):      150-450 10ˆ9/L 
Mean platelet volume:     7.4-10.4 fL 
Neutrophil count:      2.2-6.3 10ˆ9/L 
Lymphocyte count:      1.3-4.0 10ˆ9/L 
Monocyte count:      0.2-1.0 10ˆ9/L 
Eosinophil count:      0-0.4 10ˆ9/L 
Basophils:        0-0.1 10ˆ9/L 
 
Females 
Plasma glucose:       Normal ≤ 6 mmol/L 
 
Liver function test 
Total protein:        60-80 g/L 
Albumin:        35-50 g/L 
Total Bilirubin:       3-20 µmol/L 
Alkaline Phosphatase (ALP):      45-130 IU/L 
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AST:         3-35 IU/L 
Gamma GT:        1-55 IU/L 
Globulin:        25-35 g/L 
 
Full blood count 
White blood cells:       4.00-11.00 10ˆ9/L 
Red blood cells:       3.8-5.8 10ˆ12/L 
Haemoglobin:       11.5-15.5 g/dL 
PCV:         0.370-0.470 L/L 
MCV:        77-95 fL 
MCH:        25-34 pg 
MCHC:        33.0-37.0 g/dL 
RDW:        11.0-15.0 % 
PLT:        150-450 10ˆ9/L 
Mean platelet volume:     7.4-10.4 fL 
Neutrophil count:      2.2-6.3 10ˆ9/L 
Lymphocyte count:      1.3-4.0 10ˆ9/L 
Monocyte count:      0.2-1.0 10ˆ9/L 
Eosinophil count:      0-0.4 10ˆ9/L 
Basophils:        0-0.1 10ˆ9/L 
 
 
Study visit assays 
 
Parathyroid hormone (PTH):     10-70 ng/L 
Calcium corrected for albumin:    2.15-2.6 nmol/L 
Direct renin :       5.4 – 60 mIU/L 
High sensitivity C-reactive protein:    Low: less than 1.0 mg/L  
Average: 1.0 to 3.0 mg/L  
High: above 3.0 mg/L  
Matrix metalloproteinase-9:     169 – 705 ng/mL 
C-peptide:       298 – 2350 pmol/L 
Fibrinogen:       1.5 – 4.5 g/L 
FVIIc:        50 - 200% of standard 
Total cholesterol:      ideally ≤5.0 mmol/L 
HDL-cholesterol: >1.0 mmol/L in men and 
>1.3 mmol/L in women 
LDL-cholesterol:      <3.0 mmol/L 
Triglycerides:       <1.7 mmol/L 





APPENDIX 17 Malted milk drink analysis for D2/D3 study 
Analysis of samples at the beginning of the study - International Food Network Ltd, 
Science & Technology Centre, Reading, RG6 6BZ 
 



















Analysis of samples at the end of the study – LGC (Government Chemist), Queens 





















Average per 25g 
serving (µg) 
Placebo D2 <0.5 <0.125 
 D2 <0.5 <0.125 
 D3 <0.5 <0.125 
 D3 <0.5 <0.125 
Vit D2 5µg D2 6.6 1.65 
 D2 7.2 1.80 
Vit D2 10µg D2 15.6 3.90 
 D2 16.4 4.10 
Vit D3 5µg D3 21.8 5.45 
 D3 19.8 4.95 
Vit D3 10µg D3 42.4 10.6 







Average per 25g 
serving (µg) 
Placebo D2 Not detected Not detected 
 D3 Not detected Not detected 
Vit D2 5µg D2 19.05 4.76 
Vit D2 10µg D2 30.08 7.52 
Vit D3 5µg D3 11.49 2.87 
Vit D3 10µg D3 20.35 5.09 
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APPENDIX 18 Raw data for 25-OH-D2, 25-OH-D3 and total 25-OH-D measured by ultra 
high pressure liquid chromatography tandem mass spectrometry (UPLC-MS/MS) in 
study 1 (vitamin D2/D3 comparison). 
 
25-OH-D2 (nmol/L) by treatment group over 4 wk of supplementation with 5 or 10 µg 
D2 or D3/d, or placebo (a value of 2.4 nmol/L has been assigned to values below the 







Screening Baseline Wk 1 Wk 2 Wk 3 Wk 4 
3 Placebo 5.03 5.01 4.91 5.42 4.11 4.67 
19 Placebo 0.00 0.00 0.00 0.00 0.00 0.00 
20 Placebo 2.82 0.00 0.00 0.00 3.02 0.00 
24 Placebo 5.28 5.06 4.65 4.18 3.84 2.92 
27 Placebo 0.00 0.00 0.00 0.00 0.00 0.00 
39 Placebo 0.00 0.00 0.00 0.00 0.00 0.00 
41 Placebo 0.00 3.26 0.00 0.00 0.00 0.00 
43 Placebo 4.16 3.96 3.87 4.62 4.55 5.30 
2 D2 10µg 0.00 0.00 16.27 27.51 41.34 38.45 
4 D2 10µg 2.42 2.42 10.17 16.00 19.07 21.79 
5 D2 10µg 2.46 3.33 9.95 12.55 14.59 12.23 
9 D2 10µg 2.70 3.26 10.97 14.32 18.05 21.11 
25 D2 10µg 4.35 3.77 10.87 15.27 18.68 21.45 
26 D2 10µg 2.42 2.53 4.28 4.13 4.40 4.99 
35 D2 10µg 2.42 2.42 13.84 19.77 22.89 27.00 
40 D2 10µg 2.42 2.42 5.64 10.94 15.18 16.25 
1 D2 5µg 2.42 2.42 7.20 11.94 13.40 14.32 
8 D2 5µg 2.42 2.42 8.32 10.63 13.96 13.81 
12 D2 5µg 25.56 26.61 31.69 32.01 34.61 34.85 
21 D2 5µg 4.55 3.26 6.83 8.22 10.53 10.34 
22 D2 5µg 5.47 4.94 11.38 13.72 17.32 19.67 
23 D2 5µg 2.42 2.42 5.23 10.09 11.70 11.33 
33 D2 5µg 2.42 2.42 2.42 2.42 2.42 2.42 
48 D2 5µg 2.70 2.42 8.12 11.65 12.70 14.52 
11 D3 10µg 2.42 2.42 2.42 2.42 2.42 2.42 
15 D3 10µg 2.42 2.42 2.42 2.42 2.42 2.42 
16 D3 10µg 3.06 2.43 2.89 2.42 2.42 2.42 
17 D3 10µg 2.42 2.42 2.42 2.42 2.42 2.42 
30 D3 10µg 2.42 2.42 2.50 2.42 2.42 2.42 
37 D3 10µg 2.42 2.42 2.42 2.85 2.42 2.42 
44 D3 10µg 2.42 2.42 2.42 2.42 2.42 2.42 
47 D3 10µg 2.42 2.42 2.42 2.42 2.42 2.42 
6 D3 5µg 2.42 2.42 2.42 2.42 2.42 2.42 
13 D3 5µg 2.42 2.42 2.42 2.63 2.42 2.42 
28 D3 5µg 2.42 2.42 2.42 2.42 2.42 2.42 
31 D3 5µg 2.42 2.42 
    
36 D3 5µg 2.42 2.42 2.42 2.42 2.42 2.42 
38 D3 5µg 2.42 2.42 2.42 2.42 2.42 2.42 
42 D3 5µg 2.42 2.42 2.42 2.42 2.42 2.42 
46 D3 5µg 4.47 4.01 4.11 3.50 4.16 3.77 
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25-OH-D3 (nmol/L) by treatment group over 4 wk of supplementation with 5 or 10 µg 











Screening Baseline Wk 1 Wk 2 Wk 3 Wk 4 
3 Placebo 31.52 24.66 28.68 29.78 31.15 27.46 
19 Placebo 55.81 40.76 36.62 33.45 35.74 36.39 
20 Placebo 53.86 53.16 51.72 53.81 55.74 56.61 
24 Placebo 14.18 14.73 12.36 11.01 10.28 9.81 
27 Placebo 21.99 19.74 20.59 22.59 22.14 20.37 
39 Placebo 30.15 26.86 25.41 25.16 24.36 21.72 
41 Placebo 21.14 26.88 25.46 24.49 21.99 28.83 
43 Placebo 43.26 37.56 38.21 31.82 33.55 31.77 
2 D2 10µg 40.73 36.37 34.74 32.35 38.06 32.60 
4 D2 10µg 29.48 25.58 27.76 30.45 27.03 22.86 
5 D2 10µg 41.48 38.16 33.55 39.49 36.29 41.53 
9 D2 10µg 63.65 56.88 56.46 49.37 46.35 49.25 
25 D2 10µg 36.39 36.77 37.96 33.85 39.01 43.85 
26 D2 10µg 51.94 48.00 48.60 55.36 47.82 53.89 
35 D2 10µg 21.29 18.35 17.20 18.22 18.47 20.34 
40 D2 10µg 62.72 52.57 56.14 45.65 51.32 42.68 
1 D2 5µg 7.86 11.78 12.03 13.90 13.68 15.18 
8 D2 5µg 75.60 72.23 65.32 62.28 61.20 60.90 
12 D2 5µg 34.32 29.18 30.58 27.61 27.36 27.31 
21 D2 5µg 65.79 52.67 44.73 40.31 44.05 41.23 
22 D2 5µg 40.26 37.29 35.84 31.65 40.26 43.63 
23 D2 5µg 53.24 50.77 50.67 51.44 47.35 51.87 
33 D2 5µg 97.59 97.74 99.62 99.57 98.32 99.64 
48 D2 5µg 35.12 28.40 27.83 30.45 26.88 25.51 
11 D3 10µg 27.43 26.36 32.07 42.23 42.18 44.68 
15 D3 10µg 15.10 13.40 23.66 34.05 34.92 36.69 
16 D3 10µg 21.29 16.42 35.34 38.64 47.95 55.04 
17 D3 10µg 17.27 18.55 26.76 36.54 38.76 41.98 
30 D3 10µg 105.06 95.35 92.95 85.81 84.69 92.43 
37 D3 10µg 28.60 25.38 33.85 40.16 44.68 46.08 
44 D3 10µg 55.34 51.64 54.79 66.24 63.12 75.78 
47 D3 10µg 20.89 19.97 32.82 35.19 42.58 44.45 
6 D3 5µg 10.76 11.78 13.90 13.70 14.93 14.80 
13 D3 5µg 81.57 69.89 70.56 70.81 62.95 69.81 
28 D3 5µg 10.26 9.43 10.61 12.23 20.44 20.59 
31 D3 5µg 12.08 11.81 
    
36 D3 5µg 31.92 32.20 35.47 39.54 42.76 47.87 
38 D3 5µg 43.73 39.79 45.28 60.15 48.40 60.38 
42 D3 5µg 40.78 35.39 39.01 45.75 50.62 58.46 
46 D3 5µg 33.87 30.68 33.62 39.59 45.58 52.84 
 312 
 
Total 25-OH-D (nmol/L) by treatment group over 4 wk of supplementation with 5 or 











Screening Baseline Wk 1 Wk 2 Wk 3 Wk 4 
3 Placebo 36.54 29.65 33.57 35.18 35.25 31.55 
19 Placebo 58.23 43.18 39.04 35.87 38.17 38.82 
20 Placebo 56.67 55.59 54.14 56.24 58.74 59.61 
24 Placebo 19.44 19.77 16.98 15.18 14.11 13.64 
27 Placebo 24.41 22.17 23.02 25.01 24.56 22.79 
39 Placebo 32.58 29.28 27.83 27.58 26.78 24.14 
41 Placebo 23.56 30.13 27.88 26.91 24.41 31.25 
43 Placebo 47.40 41.51 42.07 36.43 38.08 36.31 
2 D2 10µg 43.16 38.79 50.96 59.76 79.26 73.79 
4 D2 10µg 31.90 28.01 37.89 46.40 46.03 41.86 
5 D2 10µg 43.93 41.48 43.46 51.99 50.83 56.07 
9 D2 10µg 66.34 60.13 67.39 63.64 64.33 67.23 
25 D2 10µg 40.73 40.52 48.80 49.06 57.62 62.47 
26 D2 10µg 54.37 50.52 52.86 59.48 52.21 58.28 
35 D2 10µg 23.71 20.77 30.99 37.92 41.27 43.15 
40 D2 10µg 65.15 54.99 61.76 56.56 66.44 57.80 
1 D2 5µg 10.29 14.20 19.20 25.80 27.03 28.53 
8 D2 5µg 78.03 74.66 73.61 72.87 75.11 74.81 
12 D2 5µg 59.79 55.69 62.15 59.50 61.84 61.79 
21 D2 5µg 70.33 55.91 51.54 48.50 54.55 51.73 
22 D2 5µg 45.71 42.21 47.18 45.32 57.51 60.88 
23 D2 5µg 55.66 53.19 55.88 61.50 59.01 63.52 
33 D2 5µg 100.02 100.17 102.04 101.99 100.74 102.06 
48 D2 5µg 37.81 30.83 35.92 42.06 39.53 38.16 
11 D3 10µg 29.85 28.78 34.50 44.66 44.61 47.10 
15 D3 10µg 17.52 15.83 26.09 36.47 37.34 39.11 
16 D3 10µg 24.34 18.85 38.23 41.06 50.37 57.46 
17 D3 10µg 19.70 20.97 29.18 38.96 41.19 44.41 
30 D3 10µg 107.48 97.77 95.45 88.24 87.11 94.85 
37 D3 10µg 31.03 27.81 36.27 43.00 47.10 48.50 
44 D3 10µg 57.76 54.07 57.21 68.67 65.55 78.20 
47 D3 10µg 23.31 22.39 35.25 37.62 45.01 46.88 
6 D3 5µg 13.18 14.20 16.33 16.12 17.35 17.22 
13 D3 5µg 83.99 72.31 72.99 73.43 65.37 72.24 
28 D3 5µg 12.68 11.86 13.03 14.65 22.87 23.02 
31 D3 5µg 14.50 14.23 
    
36 D3 5µg 34.35 34.62 37.89 42.37 45.18 50.30 
38 D3 5µg 46.15 42.21 47.70 62.58 50.82 62.80 
42 D3 5µg 43.21 37.82 41.44 48.18 53.04 60.88 
46 D3 5µg 38.33 34.67 37.72 43.08 49.72 56.98 
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APPENDIX 22 Recruitment email for DRISK study 
“Circular email for use for recruitment of volunteers for study ref: 11/LO/1626, 
approved by the NHS Research Ethics Committee London - Westminster. This project 
contributes to the College’s role in conducting research, and teaching research 
methods. You are under no obligation to reply to this email, however if you choose to, 
participation in this research is voluntary and you may withdraw at any time.” 
Title of project: The effect of low dose vitamin D2, provided in a malted milk drink, on 
cardiovascular risk. 
We need volunteers to help us investigate whether vitamin D2 can influence factors 
associated with the development of cardiovascular disease, such as how well your 
blood vessels and circulation work (called ‘vascular function’). 
 
If you are a healthy non-smoking male or non-smoking postmenopausal female and 
aged between 50 and 70 years then you may be able to help us.  
 
What you will need to do: 
 Complete a short telephone questionnaire (approximately 10 minutes). 
 Attend a screening visit at either King’s College London Franklin-Wilkins 
building, or the Clinical Research Facility at St Thomas’ Hospital having fasted 
for 3 hours (nothing to eat or drink apart from water). Prior to this visit we will 
ask you to complete a lifestyle questionnaire that asks questions about your 
medical history and dietary habits (about 30 minutes to complete), and you will 
be asked to bring this along to the visit. We will measure your body mass index, 
height, weight and waist circumference and take a blood sample (20 mL/4 
teaspoonfuls). We shall show you how to use an ambulatory blood pressure 
monitoring device, which you will wear for 24 hours. This may slightly restrict 
your activities (e.g. washing rather than having a shower) but normal daily 
functions can all be easily performed. 
 If you are eligible for the study, after the screening visit you will need to come 
for three other visits (each approximately 2 hours in length) over the duration 
of the study (baseline, mid-point at 6 weeks, and final visit at 12 weeks). These 
will take place at the Clinical Research Facility at St Thomas’ Hospital. 
 At each of the visits you will be fitted with the ambulatory blood pressure 
monitor and asked to wear it for the next 24 hours. We will measure the health 
of your arteries and take a small blood sample (20 mL/4 teaspoonfuls). You will 
also be asked to complete a 20 minute test on a computer to see whether 
vitamin D supplementation can influence mood and the ability to conduct 
mental tasks. 
 You would need to consume a malted milk drink, made up with hot water 3 
times a week for 12 weeks. 
 
For further information please contact us to request an information leaflet about the 
study. You will be compensated for your time on completion of the study. If you are 
interested or have any questions relating to the study please contact Catherine Fisk at 
drisk@kcl.ac.uk or on 020 7848 4301.  
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FOR NUTRITION RESEARCH 
 
We are conducting a study to find out whether vitamin D, 
provided in a malted milk drink, can influence factors 
associated with the development of heart disease when 
exposure to sunlight is low. 
 
We are looking for non-smoking men and non-smoking 
postmenopausal women: 
 
 Aged 50 – 70 years 
 Willing to take part in a 3-month nutrition study 
 Able to attend King’s College London and St Thomas’ 
Hospital, near Waterloo Station, for three visits 
spread throughout the study. 
 
You will be reimbursed for your time and travel expenses 
and you will get a cardiovascular health check. 
 
 
































Vitamin D trial at King’s College London 
We need to find men and postmenopausal women to 
take part in a research study to find out if vitamin D, 
provided in a malted milk drink, can influence factors 
associated with the development of heart disease. 
If you are in good health, aged 50-70 years, a non-smoker 
and interested in taking part, please email 
drisk@kcl.ac.uk for further information. You will be 
compensated for your time and travel expenses (we are 
near Waterloo station). 
Research Ethics Committee Ref: 11/LO/1626. 
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PHYSICAL ACTIVITY QUESTIONNAIRE 
 
We are interested in finding out about the kinds of physical activities that people do as 
part of their everyday lives because it is associated with risk of cardiovascular disease. 
The questions are about the time you spent being physically active in the last 7 days. 
They include questions about activities you do at work, as part of your house and 
garden work, to get from place to place, and in your spare time for recreation, exercise 
or sport. 
Your answers are important. 
 
Please answer each question even if you do not consider yourself to be an 
active person. 
 
THANK YOU FOR PARTICIPATING. 
 




























 vigorous physical activities refer to activities that take hard physical effort 
and make you breathe much harder than normal. 
 
 moderate activities refer to activities that take moderate physical effort and 




1a) During the last 7 days, on how many days did you do vigorous physical activities 
like heavy lifting, digging, aerobics, or fast bicycling? 
 
Think about only those physical activities that you did for at least 10 minutes at a time. 
 




       none 
 
 
2a. Again, think only about those physical activities that you did for at least 10 minutes 
at a 
time. During the last 7 days, on how many days did you do moderate physical activities 
like carrying light loads, bicycling at a regular pace, or doubles tennis? Do not include 
walking. 
 




       none 
 
 
3a. During the last 7 days, on how many days did you walk for at least 10 minutes at a 
time? This includes walking at work and at home, walking to travel from place to place, 
and any other walking that you did solely for recreation, sport, exercise or leisure. 
 
________ days per week  
or 
 
      none 
 
 
The last question is about the time you spent sitting on weekdays while at work, at 
home, while doing course work and during leisure time. This includes time spent 
sitting at a desk, visiting friends, reading traveling on a bus or sitting or lying down to 
watch television. 
 
4. During the last 7 days, how much time in total did you usually spend sitting on a 
week day? 
 
____ hours ______ minutes 
 
This is the end of questionnaire, thank you for participating 
1b. How much time in total did you 
usually spend on one of those days 
doing vigorous physical activities? 
__________hours_________minutes 
2b. How much time in total did you 
usually spend on one of those days 
doing moderate physical activities? 
__________hours_________minutes 
3b. How much time in total did you 





APPENDIX 28 Raw data for 25-OH-D2, 25-OH-D3 and total 25-OH-D in the DRISK 
study. Screening samples measured by chemiluminescent immunoassay and study 
day samples measured by ultra-high pressure liquid chromatography tandem mass 
spectrometry (UPLC-MS/MS). 
25-OH-D2 (nmol/L) by treatment group over 12 wk of supplementation with an 
intake equivalent to 10 µg D2/d or placebo (a value of 2.4 nmol/L has been assigned 



























Baseline Wk 6 Wk 12 
4 Placebo 2.42 2.42 5.04 
7 Placebo 4.97 5.84 6.18 
9 Placebo 2.42 2.42 4.65 
13 Placebo 2.42 2.42 2.42 
14 Placebo 2.42 2.42 2.79 
16 Placebo 2.42 
  
19 Placebo 2.42 6.01 10.23 
20 Placebo 2.42 2.42 4.99 
21 Placebo 2.42 2.42 2.42 
27 Placebo 3.03 2.42 2.42 
28 Placebo 2.54 2.42 2.42 
33 Placebo 2.42 2.42 3.59 
36 Placebo 3.39 3.15 2.42 
38 Placebo 2.42 2.42 2.47 
39 Placebo 2.42 
  
43 Placebo 2.42 2.42 2.42 
44 Placebo 2.42 2.42 2.67 
47 Placebo 2.42 2.42 2.42 
48 Placebo 5.79 4.14 6.93 
49 Placebo 6.11 4.36 2.69 
1 D2 2.42 12.16 15.56 
5 D2 2.42 18.88 23.38 
8 D2 2.42 2.42 2.42 
10 D2 2.42 16.36 28.28 
11 D2 2.42 5.72 2.42 
12 D2 2.42 12.62 18.10 
18 D2 2.42 17.25 25.08 
23 D2 2.42 16.60 23.50 
25 D2 2.42 2.83 2.42 
26 D2 2.42 34.65 42.89 
29 D2 2.42 47.49 46.28 
31 D2 2.42 30.05 27.38 
32 D2 5.23 24.96 43.37 
34 D2 2.42 34.41 27.38 
35 D2 2.42 25.44 33.44 
40 D2 4.39 16.28 22.99 
41 D2 2.74 28.83 29.56 
42 D2 2.42 32.47 36.35 
45 D2 2.42 25.20 25.93 
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25-OH-D3 (nmol/L) by treatment group over 12 wk of supplementation with an 






























Baseline Wk 6 Wk 12 
4 Placebo 61.55 47.40 49.42 
7 Placebo 43.01 32.30 32.32 
9 Placebo 27.26 19.19 17.20 
13 Placebo 38.31 28.88 26.63 
14 Placebo 68.74 57.71 63.40 
16 Placebo 51.64 
  
19 Placebo 18.92 14.45 20.67 
20 Placebo 25.58 20.34 19.89 
21 Placebo 34.74 36.84 38.21 
27 Placebo 13.48 20.49 18.02 
28 Placebo 24.94 18.57 16.45 
33 Placebo 45.18 28.70 53.41 
36 Placebo 16.55 19.17 20.29 
38 Placebo 16.82 11.76 18.10 
39 Placebo 52.92 
  
43 Placebo 40.44 47.67 58.16 
44 Placebo 22.91 25.71 27.46 
47 Placebo 64.65 90.60 72.63 
48 Placebo 94.85 50.17 57.91 
49 Placebo 94.35 98.84 81.12 
1 D2 52.19 42.93 41.66 
5 D2 63.97 44.23 43.78 
8 D2 41.51 35.32 37.22 
10 D2 46.43 28.85 28.60 
11 D2 53.26 39.59 42.93 
12 D2 17.57 18.84 23.74 
18 D2 15.90 14.33 16.07 
23 D2 65.35 51.47 50.69 
25 D2 36.39 35.12 42.48 
26 D2 23.89 22.41 29.95 
29 D2 32.45 40.68 36.44 
31 D2 37.94 29.95 33.45 
32 D2 13.45 14.93 24.19 
34 D2 35.44 41.68 31.95 
35 D2 25.96 21.09 23.09 
40 D2 29.45 26.46 24.14 
41 D2 31.45 42.93 36.69 
42 D2 50.92 36.19 32.95 
45 D2 34.69 32.20 27.96 
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Total 25-OH-D (nmol/L) by treatment group over 12 wk of supplementation with an 































Screening Baseline Wk 6 Wk 12 
4 Placebo 50.9 63.97 49.82 54.46 
7 Placebo 32.7 47.97 38.14 38.50 
9 Placebo 23.5 29.68 21.62 21.85 
13 Placebo 31.9 40.74 31.30 29.06 
14 Placebo 59.9 71.16 60.13 66.18 
16 Placebo 37.9 54.07   
19 Placebo 21.5 21.34 20.46 30.89 
20 Placebo 29.5 28.01 22.77 24.88 
21 Placebo 31.9 37.17 39.26 40.64 
27 Placebo 20.2 16.51 22.92 20.44 
28 Placebo 28.5 27.48 20.99 18.87 
33 Placebo 39.4 47.60 31.13 57.00 
36 Placebo 24.5 19.94 22.32 22.72 
38 Placebo 14.0 19.25 14.18 20.57 
39 Placebo 49.2 55.34   
43 Placebo 36.2 42.86 50.10 60.58 
44 Placebo 22.0 25.34 28.13 30.12 
47 Placebo 46.2 67.07 93.03 75.06 
48 Placebo 62.6 100.64 54.31 64.84 
49 Placebo 50.7 100.45 103.20 83.81 
1 D2 44.2 54.61 55.09 57.21 
5 D2 53.4 66.40 63.10 67.16 
8 D2 34.4 43.93 37.74 39.64 
10 D2 48.7 48.85 45.21 56.88 
11 D2 51.4 55.69 45.30 45.35 
12 D2 18.2 19.99 31.47 41.84 
18 D2 17.0 18.32 31.58 41.15 
23 D2 54.4 67.77 68.07 74.20 
25 D2 30.2 38.81 37.95 44.90 
26 D2 32.4 26.31 57.06 72.84 
29 D2 43.9 34.87 88.18 82.72 
31 D2 47.7 40.36 60.00 60.83 
32 D2 32.4 18.69 39.88 67.56 
34 D2 40.7 37.87 76.09 59.33 
35 D2 25.2 28.38 46.53 56.53 
40 D2 46.9 33.84 42.74 47.13 
41 D2 30.7 34.19 71.76 66.25 
42 D2 40.4 53.34 68.66 69.29 
45 D2 40.4 37.12 57.40 53.88 
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APPENDIX 29 24 h day-time and night-time blood pressure for DRISK study 
 
Table A Effects of and intake equivalent to 10 μg vitamin D2/d vs. placebo on 
day-time systolic (SBP) and diastolic (DBP) blood pressure and heart rate in healthy 






















Mean values (SD); Treatment effect from Generalised Linear Models with baseline value as offset. 
Adjusted changes and treatment effects are the marginal means adjusted for the covariates age, BMI 
and gender. 
  
  Placebo 
(n = 18) 
Vitamin  D2  
(n = 21) 
Treatment effect 
(95% CIs)  
P value 
SBP, mm Hg     
Baseline 1 124 (11) 125 (13)     
Baseline 2 123 (14) 123 (10)     
Mean baseline 124 (12) 124 (11)     
6 wk 125 (12) 122 (12)     
12 wk 126 (12) 123 (9)     
Mean treatment 125 (11) 122 (10)   
Mean change (95% CIs) 1.6 (-1.0, 4.3) -1.9 (-4.3, 0.6)   
Change adjusted 1.6 (-0.9, 4.0) -1.8(-4.0, 0.5) -3.3 (-6.7, 0.0) P=0.050 
          
DBP, mm Hg       
Baseline 1 76 (7) 76 (9)     
Baseline 2 76 (10) 75 (8)     
Mean baseline 76 (8) 76 (8)     
6 wk 78 (8) 75 (8)     
12 wk 77 (8) 75 (7)     
Mean treatment 77 (7) 75 (7)   
Mean change (95% CIs) 1.33 (-0.9, 3.6) -1.0 (-3.0, 1.1)   
Change adjusted 1.2 (-0.9, 3.3) -0.8 (-2.7, 1.1) -2.1 (-4.9, 0.8) P=0.155 
     
Heart rate, beats/min       
Baseline 1 75 (6) 71 (8)     
Baseline 2 75 (7) 72 (9)     
Mean baseline 75 (6) 71 (8)     
6 wk 75 (6) 68 (8)     
12 wk 76 (7) 74 (8)     
Mean treatment 76 (6) 71 (7)   
Mean change (95% CIs) 0.6 (-1.3, 2.6) -0.2 (-2.2, 1.6)   
Change adjusted 0.5 (-1.3, 2.2) -0.1 (-1.8, 1.6) -0.6 (-3.0, 1.9) P=0.662 
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Table B Effects of 10 μg vitamin D2/d vs. placebo on night-time systolic (SBP) 
and diastolic (DBP) blood pressure and heart rate in healthy men and women aged 
50-70 years. 
Mean values (SD); Treatment effect from Generalised Linear Models with baseline value as offset. 










  Placebo 
(n = 18) 
Vitamin  D2  
(n = 21) 
Treatment effect 
(95% CIs)  
P value 
SBP, mm Hg       
Baseline 1 106 (14) 107 (10)     
Baseline 2 105 (12) 107 (9)     
Mean baseline 105 (12) 107 (9)     
6 wk 108 (11) 106 (13)     
12 wk 108 (11) 105 (9)     
Mean treatment 108 (11) 105 (10)   
Mean change (95% CIs) 2.7 (0.3, 5.1) -2.1 (-4.3, 0.1)   
Change adjusted 2.6 (0.4, 4.8) -2.1 (-4.1, -0.0) -4.7 (-7.7, -1.7) P=0.002 
          
DBP, mm Hg     
Baseline 1 64 (9) 64 (7)     
Baseline 2 63 (8) 64 (7)     
Mean baseline 63 (8) 64 (6)     
6 wk 65 (7) 64 (8)     
12 wk 65 (8) 63 (7)     
Mean treatment 65 (7) 63 (7)   
Mean change (95% CIs) 1.5 (-0.5, 3.5) -0.5 (-2.3, 1.4)   
Change adjusted 1.4 (-0.4, 3.2) -0.4 (-2.0, 1.3) -1.7 (-4.2, 0.7) P=0.161 
     
Heart rate, beats/min       
Baseline 1 63 (7) 62 (9)     
Baseline 2 63 (8) 64 (10)     
Mean baseline 63 (7) 63 (8)     
6 wk 62 (6) 61 (8)     
12 wk 62 (6) 61 (7)     
Mean treatment 62 (6) 61 (7)   
Mean change (95% CIs) -1.0 (-3.0, 1.0) -1.7 (-3.5, 0.1)   
Change adjusted -1.0 (-2.8, 0.9) -1.7 (-3., 0.0) -0.7 (-3.3, 1.9) P=0.592 
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APPENDIX 30 Norms and minimum performance levels for COMPASS tests from the 
The Brain Performance and Nutrition Research Centre (BPNRC) at Northumbria 
University. 
 
Test Norm Min 
Word recognition % Correct 80 55 
Word recognition Overall Reaction Time 943 1104 
Simple reaction time 289 365 
Stroop % Correct 96 78 
Stroop Overall Reaction Time 687 919 
P&B Average RT Complete 4511 4951 
P&B Average RT Thinking 1653 2319 
Corsi Block Span Score 6 5 
  
 
 
